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Tuberculosis  
Tuberculosis (TB) is an infectious disease with a very long history. It has been 
hypothesized that the origin of the genus Mycobacterium emerged during the Jurassic 
era, more than 150 million years ago.1 In Ancient Greece, phthisis – a disease with 
symptoms and lung lesions similar to those of TB in modern medicine – was well 
known.2 In the Middle Ages, people found that the disease also affected the cervical 
lymph nodes; it was called scrofula.3 In thirteenth-century England and France, where 
it was believed that monarchs were endowed with supernatural power from God,3 it was 
also believed that scrofula could be diagnosed and cured by the “royal touch” – a 
practice used by French kings and English kings and queens to heal their people. The 
illness was known as the King’s evil, and the “royal touch” was used until 1712 in 
England and 1825 in France.2  
During the industrial revolution, the disease spread widely in poor communities, due 
largely to malnutrition, bad working conditions, bad sanitation, and overcrowded, 
poorly ventilated housing.1, 2 In the late 19th century, many physicians and researchers 
undertook experiments, including the sanatorium cure, which was introduced in 
Germany by Herman Brehmer, who stated in his doctoral dissertation that TB was a 
curable disease.2 On March 24, 1882, Dr. Robert Koch successfully identified 
Mycobacterium tuberculosis as its cause.4 After centuries of speculation, this significant 
event produced a new understanding of the disease. Eventually, this led to the 
development of a strategy that combined drug discovery, effective treatment, and 
socioeconomic development.  
In the early 20th century, TB mortality rates in Europe, Japan, and North America 
declined rapidly.5, 6 Due to this successful reduction in the incidence and mortality of 
TB, the disease was often regarded as a disease of the past. But in other parts of the 
world, particularly low and middle-income countries, the disease burden of TB was still 
high. In 1993, the World Health Organization (WHO) declared that TB was a global 
health emergency, and that national and global efforts to combat it should be 
intensified.6  
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Global TB epidemiology  
In 2017, despite drug development and socioeconomic improvements, there were still 
an estimated 10 million incident cases of TB worldwide7 – equivalent to 133 cases per 
100 000 population. Most cases occurred in South-East Asia (44%) and in African 
regions (25%) (Figure 1). Some 87% of all estimated incident cases occurred in TB 
high-burden countries (HBCs), and were concentrated in eight countries: India (27%), 
China (9%), Indonesia (8%), Philippines (6%), Pakistan (5%), Nigeria (4%), 
Bangladesh (4%), and South Africa (3%). 
 
 
Figure 1 Estimated TB incidence in 2017 for countries with at least 100 000 incident cases 
(Source: WHO, 2018) 
Globally, progress has been made in reducing TB mortality. Between 2000 and 2016, 
the number of deaths due to TB fell by 24%, while the mortality rate due to TB (deaths 
per 100 000 people per year) fell by 37%.6 However, TB among HIV-negative people 
is still the tenth most important cause of death worldwide (Figure 2). If estimates include 
TB-related deaths among people who are HIV positive, the number of deaths is even 
higher. Worldwide, an estimated 1.33 million TB patients died in 2017. Approximately 
1.3 million of these deaths occurred among TB patients who were HIV negative, and 
300 000 among people who were HIV positive. TB deaths were concentrated in the 
African and South-East Asian regions, which between them accounted for 82% of all 
TB-related deaths.7, 8 In addition, of all single infectious agents, TB is the top cause of 
death, causing a larger number of deaths than HIV/AIDS.  
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Figure 2 Top causes of death worldwide in 2016 (Source: WHO, 2018). With regard to 
tuberculosis, the blue bar indicates TB deaths among HIV-negative people, and the gray bar TB 
deaths among HIV-positive people. 
 
Global TB control 
These statistics show that vast national and global efforts are still required to eliminate 
TB. In a resolution issued in the World Health Assembly (WHA) in 1991, the World 
Health Organization (WHO) stressed the importance of combating TB, declaring that 
TB was a global health emergency.6, 9 The resolution was supported by the introduction 
of an internationally recommended TB control strategy known as DOTS (Directly 
Observed Treatment Short-course),10 whose key components included government 
commitment, case detection, standardized short-course chemotherapy with supervision 
and patient support, regular drug supply, and system monitoring and evaluation. 
In 2000, the first Global Plan to Stop TB was launched by setting up actions to control 
TB over the 2001–2005 period. The strategy has been supported by initiatives such as 
the Amsterdam Declaration (2000), the Washington Commitment to Stop TB (2001), 
and the Stop TB Partners’ Forum in Delhi (2004).9 Global and national TB elimination 
programs were also engaged in the efforts to achieve the Millennium Development 
Goals (MDGs) target of “halving TB prevalence and TB mortality rates by 2015 
compared with their levels in 1990”.9, 11  
The assessment of the MDGs’ and Stop TB Strategy’s targets indicated that, on a 
worldwide basis, the target were achieved. Global TB prevalence had declined by 42% 
compared with the level in 1990. In three WHO regions – the Americas, South-East 
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Asia, and the Western Pacific regions – and in nine HBCs, the decline rates were more 
than 50%.11 The global TB mortality rate also declined by 47% compared the rate in 
199012 while the overall number of TB deaths declined by 24% between 2000 and 
2016.6 The target of halving TB mortality was achieved in four WHO regions – the 
Americas, the Eastern Mediterranean, the South-East Asia, and the Western Pacific 
regions – and eleven HBCs.  
However, the global target of eliminating TB still faces many challenges. Although the 
incidence of TB has declined over the years, the rate of decline has been slow: only 1.4-
1.5% per year in the period 2000-2017,6, 12 and 1.8% between 2016 and 2017.7 There 
has also been an increase in TB drug resistance, not only in Rifampicin Resistant TB 
(RR-TB), in which the disease is resistant to rifampicin as the first-line drug, but also 
multidrug-resistant TB (MDR-TB), in which it is resistant both to rifampicin and to 
isoniazid. In 2017, the global incidence of MDR-TB and RR-TB concerned an 
estimated 558 000 cases,7 most of them in China, India, and Russia. As experience in 
some Eastern European countries has shown, treatment success may be greatly reduced 
by the high prevalence of MDR-TB.12  
The global response to these challenges were embodied the Sustainable Development 
Goals (SDGs) and the WHO’s latest End TB Strategy. One of the targets of the SDGs 
is to “end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, 
and [to] combat hepatitis, water-borne diseases, and other communicable diseases” by 
2030.13 In numerical terms, this target means that, relative to the rates in 2015, the TB 
incidence rate must be reduced by 80% and TB death rates by 90%. The WHO End TB 
Strategy, in parallel, has set targets to reduce the incidence by 90% and death rates by 
95% by 2035. The End TB Strategy has a longer timeframe in which it ends in 2035 
rather the SDG’s timeframe which ends in 2030.7, 14 These two targets are ambitious 
and need huge efforts by national and global policymakers.  
 
TB in Indonesia 
Indonesia is among the world’s 30 high-burden TB countries. In 2018, the country had 
845 000 new TB cases, which accounted for 8% of TB cases worldwide.15 As its 
incidence of TB was 316 per 100 000 population, Indonesia is third highest in the 
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worldwide ranking, with a TB mortality rate of 40 per 100 000 population. These stark 
figures indicated that TB was still the top burden of diseases in Indonesia. 
In the era of the MDGs (2000–2015), Indonesia had set two main indicators to monitor 
achievement of the MDG target related to TB control: increasing the detection of new 
smear-positive TB cases to 70%, and increasing the cure rate to 85% of such cases by 
the year 2000.6, 9 Setting up the indicator of increasing new smear-positive TB case 
detection to 70% based on the fact that TB case detection in practice was not effective. 
There was a high proportion of detected smear-negative TB cases, which are more likely 
found by X-ray test rather than by sputum smear examination, and are also less 
contagious. In addition, there had been also a high number of undetected TB smear-
positive cases. To achieve this indicator, the Indonesian National Tuberculosis Program 
(NTP) intensified the DOTS strategy – the internationally recommended strategy for 
TB control. In 2015, at the end of the MDGs era, Indonesia had achieved these two 
indicators (improving TB case detection and cure rate), but had failed to halve TB 
prevalence and mortality rates.11, 16  
The achievement and the failure both indicated the complex situation of TB in 
Indonesia, which is characterized by three main problems. The first – a high number of 
undetected cases7, 17 – results from the failure of healthcare providers to comply with 
the standard of TB diagnosis recommended in the national TB practice guidelines. This 
may be due to limited knowledge on the part of physicians, or to limited healthcare 
facilities – particularly laboratory facilities – for the sputum smear examination. One 
way and another, the high number of undetected cases leads to patient diagnostic delays, 
the spread of TB in the community, and potentially high costs for patients and their 
households.17-19  
The second problem is a high number of cases that have been detected but not notified. 
This problem was captured by a national inventory study in 2017.7, 17 Despite the 
achievement that 85% of TB cases had been detected in 2015, the estimated incidence 
– which was used to estimate the detection rate – had been generated from the data 
stored in the NTP information system (the Integrated Information System for 
Tuberculosis, or Sistem Informasi Tuberkulosis Terpadu, SITT). Only healthcare 
providers linked with NTP report to the SITT. While a substantial proportion of TB 
patients seek care from healthcare providers that are not linked to the NTP, many TB 
cases are not captured by the SITT.7, 20 As a result, the TB cases detected in these health 
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facilities were not notified to the NTP. This in turn led to an underestimation of TB 
incidence, as it was based solely on the data in SITT, and also to a substantial 
overestimation of the case-detection rate.  
The third problem is the high number of patients who are lost to follow up, i.e., as having 
missed TB treatment for more than two consecutive months. There are various reasons 
a patient may stop treatment: lack of knowledge, unawareness of the consequences of 
stopping TB treatment before completion, adverse effects of TB drugs, poor access to 
healthcare facilities, and high costs incurred during TB treatment.19, 21  
 
TB care system in Indonesia 
To reduce the TB burden, Indonesia’s NTP operates under the auspices of the Ministry 
of Health.22 As the body responsible for running the TB control program, the NTP 
coordinates directly with Provincial Health Offices (PHOs) and District Health Offices 
(DHOs) (Figure 3). The NTP has a sizeable primary care network, which consists 
mostly of publicly funded primary health centers (PHCs) or Puskesmas. There are two 
main types of PHC or Puskesmas in Indonesia: Puskesmas, which operate at sub-district 
level, and auxiliary Puskesmas (Puskesmas Pembantu, Pustu), which operate at village 
level. The NTP delivers free TB drugs to Puskesmas through the DHOs. Most 
Puskesmas have large facilities, including laboratories, so that they can run TB 
diagnostic tests for suspected TB patients. This type of Puskesmas functions as a 
“referral microscopic center” for diagnosis. Puskesmas or Pustu with very limited 
facilities have to refer suspected TB patients to referral Puskesmas for diagnosis and to 
obtain free TB drugs. In addition, the NTP also has a network of public hospitals and 
clinics under the authority of ministries, such as the prison clinics under the Ministry of 
Law and Human Rights. 
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Figure 3 Referral for diagnostic tests under the network of Indonesia’s national tuberculosis 
program 
Private clinics and private hospitals can be linked to the NTP through mutual 
agreements with either a Puskesmas or a DHO. To be eligible for this, they must meet 
various requirements: physicians in the clinics or hospitals must have completed a 
DOTS training, and the clinics and hospitals must agree to comply with the national TB 
guidelines and report TB case findings and management to the NTP. If clinics linked 
with the NTP have a laboratory for TB diagnostic tests, they can provide these tests free 
of charge. In other cases, they should refer suspected TB patients to a referral 
Puskesmas, a hospital, or a provincial/district laboratory center. If the suspected patient 
is TB-positive, a private clinic can, according to its mutual agreements, submit a request 
for free TB drugs to either a Puskesmas or the DHO. The private clinic is then required 
to submit a TB case-management report. Private hospitals linked to the NTP receive 
free TB drugs from the DHO, to which they should then report on the TB case 
management.  
Until 2014, however, only about 11 000 of the 70 000 (16%) private healthcare 
providers were linked to the NTP network.17, 23 According to the TB National 
Prevalence Survey (2014), almost 75% of suspected TB patients first sought care with 
private providers.17 As a result, the providers were unable to provide free access to TB 
diagnostic tests and TB drugs. 
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Universal health coverage in Indonesia 
In 2014, Indonesia started a national health insurance program (Jaminan Kesehatan 
Nasional, JKN) to achieve universal health coverage (UHC). It is run by a Social 
Security Agency for Health (Badan Penyelenggara Jaminan Sosial – Kesehatan, BPJS-
K) that was set up for the purpose. In its first five years of operation, the program’s 
population coverage increased from 46% to 75%.23 The government covers the monthly 
contribution fee for poor households, which, using data from the National Statistical 
Agency, was established on the basis of a household’s ability to fulfill its basic food 
and non-food needs.24 Non-poor households pay a contribution fee that varies according 
to the type of BPJS-K membership.  
The BPJS-K has an extensive network of public and private providers, where patients 
who are the beneficiaries of the national health insurance can access free essential health 
services. All public healthcare providers are automatically linked to the BPJS-K. In 
2018, there were also approximately 11 500 private providers in the BPJS-K network.25 
The numbers of private healthcare providers linked to BPJS-K will continue to grow. 
After the implementation of UHC, TB care service is delivered through two separated 
system (Figure 4). First, as mentioned above, the NTP coordinates TB care system from 
the direction of the Ministry of Health (national level) to the PHOs, the DHOs, and its 
network of providers (Puskesmas, clinics, laboratories, and hospitals). The budget of 
providing TB care services is arranged entirely by the government. By this system, 
suspected TB patients could access free TB diagnostic tests only at health providers that 
were linked to the NTP. All free TB drug is provided only though the NTP network. 
Second, the BPJS-K also allows free TB diagnostic tests at private providers that are 
linked to BPJS-K, regardless of the providers’ status in the NTP network. Private 
providers who do not have a laboratory can refer suspected TB patients for diagnostic 
tests to a BPJS-linked facility.26  
However, not all private providers who are linked to BPJS-K also have direct links to 
the NTP network. If the private providers are part of the NTP network, they can receive 
free TB drugs and deliver the drugs to the TB patient. Private providers who are not 
linked to the NTP cannot provide free TB drugs, and should refer TB patients to an 
NTP-linked health provider. With this new approach and with a strongly increasing 
number of private providers that are linked to BPJS-K, it is assumed that UHC in 
Indonesia will improve its TB control program and reduce patients’ direct medical costs.  
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Figure 4 The latest guidelines for diagnostic tests referral after the implementation of UHC. 
Still, the BPJS-K is not linked directly to the Indonesian NTP. If health providers are 
not part of the NTP network, they may not have attended the DOTS training and may 
not have managed suspected TB patients and diagnosed TB patients according to the 
NTP’s guidelines. At present, however, the BPJS-K provides no specific requirements 
or guidelines on managing TB cases according to the NTP guideline, DOTS, or the 
International Standard of Tuberculosis Care (ISTC).  
The overall picture shows that the provision of care for TB in Indonesia is fragmented 
across the BPJS-K and the NTP systems. While the basic assumption is that the national 
health insurance program can improve TB control program and reduce patients’ direct 
medical costs, there is insufficient evidence on whether the UHC can mitigate the high 
costs incurred by TB patients and TB-affected households. It is also important to assess 
whether it has still been possible for patients to incur costs due to TB since UHC was 
implemented, and, if so, for what cost item and how much the costs are incurred. 
  
The financial burden due to TB 
Accessing TB-related services is often costly. Overall, without sufficient insurance or 
program coverage, patients often incur high direct medical costs, for, among others, 
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diagnostic procedures, TB drugs, and consultation fees.27 Patients may face high costs, 
starting in the pre-diagnostic phase, i.e., the period between the occurrence of the first 
symptoms or signs and TB diagnosis. Costs during this phase can be high due to 
diagnostic or health-system delays, which are defined as the time that elapses between 
a patient’s first healthcare facility visit and the date of starting of TB treatment.28-30 
Since patients may seek care with multiple health providers before obtaining the 
definitive diagnosis of TB, the length of such delays can vary. 27, 31  
When a patient is diagnosed with TB, he or she needs to undergo a long TB treatment 
without any interruption.32 Those who are newly infected (Category 1) should complete 
a six-month course of treatment – two months in the intensive phase and four months 
in the continuation phase. Those who have become re-infected (Category 2) should 
complete eight months of treatment – three months in the intensive phase and five 
months in the continuation phase.  
Even though patients receive free TB drugs and medical consultations, they still incur 
high costs for direct non-medical costs, such as transportation and food during their 
visits to the healthcare facility.33, 34 Patients in Indonesia need to visit their healthcare 
provider approximately 2-4 times a month during the intensive phase and 1-2 times a 
month during the continuation phase. The number of visits is higher for those 
undergoing Category 2 treatment. If a patient needs one or more family member to 
accompany them during the healthcare visits, these costs may increase.  
As well as direct medical and non-medical costs, TB patients or their guardians may, 
due to their frequent visits to the healthcare provider, also face losses of income, 
productivity, and time.27, 34, 35 Patients may also experience job loss, typically for 
reasons such as the high frequency of healthcare visits, their worse health, or 
stigmatization in the workplace.  
Such economic consequences can be catastrophic, particularly for poor households. On 
the one hand, accessing TB-related services may further reduce their financial capacity, 
eventually casting them into a poverty trap.36, 37 On the other hand, catastrophic costs 
may hamper their further access to healthcare.  
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Catastrophic costs due to TB 
In 2015, the WHO End TB Strategy set a target for the first milestone (2020): reducing 
to zero percent the percentage of TB-affected households that faced catastrophic costs.38 
This definition of “catastrophic costs” is different from that of another, similar-sounding 
indicator, “catastrophic expenditures,” which is commonly used to measure progress 
towards UHC.39, 40 While catastrophic costs are a UHC indicator that focuses on direct 
medical costs only, the End TB indicator captures the total economic burden of TB, and 
therefore incorporates indirect costs into its calculation of catastrophic costs.40-42  
Measuring the economic impact of TB thus incorporates three types of cost. The first, 
direct medical costs, represent actual spending on medical services, such as 
administration and consultation fees, and costs for laboratory tests, treatment, and 
hospitalization. The second, direct non-medical costs, are often incurred during 
healthcare visits, and consist of indirect costs or income loss. They are associated with 
healthcare utilization, such as transportation costs and food costs. The third, indirect 
costs, are any loss of income that result from accessing TB-related services.  
The WHO recommends two approaches to measuring catastrophic costs and whether or 
not the zero-percent target of households facing such costs has actually been achieved. 
The first approach defines catastrophic costs as the total costs incurred by TB-affected 
households that exceed a specific threshold – such as 20% – of the household’s annual 
income. The second approach defines catastrophic TB-related costs as the share of TB-
affected households that experience dissaving by taking a loan or selling property or 
livestock to deal with TB-related costs.41  
In Indonesia, no evidence has yet been produced on measurements of the incidence of 
catastrophic costs due to TB according to the new approach introduced by the End TB 
Strategy in 2015, i.e., measuring all direct and indirect costs. Neither is there currently 
any evidence on the extent to which households still face catastrophic costs since UHC 
was implemented through the JKN program. As we approach the 2020 milestone of the 
End TB Strategy – i.e., a zero percent incidence of catastrophic costs – it is crucial to 
assess the current situation in Indonesia. It is essential to assess whether Indonesia’s 
universal health insurance program is sufficient to protect TB patients from catastrophic 
costs, or whether they need additional protection against the economic impacts of TB.  
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The aim, research questions, and outline of the thesis 
In the context of UHC in Indonesia, this thesis aims to provide an evidence base on the 
following: 1.) the household-level economic impact of TB, 2.) the relationship between 
catastrophic costs and TB treatment outcomes, and 3.) the social-protection 
improvements required to further reduce TB-related catastrophic costs. In more specific 
terms, this thesis intended addresses the research questions below. 
1. What is the economic impact of TB faced by TB-affected households? 
2. What is the contribution of private health care providers to this economic impact of 
TB? 
3. Do catastrophic costs affect patients’ TB treatment adherence and treatment 
outcome? 
4. What is the potential effect on the incidence of catastrophic costs of further social 
protection measures beyond UHC? 
The thesis consists of seven chapters. Chapter 2 describes the development and 
adaptation of the tool developed by the WHO to measure TB-related costs in the context 
of Indonesia since the implementation of the UHC. In answer to the first research 
question, Chapters 3 and 4 quantify the economic impact of TB, including the incidence 
of TB-related catastrophic costs. Chapter 4 explores the contribution of private 
healthcare providers to the economic impact due to TB. Chapter 5 describes whether or 
not catastrophic costs, and at which percentage of costs related to annual household 
income, affect TB treatment outcome and TB treatment adherence. After presenting a 
simulation of eight financial support scenarios for reducing the incidence of 
catastrophic costs, Chapter 6 explores the patients’ remaining needs for additional 
financial or social protection. The general discussion in Chapter 7 summarizes and 
discusses our findings, and makes recommendations for further research and policy 
development regarding the TB-control program and social protection.  
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Abstract 
 
Aim:  
To adapt the Tool to Estimate Patient Costs which measures total costs and catastrophic 
total costs for tuberculosis-affected household to the Indonesian context.  
 
Methods:  
The Tool was adapted using best-practice guidelines. On the basis of pre-testing 
performed in a previous study (referred to as Phase 1 Study), we refined the adaptation 
process by comparing it with the generic tool introduced by the WHO. We also held an 
expert committee review and did pre-testing by interviewing 30 TB patients. After pre-
testing and before finalization, the Tool was provided with complete explanation sheets. 
 
Results:  
Seventy-two major changes were made during the adaptation process including 
changing choices to match the Indonesian context, refining the flow of questions, 
deleting questions, changing some wordings, and restoring original questions that had 
been changed in Phase 1 Study. Participants indicated that most questions were clear 
and easy to understand. To solve recall difficulties, we made some adaptations to obtain 
data that might be missing, such as tracking data to a patient’s medical records, making 
a proxy of costs, and guiding interviewers to ask for a specific value when participants 
were uncertain about the estimated market value of property they had sold. 
 
Conclusions:  
The adapted Tool to Estimate Patients’ Costs in Bahasa Indonesia is comprehensive, 
ready for use in future studies on TB-related costs catastrophic costs, and suitable for 
monitoring progress towards the target of the End TB Strategy. 
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Introduction 
Indonesia is achieving slow progress in its struggle to eliminate tuberculosis (TB). With 
the world’s second-highest TB incidence worldwide,1  it urgently requires 
improvements and innovations beyond the strategies currently being implemented 
throughout the country. While training of healthcare workers is essential, it is also 
important to note that access to healthcare often brings financial hardship to TB patients. 
The most vulnerable are those living in poor families, who must deal not only with 
medical costs, but also with non-medical costs, such as travel and supplementation 
costs, which can drain up to half of their annual income.2,3 All these costs are 
compounded by potential income loss.4   
Challenges in eliminating TB therefore go beyond clinical management, and are often 
related to socioeconomic problems. These problems can increase delay in TB diagnosis 
and treatment, and plunge patients into a more severe state of TB illness and a higher 
risk of treatment failure and MDR-TB development.2–4 This, in turn, will lead to more 
complicated cases with substantial implications for clinical management. Clinicians 
should therefore consider the financial problems faced by TB patients and their affected 
families during consultations.  
Many patients, because of embarrassment, prefer firstly seek care to private providers 
rather than to public health facilities, regardless their financial capacity. Assessing 
patients’ financial capability will help clinicians to decide whether they can prescribe 
additional diagnostic tests, such as X-ray, and branded drugs that may be unaffordable 
for patients. Otherwise, they should refer patients to public health facilities linked to 
National Tuberculosis Program (NTP) that provide free-of-charge laboratory 
examination and TB drugs. During TB treatment, clinicians should also assess whether 
patients can afford transportation costs before deciding the number of visits per month. 
Assessing all of these issues is important to increase patients’ adherence to the TB 
diagnostic procedures and treatment, as well as TB treatment success. 
Understanding the complexity of TB burden, the End TB Strategy acknowledges the 
importance of these socio-economic determinants in its target that, by 2020, no TB-
affected family should face catastrophic spending due to TB.5–7  In countries such as 
Indonesia, it is very important that progress towards this target is monitored properly. 
One fundamental step in monitoring progress is preparing a validated tool for measuring 
total patient costs and catastrophic total costs. The World Health Organization (WHO) 
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recommends using a version of the generic questionnaire “The Tool to Estimate Patient 
Costs”7,8 (henceforth referred to as the Generic Tool) that has been adapted to the local 
cultural context in order to interpret findings correctly.9,10 Before Indonesia’s 
implementation of universal health coverage (UHC) in 2014, Van den Hof et al. adapted 
the Generic Tool for use in Indonesia; it was pretested in 2013. For the sake of 
convenience, we refer to this study as the Phase 1 Study.11,12  
However, due partly to the implementation of UHC, various answer categories in the 
Phase 1 Tool (such as those relating to health insurance and healthcare facilities), no 
longer matched the new situation. Also, as pretesting in the Phase 1 Study involved only 
five multi-drug-resistant (MDR) TB patients, a larger sample size was needed to perfect 
the adaptation.  
To monitor progress towards the target of eliminating catastrophic spending on TB in 
Indonesia, the present study aimed to further adapt the questionnaire resulted from the 
Phase 1 Study. 
  
Methods 
Study design 
The adaptation of the Tool consisted of two phases. The first phase had been conducted 
separately by van den Hof et al.12 for a previous Indonesian study (the Phase 1 Study) 
in 2013. Our study (referred to henceforth as the Phase 2 Study) comprised the second 
phase of adapting the Generic Tool. Our study had a cross-sectional design and was 
conducted in 2016. In line with existing guidelines,13,14 the whole process of adaptation 
consisted of seven steps. While the Phase 1 Study went through all the steps from I to 
VII, our Phase 2 Study re-ran steps V to VII, i.e. production of the definitive Bahasa 
Indonesia version of the Tool. (Figure 1) 
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Figure 1 Study design: adaptation of the Tool 
 
Study population 
We interviewed 30 TB patients who had undergone at least one month of TB treatment 
in two sub-district Primary Health Centres (PHCs, Puskesmas), East Jakarta, which 
were Puskesmas Cakung and Puskesmas Jatinegara. We tracked patients registered on 
the TB patient list and chose patients who met the inclusion criteria consecutively from 
the most recent starting date of treatment. In Puskesmas Cakung, we invited TB and 
MDR-TB patients to come to PHC, and interviewed patient coming to the PHC 
consecutively. In three consecutive days, we interviewed 18 patients. In Puskesmas 
Jatinegara, we phoned patients to make an appointment, and visited them at home for 
an interview until reaching 12 TB and MDR-TB patients. If a patient could not be 
interviewed because he/she was unable to communicate or was not available at the time 
of interview, we asked his/her caregiver (termed “drug observer”) to participate in the 
study. This brought the total number of interviewees to 30. 
 
Phase 1 Study 
The principal investigator of the Phase 1 Study was a researcher from the KNCV 
Tuberculosis Foundation in the Netherlands, where the Generic Tool was originally 
developed. The study was prepared in Indonesia together with local researchers, one of 
whom was appointed to prepare for the forward translation into Bahasa Indonesia. 
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Various questions, such as those on insurance types, types of healthcare facility, and 
reimbursement schemes, were adapted to the local context. To check for interpretation 
errors, the questionnaire was back-translated, and then pre-tested on five MDR-TB 
patients at Persahabatan Hospital, in Jakarta.11 Its clarity for patients and interviewers 
was tested. After this pre-testing, further adaptations were made, culminating in the 
final version of the Phase 1 Study Tool. We obtained this final version, and compared 
it with the English Generic Tool.  
 
Phase 2 Study  
In our Phase 2 Study, we further refined this adapted version of the Tool to the current 
Indonesian context. Rather than going through all the steps again, we used the Phase 1 
Study Tool as a starting point for adaptation and began the process at step V (expert 
committee review). Before doing so, we contacted the researchers of the Phase 1 Study 
by telephone and email, and asked their permission to use their version for further 
adaptation. 
  
Expert committee review 
The objective of the expert committee review (step V) was to check the content of the 
Tool once again. For the purpose, we invited key persons to discuss the Phase 1 Tool. 
As well as local researchers, this meeting included the following external experts: a 
pulmonologist specialized in infection, a staff member from the Sub-Directorate for 
Tuberculosis at the Ministry of Health, Republic of Indonesia; and a psychometrics 
expert.  
Before the meeting, the principal investigator – an Indonesian national – made a brief 
report in which he commented on questions and choices in the Generic Tool that 
remained uncertain or could be misinterpreted. The committee then compared the 
Generic Tool and the Phase 1 Study Tool, focusing on various sections in the WHO 
protocol that would need to be adapted to the local context. The adaptations included 
provider type, the TB care-delivery model, socio-demographic variables, net revenue 
from labour-related activities, health insurance and social protection; and household 
assets. In addition to revising these sections, the committee also checked the entire 
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Generic Tool and suggested some changes to the Phase 1 Study Tool. This stage resulted 
in a penultimate version of the Indonesian translation of the tool.  
 
Pre-testing 
In a one-day training before the pre-testing, we trained six medical students to interview 
30 TB and MDR-TB patients or his/her caregiver (if the patient was unable or 
unavailable for interview) in two sub-district PHCs of East Jakarta. After each 
respondent had been interviewed, interviewers reported any difficulties they had 
encountered with regard to completing the tool or to the respondents’ understanding of 
the questions. The researchers also discussed the findings, made changes, and 
formulated the final version of the Tool in Bahasa Indonesia.  
 
Final version 
After pretesting and refinement, we developed the final version of the Tool. We also 
provided comprehensive explanation sheets to guide the interview. 
  
Ethical aspects 
Pre-testing the Tool was part of our main study, which assessed catastrophic total costs 
among TB-affected households. We had obtained ethical approval from the Ethical 
Committee of the Faculty of Medicine, Universitas Indonesia and Cipto 
Mangunkusumo Hospital (No. 416/UN2.F1/ETIK/VI/2016) before the study. Before 
the interview, we provided oral and written explanation to respondents and required 
them to sign informed consent. We ensured the confidentiality of all information 
collected from the interview. 
  
Results 
In total, 72 major changes were made during the adaptation process from the Generic 
Tool to the final version of Study 2 (see Annex A). The adaptations consisted of the 
following: reformulating questions and choices to reflect the current Indonesian 
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context; re-structuring the ordering of several questions; deleting certain questions from 
the Generic Tool; and later restoring questions which had previously been deleted in 
the Phase 1 Study.  
Phase 1 Study involved 60 changes relative to the Generic Tool. As well as the addition 
of two question sets under new sub-topics (moving costs and adverse effect costs), these 
changes included changing question sets into table form, adding seven questions and 
one sub-question, altering five answer choices and two wordings, and deleting three 
question sets (sub-topics) and 33 questions.  
The most important change made in the Phase 1 Study was the overall flow of the Tool. 
In the Generic Tool, the questions are grouped on the basis of the types of cost. This 
required respondents to recall the costs they had incurred back and forth between the 
pre-diagnostic, diagnostic, and treatment phases. To facilitate the flow of interview, the 
Phase 1 Study had re-arranged the flow to match the time sequence. Other prominent 
changes involved redesigning some questions into table form, which made it easier for 
the interviewers to ask them and thereby to complete the Tool.  
During the expert review meeting in Phase 2 Study, we changed the answer choices 
relating to provider type from “Health Post (Pos Kesehatan)”, “PHC (Puskesmas), and 
“district hospital (RSUD)” to “PHC (Puskesmas)”, “private clinic”, “public hospital”, 
“private hospital”, and “other”. With reference to the TB delivery model, we changed 
the term “DOT” (Directly Observed Treatment), which respondents may not know, to 
“visit to take TB drugs” to make it easier for participants to understand the questions. 
In the section with socio-demographic questions, we changed categories relating to 
income payments (paid regularly, uncertain, paid in kind, not paid, and others). We also 
changed a question from “currently formally employed” to “formally employed before 
being diagnosed”, and followed with the question “Did you have to change or quit your 
employment after being diagnosed with TB?”. We restored a question “how many 
people regularly sleep in your household”, and modified it to “how many family 
members live in your household?”. 
As UHC had been implemented in Indonesia since the Phase 1 study, the insurance 
system had changed. Using the abbreviation BPJS to indicate the national health-
insurance agency (Badan Penyelenggara Jaminan Sosial, BPJS), we adapted the types 
of insurance to government-paid BPJS, self-paid BPJS, and private insurance. No 
changes were made to questions in the revenue section. However, we made changes in 
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the costs section, including the type of supplement taken (“drinks” to “milk”); the 
frequency of taking supplementation (from “per month” to “per week”); and the coping 
section (by changing the order of the questions on the amount of money gained from 
selling property). We also changed some wordings to make it easier for participants to 
understand questions, for example changing the term “smear” to “Basil Tahan Asam 
(BTA)”, and “pengembalian asuransi” to “reimbursement asuransi”.  
We retained 38 questions that were the result of adaptations made in the Phase 1 Study. 
We also restored 12 original questions from the Generic Tool that had been changed, 
and five original questions that had been deleted in the Phase 1 Tool. The restored 
questions included “date of first diagnostic examination”, “date of starting treatment”, 
“where did you seek treatment?”, “what symptoms did you experience?”, and “why 
didn’t you go to a public facility?”. We also deleted three questions and three answer 
choices that had been added in the Phase 1 Study. 
  
Pre-testing 
Seventy-four percent of the participants received the Category I therapy regimen; only 7% took 
MDR therapy. The majority (63%) underwent TB treatment in the continuation phase. (Table 
1) 
 
Table 1 Participants characteristics 
Characteristics N %  Characteristics N % 
Participant    Type of TB   
 TB patients 27 90 
 
 Pulmonary, smear + 22 73 
 Drug observers 3 10 
 
 Pulmonary, smear - 7 23 
Sex    
 
Pulmonary, smear 
unknown 
1 4 
 Male 15 50 
 Therapy regimen   
 Female 15 50 
 
 Cat I 22 73 
Age category, years old     Cat II 6 20 
 18-30  5 17 
 
 MDR 2 7 
 31-40 6 20 
 Therapy phase   
 41-50 5 17 
 
 Intensive phase 11 37 
 >50 14 46 
 
 Continuation phase 19 63 
Educational level        
 Low  10 33 
 
    
 Intermediate  20 67 
 
    
 
Chapter 2 
26 
 
The respondents indicated that the majority of questions were clear and easy to 
understand. However, they had problems answering some others. Most respondents 
forgot the date of their first TB examination (63%) and the date they started treatment 
(57%). Neither did they know their HIV status (53%). We therefore added explanatory 
notes for interviewers in the interview guidance. Instead of asking these data to 
participants, interviewers should track the data in the patients’ medical records. 
Respondents had difficulty to estimate transportation costs if they used their own 
vehicle. To deal with that, we guided interviewers to ask transportation-related costs 
such as parking or toll fees, but not fuel costs. 
Many participants received bills from healthcare facilities that stated total amounts 
without any itemization. They had difficulty to distinguish between administration, 
laboratory, X-ray and drug costs. In such cases, we allowed interviewers to enter the 
total amount under administration costs. We deleted sub-questions under hospitalization 
costs and left only one question on total hospitalization costs since participants could 
not detail hospital item costs. If a TB patient had sold property and did not know the 
estimated market value, we added a question “Did the price conform to the estimated 
market value?” and trained interviewers to ask the specific price when participants were 
uncertain about the market value of property they had sold.  
Annex B contains the final version of the questionnaire resulting from our Phase 2 
study, together with the explanatory notes (Annex C). 
  
Discussion 
The Tool was successfully adapted to the current Indonesian context. It is now ready 
for use in similar studies on TB cost measurement and for monitoring progress towards 
the End TB Strategy target. Under the terms of the strategy, the government should 
monitor this target until 2035. Monitoring TB related costs can help identify 
determinants of TB treatment outcomes, and reduce the risk to treatment failure, severe 
adverse outcome, and further spread of TB, MDR-TB, or even XDR-TB because of 
socio-economic problems.2,4,15–17  
In our view, the adapted Tool is suitable for the purpose: it is more comprehensive than 
previous versions and is fully consistent with the situation that has pertained in 
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Indonesia since the implementation of UHC. The Tool can measure not only total costs, 
but – as recommended by the WHO – also catastrophic total costs.7 
As well as the refinements made to the Phase 1 version of the Tool, the strengths of this 
study include the relatively large number of respondents recruited, their wide age-range, 
and the balance between the sexes. A limitation is the fact that we only interviewed 
participants who were undergoing TB and MDR-TB treatment in PHCs. Thereby we 
excluded those who underwent TB treatment in other types of health facility or who 
dropped out of TB treatment. However, this limitation is acknowledged in the WHO 
protocol, which excludes TB patients treated in facilities that are not linked to the 
national tuberculosis program. This means that the adapted Tool is now the most 
appropriate questionnaire for measuring catastrophic total costs. 
The translation that followed from the Phase 1 Study was acceptable and easily 
understood, and there was no need for re-translation from English to Bahasa Indonesia. 
However, difficulties were encountered when seeking appropriate translations for terms 
such “DOT”, “dispensary”, and “mission hospital” that have no specific equivalent in 
Bahasa Indonesia. Another potential source of misunderstanding was how participants 
define “primary income earner” or “pencari nafkah”, which may lead to confusion 
between “pencari nafkah” (primary income earner/breadwinner) and “kepala 
keluarga” (head of family). We therefore inserted an explanation of “primary income 
earner” as the highest earners who actually spent their earnings on financing the 
household.  
In rural or remote areas of Indonesia where Bahasa Indonesia is not used in daily life, 
future studies will need to further adapt the Tool to the cultural context and local 
language. It is imperative that all question items are explained clearly in the local 
languages. 
The adaptation of the tool also provides useful insights for clinical practice. Instead of 
merely focusing on clinical complaints of TB patients, clinicians should also take 
socioeconomic problems into account, including the availability of health insurance, 
traveling costs to visit the health facility, and potential income or job loss faced by the 
patient and their families. Assessing patients’ financial capacity will help clinicians to 
decide on appropriate prescription, including any additional supplements needed. 
Clinicians may also refer patients to existing social protection programs, e.g., national 
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health insurance or national employee insurance, if patients are uninsured, or refer them 
to primary health centers that provide TB diagnostic and treatment freely. 
 
Conclusion 
Our adapted version of the Tool to Estimate Patient Costs proved to be acceptable for 
use in Indonesia. Together with its explanations, it is easily understood by interviewers 
and interviewees. It is ready for use in future studies on tuberculosis-related cost 
estimation and catastrophic spending measurement.  
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Abstract 
 
Background:  
As well as imposing an economic burden on affected households, the high costs related 
to tuberculosis (TB) can create access and adherence barriers. This highlights the 
particular urgency of achieving one of the End TB Strategy’s targets: that no TB-
affected households have to face catastrophic costs by 2020. In Indonesia, as elsewhere, 
there is also an emerging need to provide social protection by implementing universal 
health coverage (UHC). We therefore assessed the incidence of catastrophic total costs 
due to TB, and their determinants since the implementation of UHC. 
Methods:  
We interviewed adult TB and multidrug-resistant TB (MDR-TB) patients in urban, 
suburban and rural areas of Indonesia who had been treated for at least one month or 
had finished treatment no more than one month earlier. Following the WHO 
recommendation, we assessed the incidence of catastrophic total costs due to TB. We 
also analyzed the sensitivity of incidence relative to several thresholds, and measured 
differences between poor and non-poor households in the incidence of catastrophic 
costs. Generalized linear mixed-model analysis was used to identify determinants of the 
catastrophic total costs.  
Results:  
We analyzed 282 TB and 64 MDR-TB patients. For TB-related services, the median 
(interquartile range) of total costs incurred by households was USD 133 (55-576); for 
MDR-TB-related services, it was USD 2804 (1008-4325). The incidence of catastrophic 
total costs in all TB-affected households was 36% (43% in poor households and 25% 
in non-poor households). For MDR-TB-affected households, the incidence was 83% 
(83% and 83%). In TB-affected households, the determinants of catastrophic total costs 
were poor households (adjusted odds ratio [aOR] = 3.7, 95% confidence interval [CI]: 
1.7-7.8); being a breadwinner (aOR= 2.9,95%CI: 1.3-6.6); job loss (aOR= 21.2; 95%CI: 
8.3-53.9); and previous TB treatment (aOR= 2.9; 95%CI: 1.4-6.1). In MDR-TB-
affected households, having an income-earning job before diagnosis was the only 
determinant of catastrophic total costs (aOR= 8.7; 95%CI: 1.8-41.7). 
Conclusions:  
Despite the implementation of UHC, TB-affected households still risk catastrophic total 
costs and further impoverishment. As well as ensuring access to healthcare, a cost-
mitigation policy and additional financial protection should be provided to protect the 
poor and relieve income losses. 
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Background 
The estimated 1.4 million deaths to tuberculosis (TB) in 2015 exemplify the persisting 
burden of TB. With a global incidence that declines by only 2% annually worldwide, 
slow progress is being made towards the target for eliminating the disease by 2035.1,2 
These stark figures show that global action should be taken to adjust strategies and to 
combine initiatives such as promoting clinical adherence and providing socio-economic 
support.3,4 
Although TB patients in most high TB-burden countries have free access to anti-TB 
drugs, they often incur high costs for travel and food, and suffer income losses that can 
amount to over half of annual household income.5,6 Such financial hardship creates an 
adherence barrier to diagnostic procedures and treatment, resulting in poor outcomes 
and increasing the risk of transmission in the community.5-8 Accessing TB-related 
services also has economic consequences. The job or income losses experienced by TB 
patients, especially those in the productive age group, can reduce the financial capacity 
of their households and cast them into the poverty trap.9-11 
To address the socio-economic determinants and financial impact of TB, the WHO End 
TB Strategy acknowledges the need for social protection by setting a clear first 
milestone that no TB-affected families should face catastrophic TB-related costs after 
2020.1,2 This target complements the Sustainable Development Goal (SDG) of 
achieving universal health coverage (UHC) through the provision of more affordable 
and high-quality healthcare services.3,12 
Indonesia started its UHC program in 2014 by offering national public insurance and 
by engaging more private providers in the network managed by the Social Security 
Agency (Badan Penyelenggara Jaminan Sosial, BPJS), the Ministry of Health and the 
Ministry of Social Affairs. It is assumed that direct medical costs, which are costs 
incurred for diagnostic tests, treatment, and follow-up tests, will be reduced by the 
national insurance scheme, which covers all medical costs in primary to tertiary care, 
including TB-related services.13 Due to Indonesians people’s strong preference for 
seeking care with private providers, the involvement of more private providers in the 
BPJS network is also expected to have an impact by reducing medical expenses which 
were reportedly three times higher than those charged by public providers,14 and by 
reducing the number of people who develop TB but are not diagnosed or cannot access 
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TB care services that conform with International Standard of Tuberculosis Care 
(ISTC).9 
Accessing healthcare services is time-consuming and costly.9,10,15-17 The Indonesian 
National TB Program (NTP) has attempted to provide support in the form of 
food/nutritional supplementation and travel vouchers, for example, in addition to 
diagnostic examination and drug costs coverage. However, the policy has changed and 
the support has been restricted or even ended. It leaves direct non-medical costs 
including travel and food/nutritional supplement costs uncovered and can lead to 
catastrophic health expenditure (CHE). As TB and multidrug-resistant TB (MDR-TB) 
require a long period of treatment, and also worsen the health status, TB patients also 
suffer from job or income losses that aggravate the risk of catastrophic costs and barriers 
to treatment adherence. 
The WHO has introduced a new term “Catastrophic total costs” as the TB-specific 
indicator that differs in essence from CHE. CHE is defined as the share of the population 
spending more than a given threshold and focuses on direct cash spending or out-of-
pocket (OOP) payments made by household to improve or restore health of household 
members. The TB-specific indicator of “catastrophic total costs” incorporates direct 
medical costs, direct non-medical costs, and overall indirect costs, and also helps to 
capture the economic burden specific for TB.18,19 It is therefore crucial for TB 
elimination programs to identify the main cost drivers, monitor financial hardship, and 
establish which further health and social policy measures should be taken.18 For this 
reason, we aimed not only to measure the incidence of catastrophic total costs caused 
by TB and the sensitivity of the incidence relative to a range of specific thresholds, but 
also to assess differences between poor and non-poor households in terms of the 
incidence of catastrophic total costs and to identify the determinants of catastrophic 
total costs since Indonesia’s implementation of UHC. 
 
Methods 
Study design 
From July to September 2016, stratified clustered sampling was used to enroll TB 
patients in an urban district (Jakarta), a suburban district (Depok) and a rural district 
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(Tasikmalaya). Per district, we randomly selected 6-8 primary health centers (PHCs) 
linked with the NTP. Until reaching our predetermined sample size, we enrolled all the 
consecutive TB patients who attended these PHCs and who also met our inclusion 
criteria: they were aged 18 years or above, had undergone the adult diagnostic 
procedure, had been treated for at least one month or had finished treatment no more 
than a month previously, and had signed informed consent. Extra-pulmonary TB cases 
were excluded. Assuming a power of 0.80, a 1꞉1꞉1 ratio of urban to suburban to rural 
districts, and that the incidence of TB-related catastrophic total costs in each district 
was 20%, 25%, and 30%, we collected a minimum of 90 patients in each district.  
MDR-TB patients were enrolled at Persahabatan Hospital, an MDR-TB referral hospital 
in Jakarta. We selected those adult MDR-TB patients who came to the hospital 
consecutively, had undergone MDR-TB treatment in the hospital for at least one month, 
had recorded a diagnostic result as MDR-TB, either by GenXpert or sputum culture; 
and had signed the informed consent form. 
  
Cost measurement 
Ten medical students and public health graduates were recruited and trained as 
interviewers. Using the adapted Bahasa Indonesia version of the Tool to Estimate 
Patient Costs, they then interviewed patients and/or their drug observer, i.e., a family 
member who was selected as the patient’s direct-observation-of-treatment supporter.20-
22 Retrospectively, each respondent reported all types of cost related to the TB care 
services they had incurred during the pre-diagnostic, diagnostic, and treatment phases. 
(Table 1) 
 
Pre-diagnostic and diagnostic costs 
The pre-diagnostic and diagnostic costs were the sum of all the direct and indirect costs 
incurred for pre-diagnostic and diagnostic visits. The direct costs included all OOP 
payments incurred after any reimbursement for medical fees and all non-medical 
expenditures made by patients or their guardian (i.e., a family member who 
accompanied them during visits). Indirect costs consisted of the income loss reported 
by patients and guardians.  
 
Chapter 3 
36 
 
Table 1 Definition of costs and income used in this study 
Variables Definition Direct costs Indirect 
costs 
Pre-diagnostic 
and diagnostic 
costs 
All types of cost incurred 
during the period between 
the onset of symptoms and 
diagnosis with TB in public 
or private healthcare 
facilities, at a pharmacy, or 
by a practitioner of 
alternative medicine. 
Medical: Costs of 
consultation, administration, 
laboratory tests, X-ray 
examinations, and drugs. 
Non-medical: Costs of food 
and travel for patient and/or 
guardian. 
Patient’s and 
guardian’s 
income 
losses. 
Treatment 
costs 
All types of cost incurred 
after being diagnosed and 
treated for TB, includes the 
costs of hospitalization and 
adverse events.  
Medical: Costs of 
administration, evaluation 
(laboratory test, X-ray 
examination, or others), 
hospitalization, and adverse 
events. 
Non-medical: Costs of food 
and travel (for patient and/or 
guardian), and food 
supplements. 
Patient’s and 
guardian’s 
income 
losses.  
 
Treatment costs 
The costs of anti-TB drugs are covered by the NTP. We calculated the administration 
or registration fee, food and travel costs that were typical for each visit. To estimate the 
costs per month, we then multiplied these cost items by the number of visits per month. 
Any travel vouchers given to patients were included as a deduction of travel costs. We 
also summed treatment evaluation costs according to the number of evaluation tests 
conducted. We estimated patient’s income losses on the basis of income changes 
reported after diagnosis with TB. To avoid underestimates for people such as taxibike 
drivers who continued to earn uncertain monthly incomes from informal jobs, we also 
estimated time-loss value. To calculate this time-loss value, we used the following 
formula: round trip in minutes for a typical visit × patient’s income loss per minute × 
the number of visits per month.5 
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We interviewed some patients in the intensive treatment phase and others in the 
continuation treatment phase. For patients interviewed during the intensive phase, we 
obtained the reported costs of the intensive phase from the patient and estimated the 
costs in the continuation phase on the basis of the data of other patients in other PHCs 
within a similar district. For patients interviewed during the continuation phase, we 
obtained reported costs from the patient in both the intensive and continuation phases, 
then extrapolated the reported costs to obtain the total costs of both phases. To estimate 
the entire treatment costs, we extrapolated the monthly costs according to the 
internationally defined durations of the intensive and continuation phases: (a) two 
months (for the intensive phase) and four months (for the continuation phase) of new 
TB treatment (Category I); (b) three and five months for re-treatment (Category II), and 
(c) eight and twelve months for MDR-TB treatment.5,23,24 
We summed other direct medical costs, e.g. hospitalization and any adverse event costs, 
that were uncovered by health insurance. We also calculated monthly nutritional/food 
supplement costs incurred by patients, such as vitamins, fruit, milk, meat, or other 
supplements consumed as a result of TB treatment. 
To measure income loss, we established the household income earned through the 
incomes of patients and other family members, through government aid, and through 
other income, before and after the patients had been diagnosed with TB. A household 
earning below USD 1.9 per capita per day was classified as a poor household.25 As 
many Indonesians live in extended families that may have more than one income earner 
per household, we defined a patient as breadwinner if his/her income was at least 10% 
higher than that of any other family member.26,27 All costs and incomes were converted 
to US dollars using the average exchange rate calculated by the World Bank for 2015 
(USD 1 = IDR 13389.41).28 
 
Catastrophic total costs 
The WHO protocol takes two approaches to measuring the percentage of patients 
experiencing catastrophic total costs. The first is based on total costs, and defines 
catastrophic total costs as total costs (direct and indirect costs) incurred by household 
that exceed 20% of the household’s annual income. The second approach defines 
catastrophic total costs as the share of TB patients who experience dissaving by taking 
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a loan or selling property or livestock to deal with costs related to TB[18]. In this study, 
we applied the first approach. Total costs due to TB were defined as the sum of the 
OOPs incurred for medical diagnosis and treatment (OOPM), OOPs for non-medical 
expenditures related to the use of TB care services (OOPNM), and patients’ and 
guardians’ reported income losses or time losses valuations (IN), net of any 
reimbursement and welfare payments. The denominator was reported annual household 
income in the year before diagnosis with TB.18 
𝐼
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As well as measuring the incidence of catastrophic total costs, referred to here as the 
headcount (H), we established the sensitivity of this headcount (i.e. incidence) relative 
to thresholds of 5%, 10%, 15%, 20%, and 25% as used in other previous studies.10,11 
For each threshold, we also calculated mean gap indicators (G) and mean positive gap 
(MPG). The G indicates the average amount by which payments, as a proportion of 
household income, exceed the threshold. The MPG is equal to G/H, and helps to identify 
how excessive the total costs are by indicating the excess expenditure per household 
that experiences catastrophic total costs.7,11,31,32 
To analyze the different pictures provided by the catastrophic total cost approach and 
the CHE approach, we compared the H’s, G’s, and MPGs per threshold between these 
two approaches.29,30 Per threshold, we also analyzed differences between poor and non-
poor households in the H’s, G’s, and MPGs of catastrophic total costs. 
Fourteen patient variables were examined as potential determinants of catastrophic total 
costs: (1) district (urban, suburban, rural), (2) household income (poor and non-poor), 
(3) sex, (4) age group, (5) educational level (primary school as “low,” junior school and 
senior high school as “intermediate”; and college and university as “high”), (6) being a 
family breadwinner, (7) having had an income-earning job before diagnosis, (8) having 
insurance before being diagnosed, (9) having had previous TB treatment, (10) HIV 
status, (11) hospitalization for the current TB treatment, (12) first contact with the 
facility after having symptoms of TB, (13) taking supplementation, and (14) 
experiencing adverse effects. 
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Data analysis 
To ensure data quality, we used Microsoft Excel 2010 and EpiInfo version 7 (CDC, 
Atlanta) to double-enter and to check the data. Abnormally distributed data were 
displayed as median (inter-quartile range [IQR, q25-q75]), while categorical variables 
were shown as numbers and proportions (%). The Mann-Whitney test was used to 
compare all types of the cost incurred for access TB-related services between poor and 
non-poor households.  
We used random effects to adjust for our cluster sampling design (19 PHCs), and used 
the generalized linear mixed model to examine determinants of the incidence with 
which TB-affected households faced catastrophic total costs. For MDR-TB cases, we 
used binary logistic regression to examine the determinants of catastrophic total costs. 
In the univariate analysis, we estimated the significance (P), the crude odds ratios 
(cORs), and their 95% confidence intervals (CIs). To identify the best model and 
estimate the significances, adjusted ORs (aORs) and the 95% CIs of the determinants, 
we included all variables with a P<0.25 in the univariate analysis in a multivariable 
analysis. 
 
Ethical issues 
Before the interview, all respondents received written and oral explanations of the study 
and signed an informed-consent form. Ethical clearance for this study was provided by 
the Ethical Committee at the Faculty of Medicine of Universitas Indonesia–Cipto 
Mangunkusumo Hospital, Jakarta, Indonesia (No. 416/UN2.F1/ETIK/VI/2016) and the 
Ethical Committee at Persahabatan Hospital, Jakarta, Indonesia (No. 
DL.01.03/II.3/3817/2016). 
 
 
Results 
Patients characteristics 
As eight (3%) of the 354 eligible TB and MDR-TB patients did not report their 
household income, we analyzed the data for 346 patients (282 TB and 64 MDR-TB 
patients). (Table 2) Most patients were of working age, had an intermediate educational 
background, and lived in a poor household. Thirty-two percent of the TB patients with 
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an income-earning job had lost their job after diagnosis, against 69% of the MDR-TB 
patients. Less than one-third (23%) of the TB patients in the urban study area did not 
have health insurance, compared with 59% in the rural study area. Most patients had 
smear-positive TB and were divided equally according to the phase of treatment. 
Most TB patients first sought care at primary health center. Our results also show that 
a high proportion of TB patients went first to a private provider; even in rural areas, this 
figure was 46%. Investigation of the reasons for not choosing a public provider showed 
that the distance to the public facility was a prominent issue, as were personal preference 
and familiarity with a specific private facility. (See Annex D) 
 
Table 2 Patient characteristics 
Characteristics 
TB (%) 
MDR-TB 
(%) 
Total  Urban  Suburban Rural  
Sex n=282 n=95 n=90 n=97 n=64 
 Male 155 (55) 51 (54) 52 (58) 52 (54) 31 (48) 
 Female 127 (45) 44 (46) 38 (42) 45 (46) 33 (52) 
Age in years           
 18-40  137 (49) 45 (47) 47 (52) 45 (46) 34  (53) 
 41-64 123 (44) 44 (46) 38 (42) 41 (42) 29 (45) 
 >64 22 (8) 6 (6) 5 (6) 11 (11) 1 (2) 
Educational level            
 Low  99 (35) 25 (26) 18 (20) 56 (58) 12 (19) 
 Intermediate 172 (61) 67 (71) 65 (72) 40 (41) 42 (65) 
 High 11 (4) 3 (3) 7 (8) 1 (1) 10 (16) 
Household income           
 Poor 175 (62) 46 (48) 45 (50) 84 (87) 23 (36) 
 Non-poor 107 (38) 49 (52) 45 (50) 13 (13) 41 (64) 
Breadwinner           
 Patient 124 (44) 48 (51) 38 (42) 38 (39) 25 (39) 
 Not patient 158 (56) 47 (49) 52 (58) 59 (61) 39 (61) 
Income-earning job           
 Yes 201 (71) 73 (77) 61 (68) 67 (69) 49 (77) 
 No 81 (29) 22 (23) 29 (32) 30 (31) 15 (23) 
Job loss           
 Job loss  64 (23) 17 (18) 18 (20) 29 (30) 34 (53) 
 No job loss  218 (77) 78 (82) 72 (80) 68 (70) 30 (47) 
Having health 
insurance 
          
 Yes 176 (62) 73 (77) 63 (70) 40 (41) 56 (87) 
 No 106 (38) 22 (23) 27 (30) 57 (59) 8 (13) 
Insurance type n=176 n=73 n=63 n=40 n=56 
 
BPJS, (paid by 
governmenta) 
119 (68) 52 (71) 33 (52) 34 (85) 24 (43) 
 BPJS, (self-paidb) 53 (30) 19 (26) 28 (44) 6 (15) 32 (57) 
 Private insurance 4 (2) 2 (3) 2 (3) 0 (0) 0 (0) 
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Characteristics 
TB (%) 
MDR-TB 
(%) 
Total  Urban  Suburban Rural  
Monthly income n=201 n=73 n=61 n=67 n=49 
 Paid regularly 90 (45) 32 (44) 39 (64) 19 (28) 34 (69) 
 Uncertain 105 (52) 37 (51) 20 (33) 48 (72) 13 (27) 
 Others 6 (3) 4 (5) 2 (3) 0 (0) 2 (4) 
 n=282 n=95 n=90 n=97 n=64 
Type of TB           
 Pulmonary, smear + 186 (66) 70 (74) 62 (69) 54 (56) 64 (100) 
 Pulmonary, smear - 80 (28) 23 (24) 24 (27) 33 (34) 0 (0) 
 Pulmonary, smear 
unknown 
16 (6) 2 (2) 4 (4) 10 (10) 0 (0) 
Therapy phase           
 Intensive phase 134 (48) 38 (40) 51 (57) 45 (46) 37 (58) 
 Continuation phase 148 (52) 57 (60) 39 (43) 52 (54) 27 (42) 
HIV status            
 Positive 6 (2) 5 (5) 1 (1) 0 (0) 0 (0) 
 Negative 92 (33) 51 (54) 17 (19) 24 (25) 32 (50) 
 Not tested/unknown 184 (65) 39 (41) 72 (80) 73 (75) 32 (50) 
Hospitalization           
 Yes 39 (14) 11 (12) 13 (14) 15 (16) 34 (53) 
 No 243 (86) 84 (88) 77 (86) 82 (84) 30 (47) 
Previous TB treatment           
 Yes 58 (21) 29 (31) 20 (22) 9 (9) 56 (87) 
 No 224 (79) 66 (69) 70 (78) 88 (91) 8 (13) 
Completed previous TB 
treatment  
n=58 n=29 n=20 n=8 n=56 
 Yes 35 (61) 19 (65) 10 (50) 6 (75) 34 (61) 
 No 22 (39) 10 (35) 10 (50) 2 (25) 22 (39) 
First contact           
 
Primary health 
center 
127 (45) 51 (54) 40 (44) 36 (37) 29 (45) 
 Private clinic 94 (33) 26 (27) 26 (29) 42 (43) 2 (3) 
 Public hospital 32 (11) 11 (12) 10 (11) 11 (11) 25 (39) 
 Private hospital 20 (7) 4 (4) 13 (14) 3 (3) 8 (13) 
 Other facility  9 (3) 3 (3) 1 (1) 5 (5) 0 (0) 
aTheir national public insurance (BPJS) premiums were paid by the government; bThey paid national public 
insurance (BPJS) premium out of their pocket.  TB-related total costs 
 
The median (IQR) of total costs was USD 133 in the TB group (55-576) and USD 2804 
in the MDR-TB group (1008-4325). (Table 3)  
 
Chapter 3 
42 
 
         
1
1
(3
-2
1
)
1
2
(4
-2
2
)
1
0
(2
-2
1
)
0
.8
5
7
2
1
(7
-4
7
)
1
5
(5
-3
5
)
2
8
(7
-6
7
)
0
.1
6
4
1
(0
-7
)
1
(0
-7
)
0
(0
-4
)
0
.1
3
6
4
(0
-1
6
)
1
(0
-8
)
5
(0
-1
9
)
0
.1
4
1
P
at
ie
nt
’s
 i
nc
o
m
e 
lo
ss
0
(0
-0
)
0
(0
-2
)
0
(0
-0
)
0
.0
8
9
0
(0
-0
)
0
(0
-0
)
0
(0
-2
)
0
.4
2
8
G
u
ar
d
ia
n’
s 
in
co
m
e 
lo
ss
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.3
9
3
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.6
5
0
1
3
(5
-3
0
)
1
5
(5
-2
9
)
1
2
(3
-3
1
)
0
.7
5
2
7
(1
3
-6
2
)
2
0
(1
1
-3
5
)
3
2
(1
4
-8
5
)
0
.0
4
9
0
(0
-6
)
2
(0
-6
)
0
(0
-3
)
0
.8
5
1
1
5
(0
-7
8
)
9
(0
-6
0
)
1
7
(0
-1
1
6
)
0
.3
2
8
A
d
m
in
is
tr
at
io
n 
co
st
s
0
(0
-2
)
0
(0
-3
)
0
(0
-2
)
0
.4
2
6
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.4
5
4
T
re
at
m
en
t 
ev
al
u
at
io
n 
co
st
s
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.1
0
4
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.1
8
8
H
o
sp
it
al
iz
at
io
n 
co
st
s
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.7
4
8
8
(0
-6
8
)
0
(0
-6
0
)
1
5
(0
-7
8
)
0
.4
9
9
A
d
v
er
se
 e
ff
ec
t 
co
st
s
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.7
3
9
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.8
6
9
3
3
(8
-9
7
)
2
9
(9
-9
0
)
4
0
(8
-1
1
7
)
0
.6
6
6
8
5
6
(4
3
0
-1
4
2
7
)
9
4
1
(4
3
0
-1
2
5
5
)
8
0
7
(4
3
0
-1
5
4
6
)
0
.6
9
0
T
ra
v
el
 c
o
st
s
7
(1
-1
7
)
9
(0
-2
1
)
4
(1
-1
0
)
0
.0
0
4
4
0
3
(1
0
8
-8
0
7
)
4
0
3
(5
4
-8
0
7
)
4
0
3
(1
0
8
-8
0
7
)
0
.4
5
7
F
o
o
d
 c
o
st
s
0
(0
-5
)
0
(0
-6
)
0
(0
-4
)
0
.6
6
2
6
9
(0
-4
5
9
)
2
1
5
(0
-4
0
3
)
2
6
9
(0
-5
3
8
)
0
.4
4
2
F
o
o
d
 s
u
p
p
le
m
en
t 
co
st
s
1
3
(0
-6
7
)
7
(0
-5
4
)
2
0
(0
-9
0
)
0
.6
4
1
1
7
9
(4
-3
4
7
)
1
7
9
(9
0
-4
4
8
)
1
7
9
(0
-2
9
1
)
0
.4
1
6
8
(0
-4
4
8
)
1
1
(0
-3
5
8
)
4
(0
-6
0
2
)
0
.2
3
6
1
3
4
4
(2
-2
5
7
7
)
2
6
9
(0
-1
8
8
2
)
1
7
9
2
(2
0
2
-2
9
1
3
)
0
.0
0
9
P
at
ie
nt
’s
 i
nc
o
m
e 
lo
ss
2
(0
-4
4
8
)
2
(0
-3
5
8
)
1
(0
-6
0
2
)
0
.1
4
3
1
3
4
4
(2
-2
5
7
7
)
2
6
9
(0
-1
6
1
3
)
1
7
9
2
(2
-2
6
8
9
)
0
.0
1
5
G
u
ar
d
ia
n’
s 
in
co
m
e 
lo
ss
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.3
8
0
(0
-0
)
0
(0
-0
)
0
(0
-0
)
0
.4
6
5
T
o
ta
l
1
1
7
(3
3
-5
4
5
)
1
0
8
(3
3
-4
5
1
)
1
3
5
(3
2
-7
8
4
)
0
.3
5
2
2
7
6
0
(9
8
9
-4
3
0
9
)
1
2
4
4
(4
4
8
-3
3
5
2
)
3
4
8
5
(1
8
5
1
-4
6
3
8
)
0
.0
1
2
1
3
3
(5
5
-5
7
6
)
1
3
2
(5
8
-4
9
2
)
1
3
8
(4
5
-7
9
2
)
0
.2
7
7
2
8
0
4
(1
0
0
8
-4
3
2
5
)
1
2
6
8
(4
6
1
-3
3
6
3
)
3
5
0
6
(1
9
1
4
-4
7
9
9
)
0
.0
1
1
P
T
o
ta
l 
c
o
s
ts
In
d
ir
ec
t 
co
st
s
D
ir
ec
t 
no
n-
m
ed
ic
al
 c
o
st
s
T
re
a
tm
e
n
t
D
ir
ec
t 
m
ed
ic
al
 c
o
st
s
In
d
ir
ec
t 
co
st
s
T
o
ta
l
P
o
o
r
N
o
n
-P
o
o
r
P
re
-d
ia
g
n
o
s
ti
c
 a
n
d
 
d
ia
g
n
o
s
ti
c
D
ir
ec
t 
co
st
sC
o
st
s
T
B
P
M
D
R
-T
B
T
o
ta
l
P
o
o
r
N
o
n
-P
o
o
r
T
o
ta
l
T
a
b
le
 3
 C
o
s
ts
 o
f 
p
re
-d
ia
g
n
o
si
s
, 
d
ia
g
n
o
s
is
, 
a
n
d
 t
re
a
tm
e
n
t 
o
f 
T
B
 s
tr
a
ti
fi
e
d
 b
y 
in
c
o
m
e
 a
t 
h
o
u
s
e
h
o
ld
 l
e
v
e
l;
m
e
d
ia
n
 (
IQ
R
) 
in
 U
S
D
 
Catastrophic costs due to TB 
43 
 
The treatment costs amounted to 88% of median total costs for TB patients and 98% for 
MDR-TB patients. (Figure 1) Despite the low medians of indirect costs and patients’ 
income loss, our results show that once patients lost their jobs, they lost a lot of their 
income. Among those who lost their jobs, average income loss amounted to 80% of 
total costs. Instead, the median annual income of TB and MDR-TB patients (USD 1344 
and USD 2241) were much lower than the Indonesian GDP per capita in 2015 (USD 
3834). 
The differences in total costs between poor and non-poor TB patients were not 
statistically significant. However, in non-poor households affected by MDR-TB, the 
total costs were higher than in poor households, due mainly to higher income losses. 
 
Figure 1 Costs incurred for TB-related services. 
Pre-diagnostic and diagnostic costs, treatment costs and total costs between poor and non-
poor patients in (a) TB groups and (b) MDR-TB groups; and costs incurred during treatment 
in (c) TB and (d) MDR-TB affected households. Means are indicated by blue rhombs, 
medians by a horizontal line, q25 by the bottom horizontal line of each box, and q75 by the 
top horizontal line of each box. 
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Catastrophic total costs 
At the 20% threshold, the incidence, i.e. headcount, of catastrophic total costs was 36% 
for TB and 83% for MDR-TB; this was similar to the respective incidences of CHE at 
the 10% threshold (22% and 84%). (Table 4) However, the catastrophic total costs 
approach consistently showed higher mean gaps (G’s) both for TB (10% vs. 4%) and 
MDR-TB (79% vs. 68%) than the CHE approach did. 
 
Table 4 The headcounts of catastrophic costs due to TB and the sensitivity of these headcounts 
Catastrophic costs 
TB MDR-TB 
5% 10% 15% 20% 25% 5% 10% 15% 20% 25% 
Catastrophic total costsa           
 Headcount (%)  50 43 36 31  94 88 83 80 
 Mean gap (%)  14 12 10 8  88 83 79 75 
 Mean positive gap (%)  28 27 27 26  93 95 95 94 
Catastrophic health 
expenditurea 
          
 Headcount (%) 42 22 16 12  94 84 69 61  
 Mean gap (%) 6 4 3 2  72 68 64 60  
 Mean positive gap (%) 14 18 19 17  77 81 93 98  
aCatastrophic total costs approach incorporates all type of costs, i.e. direct medical costs, direct non-
medical costs, and overall indirect costs,  while the CHE approach focuses only on direct cash 
spending or OOP payments made by household. 
 
There was an inverse association between catastrophic total costs and household 
income. Although their median total costs were not significantly different, poor TB-
affected households, which had lower incomes, had higher headcounts than non-poor 
households (43% vs. 25%, P= 0.006 when using the threshold of 20%). (Table 5) The 
differences in incidence of catastrophic total costs between poor and non-poor 
households were also statistically significant with the thresholds of 10% (P=0.014), 
15% (P=0.006), and 25% (P=0.009). For MDR-TB, the incidence of catastrophic total 
costs was similar for poor and non-poor households, irrespective of the threshold used. 
At the same time, the G’s indicated that poor households suffered more than non-poor 
households (138% vs. 45% when using threshold of 20%). As the MPGs indicated, the 
gap was greater in poor households that faced catastrophic total costs (167%). 
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Table 5 Differences between poor and non-poor households in catastrophic total costs 
Catastrophic total costs 
TB MDR-TB 
10% 15% 20% 25% 10% 15% 20% 25% 
Headcount         
 Poor (%) 57 50 43 37 96 87 83 78 
 Non-poor (%) 39 32 25 22 93 88 83 81 
 Total (%) 50 43 36 31 94 88 83 80 
 P 0.014 0.006 0.006 0.009 0.111 0.117 0.115 0.121 
Mean gap         
 Poor (%) 18 15 13 11 147 142 138 134 
 Non-poor (%) 8 6 5 3 54 50 45 41 
 Total (%) 14 12 10 8 88 83 79 75 
Mean positive gap         
 Poor (%) 32 30 30 30 154 164 167 171 
 Non-poor (%) 19 19 18 16 58 56 55 51 
  Total (%) 28 27 27 26 93 95 95 94 
 
Determinants of catastrophic total costs 
With regard to catastrophic total costs among TB-affected households, there were four 
determinants: poor household (adjusted odds ratio [aOR] = 3.7; 95% confidence interval 
[CI]: 1.7-7.8; P=0.001); breadwinners (aOR= 2.9; 95%CI:1.3-6.6; P=0.010); job loss 
(aOR= 21.2; 95%CI: 8.3-53.9; P<0.001); and previous TB treatment (aOR= 2.9; 
95%CI:1.4-6.1; P=0.006). (Table 6) Not being covered by health insurance was not a 
determinant of catastrophic total costs in either TB-affected or MDR-TB-affected 
households.  
 
Table 6 Determinants of catastrophic total costs in TB cases 
Determinants 
  
Catastrophic total 
costs 
P 
  
cOR (95%CI) 
  
P 
  
aOR (95%CI) 
  
Yes % No % 
Household income         
 Poor 75 43 100 57 0.006 2.20 (1.26-3.86) 0.001 3.68 (1.74-7.78) 
 Non-poor 27 25 80 75  1.00  1.00 
District         
 Urban 35 37 60 63  1.00   
 Sub-urban 22 24 68 76 0.125 0.54 (0.25-1.19)   
 Rural 45 46 52 54 0.317 1.47 (0.69-3.16)   
Sex         
 Male 57 37 98 63 0.710 1.10 (0.66-1.82)   
 Female 45 35 82 65  1.00   
Age, years old         
 18-40 49 36 88 64  1.00   
 41-64 44 36 79 64 0.977 0.99 (0.59-2.67)   
 >64 9 41 13 59 0.816 1.12 (0.43-2.90)   
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Determinants 
  
Catastrophic total 
costs 
P 
  
cOR (95%CI) 
  
P 
  
aOR (95%CI) 
  
Yes % No % 
Educational level         
 Low 41 41 58 59  1.00   
 Intermediate 58 34 114 66 0.355 0.78 (0.45-1.33)   
 High 3 27 8 73 0.479 0.60 (0.14-2.51)   
Breadwinner         
 Patient 65 52 59 48 <0.001 3.60 (2.16-6.00) 0.010 2.92 (1.29-6.60) 
 Not patient 37 23 121 77  1.00  1.00 
Income-earning job         
 Yes 90 45 111 55 <0.001 4.66 (2.38-9.14) 0.881 1.08 (0.40-2.92) 
 No 12 15 69 85  1.00  1.00 
Job loss         
 Job loss  51 80 13 20 <0.001 
14.07 (6.84-
28.93) 
<0.001 
21.17 (8.31-
53.90) 
 No job loss  51 23 167 77  1.00  1.00 
Health insurance         
 No 43 41 63 59 0.390 1.26 (0.74-2.15)   
 Yes 59 34 117 66  1.00   
HIV status         
 Negative 44 48 48 52  1.00   
 Positive 0 0 6 100 0.953 0.00 (0.00-~)   
 Not 
tested/unknown 
58 32 126 68 0.863 0.46 (0.26-0.82)   
Previous TB 
treatment 
        
 Yes 31 53 27 47 0.001 2.93 (1.56-5.48) 0.006 2.86 (1.35-6.05) 
 No 71 32 153 68  1.00  1.00 
First contact with 
facility 
        
 Private facility 46 37 77 63 0.622 1.14 (0.68-1.89)   
 Public facility 56 35 103 65  1.00   
Hospitalization         
 Yes 15 38 24 62 0.685 1.16 (0.56-2.38)   
 No 87 36 156 64  1.00   
Food supplement         
 Yes 65 34 126 66 0.370 0.78 (0.5-1.3)   
 No 37 41 54 59  1.00   
Adverse effect         
 Yes 53 43 71 57 0.029 1.77 (1.06-2.95) 0.089 1.77 (0.92-3.40) 
 No 49 31 109 69  1.00  1.00 
cOR, crude Odds Ratio; aOR, adjusted Odds Ratio 
 
With regard to MDR-TB-affected households, the multivariable analysis showed that 
the only determinant of catastrophic total costs in these households was having had an 
income-earning job before diagnosis (aOR= 8.7; 95%CI: 1.8-41.7; P=0.007). (Table 7)  
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Table 7 Determinants of catastrophic total costs in MDR-TB cases  
Determinants 
Catastrophic total 
costs P cOR (95% CI) P aOR (95%CI) 
Yes % No % 
Household income         
 Poor 19 83 4 17 0.974 0.98 (0.25-3.88)   
 Non-poor 34 83 7 17  1.00   
Sex         
 Male 27 87 4 13 0.383 1.82 (0.48-6.95)   
 Female 26 79 7 21  1.00   
Age in years         
 18-40 28 82 6 18  1.00   
 >40 25 83 5 17 0.917 1.07 (0.29-3.95)   
Educational level         
 Low 9 75 3 25  1.00   
 Intermediate 35 83 7 17 0.515 1.67 (0.36-7.76)   
 High 9 90 1 10 0.378 3.00 (0.26-34.58)   
Breadwinner         
 Patient 21 84 4 16 0.840 1.15 (0.30-4.41)   
 Not patient 32 82 7 18  1.00   
Income-earning 
job 
        
 Yes 44 90 5 10 0.012 5.87 (1.47-23.47) 0.007 8.68 (1.81-41.70) 
 No 9 60 6 40  1.00  1.00 
Job loss         
 Job loss  34 100 0 0  1.00   
 No job loss 19 63 11 37 0.998 0.00 (0.00-~)   
Health insurance         
 Yes 46 82 10 18  1.00   
 No 7 87 1 13 0.709 1.52 (0.17-13.79)   
HIV status         
 HIV negative 28 87 4 13  1.00   
 HIV not 
tested/unknown 
25 78 7 22 0.331 0.51 (0.13-2.01)   
Previous TB 
treatment 
        
 Yes 47 84 9 16 0.534 1.75 (0.29-2.01)   
 No 6 75 2 25  1.00   
First contact 
facility 
        
 Private facility 10 100 0 0 0.266 
8.66 (0.19-
403.74) 
  
 Public facility 43 80 11 20  1.00   
Hospitalization         
 Yes 30 88 4 12 0.235 2.27 (0.58-8.91) 0.090 3.92 (0.81-19.01) 
 No 23 77 7 23  1.00  1.00 
Food supplement         
 Yes 41 84 8 16 0.741 1.28 (0.29-5.77)   
 No 12 80 3 20  1.00   
Adverse effect         
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Determinants 
Catastrophic total 
costs P cOR (95% CI) P aOR (95%CI) 
Yes % No % 
 Yes 38 86 6 14 0.270 0.47 (0.13-1.79)   
 No 15 75 5 25  1.00   
cOR, crude Odds Ratio; aOR, adjusted Odds Ratio 
 
Discussion 
Despite the implementation of UHC in Indonesia, the country still has a high incidence 
of catastrophic total costs due to TB, particularly among patients who live in poor 
households and those who lose their jobs due to TB. In general, the greatest contribution 
to total costs was made by travel and food/nutritional supplementation costs. However, 
losing both job and income after diagnosis was also a critical point: once patients had 
lost their jobs, income loss became the main driver of total costs. These findings 
emphasize the importance not only of providing travel and nutritional supports but also 
social protection for those who lose income due to TB. 
Unlike CHE, the catastrophic total costs approach which incorporates direct medical 
costs, direct non-medical costs, and overall indirect costs highlights the impact of 
income loss. It also provides a clearer description of the severity of the financial impact 
than the CHE approach does. This is indicated by the consistently higher mean gap in 
the TB and MDR-TB groups.  
The determinants of catastrophic total costs shown in this study highlight both the 
magnitude of the problem of income loss and the need to address it properly. As well 
as aggravating barriers to TB treatment adherence, thereby potentially worsening TB 
outcomes, income loss increases the risk of catastrophic costs and even greater 
impoverishment. If a TB patient is the family breadwinner, the incidence of catastrophic 
total costs is doubled.  
In MDR-TB patients, coming from a poor household was not a determinant of 
catastrophic total costs. We had assumed that most MDR-TB cases would come from 
poor households, but this proportion was in fact very low. Overall, the incidence of 
catastrophic total costs was also very high: irrespective of their income level, over half 
of MDR-TB-affected households experienced such costs.   
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As our findings provide insights that contrast with the perspective of CHE, they provide 
a new basis for estimating costs, and may thus have policy implications. As well as 
supporting the WHO’s recommendation that the catastrophic total costs approach 
should be used, the main implication of our study is a strong recommendation to 
government that it should introduce a cost-mitigation policy and additional social 
protection beyond free medical services.5,22 Forms of financial protection other than 
food/nutritional supplementation and travel vouchers may be required. Cash transfers 
could be made conditional on behavioral requirements such as continuing treatment. 
Microfinance programs are also a potential form of financial support,33,34 but this 
strategy requires complex and expensive inputs. The government should target 
beneficiaries carefully, ensure the delivery to patients, provide incentives that induce 
patients to adhere to treatment, and should therefore consider reserving a budget that is 
large enough. As well as emphasizing financial incentives, it is imperative to tackle any 
stigma and discrimination in workplaces that can lead to income loss. The government 
should also strengthen the policy by supporting job protection or paid sick leave for 
formally employed TB patients. 
The high incidence of catastrophic total costs among poor patients requires inputs 
within the UHC framework. The government should incorporate strategies for widening 
population coverage, for improving the availability, accessibility, and quality of public 
health facilities; and also for involving as many private health facilities as possible in 
the BPJS network. To conform with the ISTC, they should also ensure proper training. 
This study has several limitations. First, in line with the WHO protocol, we collected 
data from TB patients who visited PHCs and excluded those who were treated in 
facilities that were not linked to the NTP. Neither did we include TB nor suspected TB 
patients who were unable to afford TB-related services or who dropped out of the 
diagnostic procedure or out of treatment. This may have led to an underestimation of 
the incidence of catastrophic total costs. Second, MDR-TB patients were only recruited 
in a pulmonary hospital in an urban area with a low proportion of poor households. We 
did not describe a situation in which patients were removed from the hospital to PHCs 
for taking MDR-TB drugs after sputum conversion, and dropped out from treatment. 
Third, although we interviewed patients with a structured questionnaire to help recall 
their spending, our findings may have been affected by recall biases. Finally, while our 
study results apply to the western part of Indonesia such as Java, Bali, and Sumatra, 
which constitute 80% of the Indonesian population,35 some parts of Indonesia may have 
Chapter 3 
50 
 
different characteristics that require careful generalization, especially the islands and 
more remote areas.  
 
Conclusions 
Both TB and MDR-TB patients are in danger of falling into even deeper poverty. Travel 
costs, food/nutritional supplementation costs, and income loss all contribute to the 
incidence of catastrophic total costs. This risk is higher in patients from poor 
households, especially when they are breadwinners who lose their jobs. These findings 
suggest that measures beyond free medical services are required to mitigate the financial 
burden of households affected by TB, particularly for patients living in at-risk groups. 
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Abstract 
 
Background:  
Although tuberculosis (TB) patients often incur high costs to access TB-related 
services, it was unclear beforehand whether the implementation of universal health 
coverage (UHC) in Indonesia in 2014 would reduce direct costs and change the pattern 
of care-seeking behaviour. After its introduction, we therefore assessed TB patients’ 
care-seeking behaviour and the costs they incurred for diagnosis, and the determinants 
of both. 
 
Methods:  
To assess their care-seeking behaviour, we interviewed adult TB patients in three areas 
of Indonesia – one urban, one suburban and one rural – in July-September 2016. All 
had been treated for at least one month. After establishing which direct and indirect 
costs they had incurred during the pre-diagnostic phase, we calculated the total costs 
(US Dollars). To identify the determinants of these costs, we applied a general linear 
mixed model to adjust for our cluster-sampling design. 
 
Results:  
Ninety-three patients of the 282 included in our analysis (33%) first sought care at a 
private clinic. The preference for such clinics was higher among those living in the rural 
district (aOR 1.88, 95% CI 0.85-4.15, P=0.119) and among those with a low educational 
level (aOR 1.69, 95% CI 0.92-3.10, P=0.090). Visiting a private clinic as the first 
contact also led to more visits (β 0.90, 95% CI 0.57-1.24, P<0.001) and higher costs 
than first visiting a Primary Health Centre, both in terms of direct costs (β=16.87, 
95%CI 10.54-23.20, P<0.001) and total costs (β=18.41, 95%CI 10.35-26.47, P<0.001).  
 
Conclusion: 
Despite UHC, high costs of TB seeking care remain, with direct medical costs 
contributing most to the total costs. First seeking care from private providers tends to 
lead to more pre-diagnostic visits and higher costs. To reduce diagnostic delays and 
minimize patients’ costs, it is essential to strengthen the public-private mix and reduce 
the fragmented system between the national health insurance scheme and the National 
TB Programme. 
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Background 
Studies in Asian countries suggest that the private healthcare sector has the potential to 
play an important role in national and global tuberculosis (TB) control.1-4 Many studies 
have shown that patients initially visit private providers to relieve them from TB-related 
symptoms.5 In Indonesia, many patients also prefer first to seek care from private 
providers [4]. However, private providers often fail to comply with TB practice 
guidelines, including those for the screening and diagnosis of TB cases.4,6 In the pre-
diagnostic phase, failure to comply with TB practice guidelines may lead to missed TB 
cases. Patients who continue to have TB related symptoms then have many healthcare 
visits,7 leading to diagnostic delays and high costs during seeking care.8,9 This 
eventually worsens disease prognosis at the individual level, increases costs in the 
household level, and spreads TB in the community.8,10  
In 2014, Indonesia started implementing a universal health coverage (UHC) scheme, 
also called the Indonesian National Health Insurance scheme (Jaminan Kesehatan 
Nasional, JKN), to ensure people’s access to healthcare. This insurance scheme is 
managed by the Social Security Agency for Health (Badan Penyelenggara Jaminan 
Sosial Kesehatan, BPJS-K) and covers all essential care services, including TB 
diagnostic tests through healthcare providers that are linked to the BPJS-K.9,11 In the 
first four years after the JKN was implemented, the number of private providers linked 
to the BPJS-K – clinics and solo practices alike – increased substantially, from 6,369 
private providers to 11,507.12  
However, BPJS-K is not directly linked to the network of the Indonesian National 
Tuberculosis Program (NTP), which are national level government boards that are 
responsible for TB control. Private providers that are linked to the BPJS-K are therefore 
also not necessarily linked to the NTP. Responding to this problem, the NTP launched 
a guideline of TB care to coordinate the care with the BPJS-K.13 Although there has 
been no direct linkage between the NTP and BPJS-K, the private providers that are 
linked with BPJS-K can conduct the TB tests in their laboratories, if available, or can 
refer suspected TB patients for diagnostic tests to a BPJS-K-linked facility.13 All 
consultation and diagnostic test fees are covered by the BPJS-K. If the suspected patient 
has received the final TB diagnosis, the private providers can refer the patient to the 
NTP-linked facilities to receive free TB treatment. As most TB patients seek initial care 
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with a private provider,6 this coordinated scheme between BPJS-K and the NTP is 
assumed to reduce patient’s direct costs during the pre-diagnostic phase. 
Nevertheless, there is no evidence available on the costs incurred during the pre-
diagnostic phase of TB and TB patients’ care seeking behaviour since the 
implementation of UHC in Indonesia. It is therefore unclear to which extent UHC has 
saved patients from high costs during this phase. The aims of this study are to assess 
the costs incurred before diagnosis by patients seeking care for TB after the 
implementation of UHC in Indonesia, and to assess care-seeking behaviour of TB 
patients in this period on the basis of the first contact facility and the number of 
healthcare visits.  
 
Methods 
Study design and setting 
To assess patients’ TB care-seeking behaviour and the costs they incurred during the 
pre-diagnostic phase, we conducted a cross-sectional study that was a part of a larger 
study on measuring catastrophic costs in Indonesia [9]. In this study, we interviewed 
patients who had undergone TB treatment in PHCs (i.e. public facilities for primary-
level care). We selected three districts in Java, the most populous island of Indonesia, 
purposively to represent urban (Jakarta), suburban (Depok), and rural (Tasikmalaya) 
areas of Indonesia.  
 
Study population 
We included all subjects who met the inclusion criteria of our main study, which were 
adult patients who had received TB treatment in a PHC for at least one month. We 
excluded extra-pulmonary cases, as these are diagnosed using different methods that 
may result in bias on pre-diagnostic costs. 
 
Sampling method 
The sample size and sampling methods in this study followed that of our larger study, 
which assumed an incidence of catastrophic costs due to TB of 20-30%.9 With 
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assumptions of a power of 0.80, an error of 0.05, and a ratio of TB patients of 1:1:1 in 
each district, we required 90 patients per district. In each district, we included all the 
PHCs that were linked to the Indonesian NTP in our sampling framework, and then 
randomly selected five PHCs per district. We chose only PHCs since most of TB 
patients were treated in PHCs. In each PHC, we selected consecutive adult TB patients 
until we reached at least 90 patients per district. If the sample size was not reached, we 
randomly selected additional PHCs until we obtained at least 90 patients per district. In 
total, 19 PHCs were included in our study. 
 
Data collection  
All patients were interviewed by four medical students and six public health graduates 
we had recruited and trained for the purpose. As a part of our main study on measuring 
catastrophic costs, the interview was conducted during the TB treatment phase – 48% 
of patient in their intensive phase and 52% of patients in their continuous phase.9 To 
interview the patients and/or the drug observer who accompanied each patient as a direct 
observation of treatment (DOT) supporter, these interviewers used the adapted and 
validated Bahasa Indonesia version of the Tool to Estimate Patient Costs.14  
Retrospectively, each respondent listed each healthcare facility he or she had visited 
between developing TB-related symptoms (e.g., chronic cough, bloody cough, weight 
loss, or night sweating) and the establishment of their TB diagnosis.14 We also 
calculated the number of healthcare visits and costs incurred during the pre-diagnostic 
phase, and then assessed the determinants of the number of visits and costs.  
 
Care seeking behaviour 
First, to assess patients’ care-seeking behaviour, we established the nature of their first 
contact facility, i.e., a primary health centre (PHC); a private clinic (whether a solo 
practice or part of a multiple practice); a public hospital; a private hospital; or ‘other’, 
such as a pharmacy, a practitioner of alternative medicine, or a mantri (i.e., a registered 
nurse practicing as an unauthorized physician). We then assessed whether the first 
contact facility was associated with the district (urban/suburban/rural), household 
income level (poor/non-poor household), educational level (low/middle-high), health 
Chapter 4 
58 
 
insurance status (being covered/not being covered by the BPJS-K scheme), and formal 
employment (yes/no).  
 
Number of visits 
Second, we calculated the number of healthcare visits made during the pre-diagnostic 
phase. To assess the determinants of the number of visits, we also included first contact 
as an independent variable, together with the other independent variables.  
 
Costs of care seeking 
Third, we asked patients the details of all the types of cost they had incurred in each 
facility visited during the pre-diagnostic phase, i.e., direct medical costs, direct non-
medical costs, and indirect costs related to seeking care for their TB-related symptoms. 
The definitions of cost items used in this study conformed with the WHO handbook on 
TB costs survey.15 The direct medical costs included all out-of-pocket (OOP) payments 
to the healthcare facilities for medical fees, such as administrative charges and the cost 
of drugs, laboratory analyses, or X-ray examinations. The direct non-medical costs 
included the cost of food and travel for patients and/or their guardian during their visits 
to healthcare facilities. The indirect costs consisted of loss of income incurred by the 
patients and their guardians on their visits to healthcare facilities. The total costs were 
the sum of direct medical costs, direct non-medical costs, and indirect costs. All costs 
were provided in Indonesian Rupiahs (IDR) and then converted to US dollars using the 
World Bank’s average exchange rate for 2015 (1 USD = 13 389.41 IDR). We then 
assessed whether the total costs, direct costs, and indirect costs were associated with the 
first contact, district, household income level, educational level, health insurance status, 
and formal employment.  
 
Data management and analysis 
Data were double-entered into Microsoft Excel 2010 and EpiInfo version 7 (CDC, 
Atlanta) and then exported to IBM SPSS 21 for data analysis. Number of visits and 
costs data were displayed as means and their 95% confidence intervals (CIs) while 
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categorical variables as numbers and proportions (%). To examine the determinants of 
the patients’ first contact facility, the number of visits, and their costs during the pre-
diagnostic phase, we applied the generalized linear mixed models (GLMMs) with 
random effects to adjust for our cluster sampling design (19 PHCs), since we selected 
the PHCs randomly. We assessed the goodness of fit for models by examining the 
Akaike corrected and the Bayesian information criterion provided by SPSS. To analyse 
the determinants of the first health-service contact, we estimated crude odds ratios 
(cORs), adjusted odds ratios (aORs), and their 95% CIs with a target distribution of 
multinomial regression. To analyse the determinants of number of visits and costs 
incurred by patients and their family, we established crude and adjusted GLMM 
regression coefficients (β) and their 95% CIs with a target distribution of linear 
regression. 
 
Ethical issues 
Before the interview, we provided all respondents with a written and oral explanation 
of the study. Only those who had signed an informed consent form were interviewed. 
Before the study, we received ethical clearance from the Ethical Committee at the 
Faculty of Medicine of Universitas Indonesia–Cipto Mangunkusumo Hospital, Jakarta, 
Indonesia (No. 416/UN2.F1/ETIK/VI/2016). 
 
Table 1 First point of care and place of TB diagnosis of a sample of 282 TB patients. 
Healthcare service 
First point  
of care 
Place of 
diagnosis 
n % N % 
Primary health centre 127 45 164 58 
Private clinic 93 33 43 15 
Public hospital 32 11 50 18 
Private hospital 20 7 25 9 
Other health provider*  10 4 0 0 
*Pharmacy, practitioner of alternative medicine, mantri, or other health provider. 
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Results 
We included the interviews of 282 patients. Whereas a PHC had been the first point of 
diagnostic care-seeking for 45% of them, 33% had first sought care at a private clinic, 
11% at a public hospital, 7% at a private hospital, and 4% at a pharmacy, practitioner 
of alternative medicine, or other healthcare provider. (Table 1) A majority of patients 
(58%) had been diagnosed at a PHC. The remainder had been diagnosed at a private 
clinic (15%), public hospital (18%), or private hospital (9%) before they were referred 
to PHCs for TB treatment.  
Figure 1 shows the most common care-seeking patterns identified in this study. 
Seventeen percent of patients had been diagnosed during their first visit at PHC. This 
was higher than the percentage of patients who had been diagnosed during their first 
visit to any of the other healthcare settings. All patients who had first sought care at a 
pharmacy, practitioner of alternative medicine or other healthcare provider had moved 
to another provider – usually a private clinic – for their second visit. 
 
Figure 1 The care-seeking pattern of TB patients onwards of their first contact. 
The figure shows the top 10 care-seeking patterns that followed the first contact with each of the 
following: (a) a PHC, (b) a private clinic, (c) a public hospital, (d) a private hospital, and (e) a pharmacy, 
practitioner of alternative medicine, or other health provider. Each coloured block indicates the type of 
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healthcare provider visited. Each rightmost box indicates the provider where the TB diagnosis was 
confirmed. The percentages to the right of each graph are the percentages of each patterns. Eighteen 
percent of patterns are not captured in these graphs. 
 
Table 2 shows that in the urban and suburban districts, more patients initially sought 
care at a PHC than at another healthcare facility. In contrast, among patients with low 
education level, the proportion of those who initially sought care at a private clinic was 
higher than at another healthcare facility. 
 
Table 2 Distribution of patients by point of first contact. 
Characteristics 
Primary 
health centre 
N (%) 
Private 
clinic 
N (%) 
Public 
hospital 
N (%) 
Private 
hospital 
N (%) 
Other 
health 
provider† 
N (%) 
Total 
Number of patients 127 (45) 93 (33) 32 (11) 20 (7) 10 (4) 282 (100) 
Districts       
 Urban 51 (54) 26 (27) 11 (12) 4 (4) 3 (3) 95 (100) 
 Suburban 40 (44) 25 (28) 10 (11) 13 (14) 2 (2) 90 (100) 
 Rural 36 (37) 42 (43) 11 (11) 3 (3) 5 (5) 97 (100) 
Household income 
level‡ 
      
 Non-Poor 51 (48) 30 (28) 12 (11) 13 (12) 1 (1) 107 (100) 
 Poor 76 (43) 63 (36) 20 (11) 7 (4) 9 (5) 175 (100) 
Education level±       
 Middle-High 89 (49) 50 (27) 22 (12) 15 (8) 7 (4) 183 (100) 
 Low 38 (38) 43 (43) 10 (10) 5 (5) 3 (3) 99 (100) 
National health 
insurance 
      
 Not covered 48 (44) 41 (37) 8 (7) 7 (6) 6 (5) 106 (100) 
 Covered 79 (46) 52 (30) 24 (14) 13 (8) 4 (2) 176 (100) 
Workers in informal 
sectors 
      
 No 41 (51) 25 (31) 7 (9) 5 (6) 3 (4) 81 (100) 
 Yes 86 (43) 68 (34) 25 (12) 15 (7) 7 (3) 201 (100) 
† Pharmacy, alternative medicine, mantri, and other health providers; ‡ household earning below 1.9 
USD per capita per day was classified as a poor household; ± a patient who did not graduate from 
elementary school was classified as having low education level. 
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Table 3 shows that more patients in the rural district preferred to seek care first at a 
private clinic (cOR 2.27, 95% CI 1.14-4.53, P=0.020). Seeking inital care at a private 
provider rather than a PHC was also greater among patients with a low educational level 
than among those with a middle to high educational level (cOR 1.93, 95% CI 1.09-3.41, 
P=0.024). Despite the borderline statistical significance of the result, multivariable 
analysis showed that the odds of seeking care at a private clinic rather than at a PHC 
was higher in the rural district (aOR 1.87, 95% CI 0.85-4.15, P=0.119) and in patients 
with low education level (aOR 1.69, 95% CI 0.51-1.65, P=0.090). There were no 
statistically significant differences regarding first contact preferences for the following: 
between patients with insurance and without insurance; between patients living in a 
poor household and a non-poor household; and between patients with and without 
formal work. 
 
Table 3 Determinants of the first point of health-service contact (private clinic or primary health 
centre). 
Characteristics 
Private 
clinic 
N (%) 
PHCa 
N (%) 
P cOR (95% CI) P aOR (95% CI) 
Districts       
 Urbana 26 (27) 51 (54)  1  1 
 Suburban 25 (28) 40 (44) 0.557 1.24 (0.60-2.55) 0.462 1.32 (0.63-2.76) 
 Rural 42 (43) 36 (37) 0.020 2.27 (1.14-4.53) 0.119 1.88 (0.85-4.15) 
Household income 
level‡ 
      
 Poor 63 (36) 76 (43) 0.355 1.32 (0.74-2.35) 0.824 1.07 (0.57-2.01) 
 Non-Poora 30 (28) 51 (48)  1  1 
Education level±       
 Low 43 (43) 38 (38) 0.024 1.93 (1.09-3.41) 0.090 1.69 (0.92-3.10) 
 Middle to higha 50 (27) 89 (49)  1  1 
National health 
insurance 
      
 Covered 52 (30) 79 (46) 0.468 0.81 (0.46-1.43) 0.768 0.92 (0.51-1.65) 
 Not covereda 41 (37) 48 (44)  1  1 
Workers in 
informal sectors 
      
 Yes 68 (34) 86 (43) 0.364 1.32 (0.72-2.41) 0.284 1.40 (1.76-2.58) 
  Noa 25 (31) 41 (51)   1   1 
aReference category; ‡ household earning below 1.9 USD per capita per day was classified as a poor 
household; ± a patient who did not graduate from elementary school was classified as having low 
education level. 
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The average number of visits during the pre-diagnostic phase was 2.56 (95% CI 2.41-
2.71). Patients who first sought care at private clinics and other health care providers 
had more visits until their diagnosis was confirmed than patients who first visited a PHC 
(aβ 0.90, 95% CI 0.57-1.24, P <0.001 for private clinics and aβ 1.77, 95% CI 0.97-2.57, 
P <0.001 for other health care providers). (Table 4). There were no statistically 
significant differences in the number of visits regarding the following determinants: 
district, household income level, educational level, having insurance, and employment 
status.  
Table 4 Determinants of the number of healthcare visits during the pre-diagnostic phase. 
Variables 
No of visits  
mean (95% CI) 
cβ (95% CI) P aβ (95% CI) P 
Total number of visits 2.56 (2.41-2.71)     
First contact facility      
 Primary Health 
Centre 
2.18 (1.96-2.41) Ref 
 
Ref 
 Private clinic 3.06 (2.83-3.30) 0.89 (0.57-1.22) <0.001 0.90 (0.57-1.24) <0.001 
 Public hospital 2.13 (1.77-2.48) -0.07 (-0.55-0.41) 0.766 -0.08 (-0.56-0.41) 0.750 
 Private hospital 2.65 (2.06-3.24) 0.44 (-0.14-1.02) 0.140 0.39 (-0.20-0.99) 0.194 
 Other health 
provider 
3.9 (2.66-5.14) 1.70 (0.91-2.49) <0.001 1.77 (0.97-2.57) <0.001 
District  
    
 Urban 2.49 (2.18-2.63) Ref 
 
Ref 
 
 Suburban 2.63 (2.37-2.90) 0.21 (-0.29-0.70) 0.406 0.17 (-0.31-0.66) 0.484 
 Rural 2.56 (2.34-2.78) 0.11 (-0.39-0.62) 0.667 -0.05 (-0.57-0.48) 0.861 
Household income 
level‡ 
 
    
 Poor 2.58 (2.38-2.77) 0.07 (-0.25-0.40) 0.656 0.02 (-0.34-0.31) 0.927 
 Non-poor 2.53 (2.29-2.78) Ref 
 
Ref 
 
Education level±  
    
 Low 2.66 (2.39-2.92) 0.16 (-0.17-0.49) 0.336 0.14 (-0.22-0.43) 0.526 
 Middle-high 2.51 (2.32-2.70) Ref 
 
Ref 
 
National health 
coverage 
 
    
 Covered 2.58 (2.37-2.79) 0.07 (-0.25-0.39) 0.673 0.18 (-0.13-0.49) 0.259 
 Not covered 2.53 (2.32-2.74) Ref 
 
Ref 
 
Workers in informal 
sectors 
 
    
 Yes 2.55 (2.37-2.72) -0.07 (-0.41-0.27) 0.692 -0.12 (-0.44-0.21) 0.480 
  No 2.59 (2.29-2.90) Ref 
 
Ref 
 
β is the GLMM coefficient of the expected change in the number of visits compared to the reference category; cβ, 
crude coefficient β; aβ, adjusted coefficient β; CI, confidence interval; Ref, reference; P, value of significance; ‡ 
household earning below 1.9 USD per capita per day was classified as a poor household; ± a patient who did not 
graduate from elementary school was classified as having low education level. 
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The average total cost incurred during the pre-diagnostic phase was USD 22 (95% CI 
18-26). It consisted mainly of direct costs (USD 16, 95% CI 13-19). (Table 5) Visiting 
a private clinic as the first point of contact led to statistically significantly higher costs 
than visiting a PHC as the first contact, both in terms of direct costs (β 16.87, CI 95% 
0.54-23.20, P<0.001) and of total costs (β 18.41, CI 95% 10.35-26.47, P<0.001). 
Patients who visited a private hospital as the first contact also incurred statistically 
significantly higher direct costs (β 28.38, CI 95% 17.18-39.58, P<0.001) and total costs 
(β 24.96, CI 95% 10.64-39.28, P=0.001) than those visiting a PHC as the first contact. 
The direct medical costs incurred by patients who first sought care at private clinics 
(USD 21; 95% CI USD 15-28) and private hospitals (USD 32; 95% CI USD 17-48) 
were significantly higher than those who first sought care at PHCs (USD 5; 95% CI 
USD 3-7), while travel costs between private providers and PHCs did not differ 
significantly (See Annex E).  
Despite involving a higher number of visits, first visiting a pharmacy, practitioner of 
alternative medicine or other health provider did not lead to significantly higher costs 
than those incurred by patients who first sought care at a PHC. Between districts, 
insurance coverage, household income level, and education level, the differences in the 
total costs, direct costs, and indirect costs incurred were not statistically significant. 
Indirect costs during the pre-diagnostic phase were associated with employment status. 
In addition, patients who were formally employed had higher indirect costs than patients 
who did not have a job or were not formally employed (β 3.92, CI 95% 0.88-6.96, 
P=0.012). No other variables determined the indirect costs.  
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Discussion 
Our results show that patients still incur high costs while seeking TB care. Direct 
medical costs contributed most to the total costs of TB care seeking, despite the 
implementation of UHC in Indonesia. Most patients who were treated for TB in a PHC 
had started their care-seeking in private sector. The number of those who first sought 
care at a private clinic first was significantly greater among patients who lived in the 
rural district and among those with a lower educational level. Before being diagnosed 
with TB, patients who had first sought care at such clinics made more healthcare visits 
and had higher costs than those whose first point of contact was a PHC.  
Rural patients’ preference for starting to seek care at a private clinic may have been 
affected by the greater distance they had to travel to a PHC. The number of PHCs in 
these areas is limited, the cost of transport to them is higher, and the waiting times can 
be long.16 This encourages patients to visit any private healthcare provider – whether 
clinic, solo practice or other – that is closer to their house. 
However, to have their diagnosis of TB confirmed, patients whose first point of contact 
was a private clinic needed more visits than those who first visited a PHC. This higher 
number of visits may have been due to the poorer TB-service readiness of private 
clinics, most of which – particularly private solo practices – do not have appropriate 
facilities for TB diagnostic tests, i.e., a laboratory for sputum smear examination.17 To 
solve this problem, we suggest that most clinics use sputum smear fixation and deliver 
the preparation for diagnosis to a referral PHC or a clinic linked with the BPJS-K.13 
Our findings also suggest that seeking care first at a private clinic or private hospital led 
to significantly higher costs during the pre-diagnostic phase. Except when covered by 
health insurance, each visit to a private hospital is costly.18,19 This explains why, despite 
the limited number of visits, high costs were incurred at private hospitals. However, 
while the high cost of private clinics sometimes resulted from the high costs per visit, it 
also may be resulted from a high number of visits or from a combination of both.  
Patients who first sought care at a pharmacy, practitioner of alternative medicine or 
other healthcare provider had a higher number of visits than those who started care-
seeking at PHCs. However, this high number of visits did not lead to significantly higher 
costs for diagnosis. This may have been because the costs of simple, generic medicine 
in a pharmacy or of consultations for alternative medicine were low. 
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Despite the implementation of UHC in Indonesia, excessive visits and costs during the 
pre-diagnostic phase remain. Although this study did not compare the situation before 
and after the implementation of UHC, we showed that there were no significant 
differences in number of visits and costs between patients who were and were not 
covered by national health insurance.  
Excessive visits and costs can result in diagnostic delays, potential catastrophic costs 
during treatment, and poor outcome.10,20 To prevent high number of visits and high 
costs, the integration between the national health insurance and the NTP, which is still 
fragmented, should be improved.21 Currently, there has been no direct link between the 
national health insurance system and the NTP. Private providers – despite linked to the 
BPJS-K – often unaware of the national tuberculosis guidelines and of TB referral 
system under the NTP.4 The current practice of TB current guidelines in private 
providers seems not optimal. There has been also lack of incentives from the national 
health insurance to improve the quality of TB care in private sector.22 Therefore, 
comprehensive strategies are imperative.  
To solve the fragmented system in TB care, the national health insurance needs to 
develop a mechanism of incentives whereby private physicians and clinics can screen 
and diagnose TB cases accurately and refer the case to facility where TB diagnostic 
tests and treatment are fully covered. In its pay-for-performance criteria,22 for example, 
BPJS-K should include the quality of the TB services a clinic provides. A contract of 
service provision that is signed between the BPJS-K and private providers should 
consider the readiness of the TB services including the availability of diagnostic tests, 
the adherence with TB management guidelines, and prior attendance of TB training. In 
addition, the strategies should include efforts to increase patients’ awareness, to reduce 
stigma and discrimination, to improve TB diagnostic options, and to increase the 
number of PHCs in rural districts.  
This study has two main limitations. The first is our collection of data from patients 
who had ended up at a PHC for TB treatment, and thus our exclusion of those who had 
had TB treatment from a private provider. This may have led us to overestimate PHCs 
as the first point of contact and to underestimate the number of pre-diagnostic visits and 
the costs incurred during the pre-diagnostic phase. It may also have led to a misleadingly 
high figure for the number of visits – by at least one visit – by patients whose first point 
of care had not been a PHC, particularly if this visit had involved a healthcare provider 
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that could not itself diagnose TB. The second limitation is that, since we relied on 
patients’ memory to obtain the information, the number of visits and the costs incurred 
may also have been affected by recall bias. A patient may not remember the frequency 
and cost of buying medicine in a drug store or pharmacy, and thereby underestimate the 
number of visits and the total pre-diagnostic costs.  
The provision of TB services in Indonesia is similar to health-service delivery in other 
high TB-burden countries in Asia that need to improve their public-private mix. 
However, our findings require careful generalization before being applied to other 
countries or even to other regions of Indonesia. As this study was conducted only on 
the island of Java, it does not necessarily reflect the situation throughout Indonesia.  
 
Conclusion 
Despite the UHC, high costs of TB seeking care remain, with direct medical costs 
contributing most to the total costs. The preference of people with TB first to seek 
diagnosis from a private provider rather than a PHC leads to more pre-diagnostic visits 
and higher costs. The UHC scheme alone is not enough to improve TB control and 
reduce patients’ costs. A comprehensive strategy is required to improve TB-related 
services in the private healthcare sectors. To reduce diagnostic delays and minimize 
patients’ costs, it is essential to reduce the fragmented system between the national 
health insurance scheme and the National TB Programme, to improve the quality of TB 
care in the private sector, and to improve the availability of PHCs, particularly in rural 
areas.  
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Abstract 
 
Background:  
While the incidence of catastrophic costs due to tuberculosis (TB) remains high, there 
is little evidence about their impact on TB treatment outcomes and adherence. We 
assessed their effect on treatment outcomes and adherence in Indonesia. 
  
Methods:  
We interviewed 282 adult TB patients who underwent TB treatment in urban, suburban, 
and rural districts of Indonesia. One year after the interview, we followed up treatment 
adherence and outcomes. We applied multivariable analysis using generalized linear 
mixed models. 
  
Results:  
Follow-up was complete for 252/282 patients. Eighteen (7%) patients had unsuccessful 
treatment and 40 (16%) had poor adherence. At a threshold of 30% of annual household 
income, catastrophic costs negatively impacted treatment outcomes (aOR=4.15, 
95%CI=1.15-15.01). At other thresholds, the associations showed a similar pattern, but 
were not statistically significant. The association between catastrophic costs and 
treatment adherence is complex because of reverse causation. After adjustment, 
catastrophic costs negatively affected treatment adherence at the 10% and 15% 
threshold (aOR=2.11, 95%CI=0.97-4.59, P=0.059 and aOR=2.06, 95%CI=0.95-4.46, 
P=0.07). At other thresholds, there was no evidence of such an effect.  
 
Conclusions:  
Catastrophic costs negatively affect TB treatment outcomes and treatment adherence. 
To eliminate TB, it is essential to mitigate catastrophic costs.  
 
Keywords: Catastrophic costs, Indonesia, Treatment adherence, Treatment outcomes, 
Tuberculosis. 
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Introduction 
Tuberculosis (TB) often result in severe economic consequences for TB-affected 
households.1 The latest World Health Organization (WHO) End TB Strategy aims by 
2020 to reduce to zero percent the percentage of TB-affected families that face 
catastrophic costs.2 However, attaining this target is challenging. In a simulation of eight 
scenarios, Fuady et al. showed  that, although the provision of a cash transfer to TB-
affected households would reduce the incidence of catastrophic costs due to TB, the 
incidence would not reach the zero-percent target.3 This failure is due to the high 
variability of costs between TB patients, particularly those due to income loss. If the 
value of cash transfer provided were the same for all patients, it would not be possible 
to eliminate catastrophic costs. This finding raises the question of whether eliminating 
catastrophic costs –apart from its importance as a proxy of poverty– is a rational target 
to be achieved.  
There are various definitions of catastrophic costs. Given that eliminating the incidence 
of catastrophic costs is a target of the WHO End TB Strategy, the definition of TB-
related catastrophic costs issued by the WHO is the most appropriate to use. The latest 
TB costs survey handbook of the WHO defines catastrophic costs as the total costs—
i.e., all direct and indirect costs, including income loss, that exceed a specific threshold 
of a household’s annual income.4 In Peru, Wingfield et al. showed that TB-related 
catastrophic costs were associated with adverse TB outcomes and suggested a threshold 
of 20% of annual household income to define catastrophic costs.5 However, there is a 
paucity of evidence from other countries, especially from TB high-burden countries. 
Indonesia is such a TB high-burden country. Despite the availability of free treatment, 
Indonesia has a high incidence of TB-related catastrophic costs: 36% in TB-affected 
households and 83% in MDR-TB-affected households.6 Income loss is the main driver 
of these costs. Catastrophic costs during the course of treatment may affect treatment 
adherence and treatment outcomes. Patients may quit treatment altogether or they may 
interrupt it and thereby extend it, and –as a consequence– they may fail to be cured, or 
may even die during treatment. There is nonetheless no evidence on the impact of 
catastrophic costs on TB treatment outcomes and treatment adherence from this high-
burden country. We aimed to establish the extent to which catastrophic costs in TB-
affected Indonesian households affect TB treatment outcomes and adherence.  
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Material and methods 
Study design 
To assess the effect of catastrophic costs on patients’ TB treatment adherence and 
outcomes, we conducted a cohort study in three districts in Indonesia, each with a 
different level of urbanization: Jakarta (urban), Depok (suburban), and Tasikmalaya 
(rural). In each district, we identified all primary health centers (PHCs) that delivered 
TB treatment services and were also linked to the Indonesian national tuberculosis 
program (NTP). For inclusion in our study, we randomly selected 5-8 PHCs per district. 
In total, 19 PHCs were included. In the baseline study (July-September 2016), we 
interviewed 282 TB patients aged 18 years old or above who had undergone TB 
treatment for at least one month, or had completed treatment no more than one month 
previously.6 One year after the interview, we followed up their TB treatment adherence 
and TB treatment outcomes. We excluded TB patients whose treatment had not been 
evaluated, and patients who had been transferred to other health facilities. 
 
Treatment outcome and adherence 
As the WHO had set treatment outcome as an essential indicator in TB control 
programs,7 treatment outcome was the primary outcome measured in this study. To 
evaluate patients’ treatment outcomes, we examined their medical records (TB 01 
forms) and cross-checked the data with the PHCs’ TB record (TB 03 form). We used 
the definitions and classification of treatment outcome issued by the WHO, defining 
treatment outcome as successful if a patient had been cured or had completed TB 
treatment, and as unsuccessful if a patient had been lost to follow-up, had died, or if the 
treatment had failed.8 (Table 1)  
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Table 1 Primary and secondary outcomes in this study 
Outcomes Definition 
Primary outcome: treatment outcomes 
Successful treatment The sum of cured and completed TB cases. 
a. Cured A TB patient who had a positive sputum smear or culture at 
the beginning of TB treatment but had a negative sputum 
smear or culture in the last month of treatment and on at least 
one previous occasion. 
b. Completed A TB patient who completed treatment but who, in the last 
month of treatment and on at least one previous occasion, 
did not have any proof of a negative sputum smear or culture 
result. 
Unsuccessful treatment Died, failed, or lost to follow-up. 
a. Died A TB patient who died for any reason during the course of 
treatment.  
b. Failed A TB patient who still had a positive sputum smear or 
culture after 5 months or more of TB treatment. 
c. Lost to follow-up A TB patient whose treatment had been interrupted for two 
consecutive months or more. 
Secondary outcome: treatment adherence 
a. Good treatment 
adherence 
A patient who treatment had been successful and whose 
treatment period had not exceeded the expected end-of-
treatment date by 14 days or more. 
b. Poor treatment 
adherence 
Sum of patients whose treatment period had exceeded the 
expected end-of-treatment date by 14 days or more than, 
plus cases lost to follow-up. 
 
Since catastrophic costs are also assumed to reduce treatment adherence, we evaluated 
treatment adherence as a secondary outcome. However, there is no commonly agreed 
definition of TB non-adherence. By defining non-adherent patients as those who had 
missed at least one prescribed dose of TB drug, some studies use stringent criteria,9, 10 
while other criteria are less stringent, such as having interrupted treatment for more than 
one month, or never having been under supervision.11-15 We defined poor adherence as 
applying (a) to a patient who had been lost to follow-up— indicating that he or she had 
not adhered to treatment— or (b) to a patient whose treatment had been successful, but 
the treatment period had exceeded the expected end-of-treatment date by 14 days or 
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more. To assess the effect of catastrophic costs on treatment adherence, we excluded 
patients who had died and those whose treatment had failed. 
 
Catastrophic costs 
In the baseline study, we interviewed patients about the total TB-related costs their 
household had incurred since the pre-diagnostic phase until the patients stopped 
treatment. We used the Tool to Estimate Patient Costs that has been adapted to the 
Indonesian context.4, 16 In compliance with the definition in the WHO handbook, total 
costs consisted of direct medical costs (i.e., administration costs, laboratory tests and 
X-ray examination costs, drug costs, hospitalization costs, and adverse drug-effects 
costs); direct non-medical costs (i.e., transportation costs, food costs, and the costs of 
food supplements); and income loss.4  
To calculate administration costs and food costs, we multiplied the number of visits by 
the administration fees and food costs incurred during visits. To measure the total 
transportation costs, we multiplied single travel costs for a return visit by the number of 
visits during treatment. The number of visits was recorded in the patient’s medical 
record. If these data were missing or if a patient had become lost to follow-up, we 
calculated costs on the basis of patients’ average number of visits to the same PHC.  
Income loss was estimated on the basis of the monthly income change reported in the 
baseline study. The monthly income change was calculated as the difference in income 
between that received before TB diagnosis and that received at the time of the interview. 
The monthly income loss was multiplied by the number of months patients had 
undergone TB treatment. Patients who earned an uncertain monthly income from jobs 
in the informal sector, such as taxi-bike drivers, often were unable to provide exact 
information on changes from one month to the next. To avoid underestimating the 
income loss of these patients, we used the human capital approach to estimate their 
income loss.4 We collected the self-reported time that patients took to seek and receive 
healthcare and the hourly rate the patient working in the informal sector normally 
charged for his/her informal work. We used the following formula to obtain total 
income loss: return trip in minutes for a typical visit × patient’s income loss per minute 
× the number of visits over the course of treatment.  
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Patients may quit treatment due to their actual or expected future financial burden. Some 
patients, may therefore not experience catastrophic costs at the time they quitted 
treatment, but would have experienced such costs if they had continued until treatment 
completion. For patients who were lost to follow-up, we therefore extrapolated the 
direct and indirect costs by multiplying their direct unit cost by the average number of 
visits of patients treated in the same PHC. To extrapolate their income loss, we 
multiplied their monthly income loss by the number of months in a standard period of 
full treatment. 
In addition to TB-related costs, patients also reported their monthly household income. 
Per patient, we calculated annual household income in the year before he or she had 
been diagnosed with TB. We calculated total costs as a share of annual household 
income, which was displayed as a proportion (%). If the proportion exceeded a specific 
threshold, e.g., 30%, we defined this as catastrophic costs.17  
 
Statistical analyses 
First, we analyzed the association between catastrophic costs (as independent variable) 
and treatment adherence and treatment outcomes (as dependent variables) using 
generalized linear mixed models (GLMM) with a logit link function, generating crude 
odds ratios (cORs) for these associations. We used random effects to adjust for our 
cluster-sampling design (19 PHCs). To determine the threshold at which catastrophic 
costs affect treatment outcomes and adherence, we ran the analysis using various 
thresholds, i.e., 10%, 15%, 20%, 25%, 30%, and 35%. The threshold at which 
catastrophic costs were statistically significantly associated with treatment outcomes 
and treatment adherence was used for further analyses.  
Next, we examined whether confounding had produced the association observed in the 
univariate analysis between catastrophic costs, treatment outcomes, and treatment 
adherence. To assess whether the effect of costs had been confounded by other 
variables, we decided a priori to include all potential confounders for which we had 
data (i.e., age, sex, district, education, previous TB treatment, initial sputum result, 
hospitalization, and adverse drug effect). To obtain adjusted ORs (aORs) and 95% CIs, 
the potential confounders were analyzed simultaneously in a multivariable analysis. 
Since catastrophic costs incorporate income in their calculation, we did not include 
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household income level, breadwinner, and job-loss variables as potential confounders 
in our multivariable analysis.  
To assess the contribution of catastrophic costs to unsuccessful treatment outcomes in 
the population, we also estimated the population-attributable fraction (PAF) for our 
study population. This was calculated as [Ppop x (OR-1)] / [Ppop x (OR-1) + 1], where 
Ppop was the proportion of exposed subjects in the entire study population, and OR was 
the odds ratio of catastrophic costs to unsuccessful treatment outcomes obtained from 
the multivariable analysis.  
Poor treatment adherence in this study included patients who had been lost to follow-
up and patients whose treatment period had been prolonged. As prolonged treatment 
may lead to higher direct and indirect costs (e.g. more healthcare visits, higher income 
loss), it may be the cause rather than the consequence of catastrophic costs. In our 
univariate and multivariable analyses, we therefore examined whether the association 
between catastrophic costs and treatment adherence was due to reverse causation. To 
do so, we simulated cost data for patients with a prolonged treatment period by adjusting 
their number of visits to the average number of visits of patients treated in the same 
PHC, and, on the basis of their expected end-of-treatment date, by the number of months 
they had lost income. After recalculating the costs, we compared (1) the incidence of 
catastrophic costs between the actual costs and recalculated costs, and (2) the effect of 
catastrophic costs on treatment outcomes. No such reverse effects were expected for 
patients who had been lost to follow-up, for patients whose treatment had failed, or for 
patients who had died, as these patients’ TB treatment had not been prolonged.  
All data were cleaned and analyzed using IBM SPSS 21.18 Costs and income data were 
entered in Indonesian Rupiah (IDR) and were then converted to US Dollars (USD) using 
the average exchange rate for 2016 (USD 1 = IDR 13,389.41).19  
 
Results 
One year after patients had been interviewed, the medical records of 27 patients were 
missing and could not be tracked for reasons such as storage relocation, the renovation 
of a PHC building, and change of several persons in charge of the TB program in PHCs. 
Three patients had moved to other healthcare facilities. In our analyses, we included 
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252 (89.4%) of the 282 subjects who had been interviewed in 2016 and whose treatment 
outcome and adherence had been recorded in 2017. (Figure 1) 
 
 
Figure 1 Number of subjects in one-year cohort 
 
TB treatment had been successful for 234 patients (93%). Over half of all patients 
(n=141, 56%) were cured, as indicated from sputum smear conversion from a positive-
smear to a negative-smear at the end of treatment, while 93 patients (37%) had 
completed the treatment without proof of smear conversion. Treatment had been 
unsuccessful in 18 patients (7%): three patients had failed, two patients had died, and 
13 had been lost to follow-up. Most patients (n=207, 84%) had good treatment 
adherence. The treatment period had been prolonged in 27 patients (11%), and thirteen 
patients (5%) had been lost to follow-up. Treatment outcome had been successful in all 
patients with a prolonged treatment period.  
Most patients lived in a poor household (61%), had an income-earning job (74%), had 
smear-positive TB (66%), and had undergone Category 1 TB treatment (the first-line 
treatment for susceptible TB patients who have not previously received TB treatment, 
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88%). (Table 2) The median of total costs incurred by the patients was USD 118 (IQR 
455). The median of total costs as a share of annual household income was 9% (IQR 
25%). The incidences of catastrophic costs were 46%, 38%, 33%, 26% and 22% at a 
threshold of 10%, 15%, 20%, 25%, and 30% of annual household income, respectively. 
 
Table 2 Sociodemographic, clinical characteristics, and costs incurred by patients. 
Characteristics N %  Characteristics N % 
Sociodemographic n=252  Clinical characteristics  
Age (years)  
 Category of treatment  
 18-40  126 (50%) 
 
 Category 1 222 (88%) 
 41-60  93 (37%) 
 
 Category 2 30 (12%) 
 >60  33 (13%) 
 Result of initial sputum test  
Sex  
 
 Positive 167 (66%) 
 Male 135 (54%) 
 
 Negative 85 (34%) 
 Female 117 (46%) 
 Was hospitalized  
Household income level†  
 
 Yes 34 (13%) 
 Poor 153 (61%) 
 
 No 218 (87%) 
 Non-Poor 99 (39%) 
 Experienced adverse drug effect(s)  
Education level  
 
 Yes 4 (2%) 
 Low 87 (35%) 
 
 No 248 (98%) 
 Middle 154 (61%) 
 
    
 High 11 (4%) 
 
    
Patient as breadwinner   Costs  
 Yes 114 (45%) 
 Total costs, USD, median (IQR) 118 (455) 
 
No 138 (55%)  
Costs as a share of annual income,  
%, median (IQR) 
9 (25) 
Patient had earned money 
before diagnosis  
 Incidence of catastrophic costs 
 
 Yes 187 (74%) 
 
 Threshold of 10% 117 (46%) 
 Fixed payment 83 (33%) 
 
 Threshold of 15% 97 (38%) 
 Uncertain 99 (39%) 
 
 Threshold of 20% 83 (33%) 
 Others 5 (2%) 
 
 Threshold of 25% 66 (26%) 
 No 65 (26%) 
 
 Threshold of 30% 55 (22%) 
Experienced job loss‡ n=187   Threshold of 35% 44 (17%) 
 Yes 73 (39%)      
 No 114 (61%)      
† Household income was divided into two groups, poor and non-poor, on the basis of the World Bank 
definition that a household is as defined poor if the income per capita per day is < USD 1.9. ‡ The 
percentages were calculated for those who had had an income-earning job before diagnosis. 
 
Our univariate analysis suggests that the odds of unsuccessful treatment outcomes were 
around 2 to 3 times higher for patients experiencing catastrophic costs compared with 
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patients not experiencing catastrophic costs at thresholds of 10%, 25% and 30% of 
annual household income. (Table 3) Nevertheless, the association was only statistically 
significant at the 0.05 level when using the 30% threshold (cOR 3.32, 95% CI 1.13-
9.69, P=0.03).  
 
Table 3 Associations between catastrophic costs and unsuccessful TB treatment outcome. 
Catastrophic costs 
Unsuccessful 
treatment† 
cOR (95% CI) P aOR (95% CI)‡ P 
Threshold of 10%      
 Yes 12/117 (10.3) 2.60 (0.87-7.80) 0.09 2.59 (0.78-8.63) 0.12 
 No 6/135 (4.4) 1  1  
Threshold of 15%      
 Yes 10/97 (10.3) 2.21 (0.76-6.38) 0.14 2.31 (0.72-7.47) 0.16 
 No 8/155 (5.2) 1  1  
Threshold of 20%      
 Yes 8/83 (9.6) 1.74 (0.61-4.97) 0.30 1.80 (0.55-5.88) 0.33 
 No 10/169 (5.9) 1  1  
Threshold of 25%      
 Yes 8/66 (12.1) 2.65 (0.92-7.69) 0.07 
3.03 (0.89-
10.31) 
0.08 
 No 10/186 (5.4) 1  1  
Threshold of 30%      
 Yes 8/55 (14.5) 3.32 (1.13-9.69) 0.03 
3.86 (1.11-
13.38) 
0.03 
 No 10/197 (5.1) 1  1  
Threshold of 35%      
 Yes 2/44 (4.5) 0.53 (0.11-2.51) 0.42 0.53 (0.10-2.86) 0.46 
 No 16/208 (7.7) 1  1  
†Displayed as the number (and percentage) of patients with unsuccessful treatment among those who 
experienced or did not experience catastrophic costs. ‡Displaying aORs of unsuccessful treatment 
comparing patients with and without catastrophic costs after adjustment for all potential confounders 
for which we had information (i.e., age, sex, district, education, previous TB treatment, initial sputum 
result, hospitalization, and adverse drug effect).  
 
After adjustment for potential confounders in a multivariable analysis, catastrophic 
costs at a threshold of 30% remained statistically significantly associated with 
unsuccessful treatment outcomes. At this threshold, the odds of unsuccessful treatment 
outcomes were 3.86 times higher (95% CI 1.11-13.38, P=0.03) in patients who had 
experienced catastrophic costs than in patients who had not. Using this adjusted odds 
ratio, the PAF was 38.6%, meaning that 38.6% of unsuccessful treatment outcome cases 
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were attributable to catastrophic costs. At the 10%-25% thresholds, the pattern of 
associations was similar, with estimated odds ratios of around 2 to 3, but these 
associations were not statistically significant at conventional levels. 
Our univariate analysis also suggests that catastrophic costs (at thresholds of 10%-25%) 
were associated with poor treatment adherence: the odds of poor adherence were 
approximately twice as high in patients who had experienced catastrophic costs as in 
those who had not. (Table 4) However, these findings were statistically significant at 
the 0.05 level only when using the 15% threshold. At this threshold, the odds of poor 
adherence among patients who had experienced catastrophic costs were 2.12 times 
higher (95% CI 1.01-4.45, P=0.046) than in those who had not. None of the other 
variables were statistically significantly associated with poor treatment adherence.    
The association between catastrophic costs and poor treatment adherence was partly 
due to reverse causation. In other words, prolonged treatment had contributed to 
catastrophic costs. We evaluated the extent of reverse causation by conducting a 
simulation analysis for patients with prolonged treatment period. When we assumed 
that patients with extended treatment duration had finished their treatment on time, the 
strength of the association between catastrophic costs and treatment adherence fell, at 
the 15% threshold from cOR 2.12 to 1.87, at the 25% threshold from cOR 1.94 to 1.35, 
and at the 20% threshold from cOR 1.88 to 1.47. When also adjusting for potential 
confounders, catastrophic costs at the 10% and 15% thresholds were associated with a 
two-times higher odds of poor adherence compared to patients without catastrophic 
costs (aOR 2.11, 95% CI 0.97-4.59, P=0.059 and aOR 2.06, 95% CI 0.95-4.46, P=0.07). 
At other thresholds, we have no evidence of such an effect.  
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Discussion 
Our study shows that catastrophic costs can have a negative impact on treatment 
outcome. Generally, the odds of an unsuccessful treatment outcome were around two 
to four times higher among patients who experienced catastrophic costs compared with 
those who had not. While our findings were statistically significant at a threshold for 
catastrophic costs of 30%, there was an indication that this may also be the case at 
thresholds between 10% and 25%. The association between catastrophic costs and poor 
treatment adherence was more complex. Poor adherence can lead to higher costs. After 
adjustment for such reverse causation, we found that catastrophic costs at the 10% and 
15% threshold were associated with an around two times higher odds of poor treatment 
adherence compared to patients who had not experienced such costs, with no effect at 
other thresholds. 
While there is currently no agreement on the specific threshold of catastrophic costs for 
research and policy-making, various studies have defined this threshold as 20% of 
annual household income, as suggested by the WHO through their taskforce.3, 16, 20 
However, there is little evidence on whether use of this threshold accurately reflects the 
effect of catastrophic costs on treatment outcomes and treatment adherence. Until now, 
the only study which assessed the association between catastrophic costs and poor 
treatment outcome was the Peruvian study (2014) which it suggested a threshold of 
20%.5 The study included multidrug-resistant (MDR)-TB patients who incurred higher 
costs, and in that study, MDR-TB was found to be one of the determinants of poor 
outcomes. Different from the Peruvian study, our study focused on susceptible TB 
patients. We found that, at a 30% threshold, catastrophic costs lead to poor treatment 
outcomes, which, in our study, mostly consisted of patients who were lost to follow-up.  
At a lower threshold (15%) catastrophic costs were associated with poor treatment 
adherence (prolonged treatment period or lost to follow-up). This association was due 
partly to reverse causation. Patients who did not adhere to their treatment course had to 
catch up with it, either under the orders of the PHC health staff (in order to comply with 
NTP program guidelines), or because they were self-motivated and wished to minimize 
the risk of recurrence. The additional visits needed to complete the full treatment course 
led to higher costs and greater income loss, which in some cases led to catastrophic 
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costs. At the same time, even after accounting for such reverse causation, catastrophic 
costs still negatively affected treatment adherence at thresholds of 10%-15%. Due to 
the size of our study and lack of statistical power, although there is indication of a 
similar effect at the thresholds of 20-30%, we need to be cautious to draw firm 
conclusion with respect to these levels. 
With regard to future global policy, our study provides evidence that can inform a 
review of the threshold at which catastrophic costs should be measured. If these 
catastrophic costs are thought to affect patient adherence, the threshold of 15% of 
annual household income, might be considered to define catastrophic costs. When 
considering TB treatment outcomes, the threshold of 30% of annual household income, 
might be used to define catastrophic costs. Nevertheless, as also suggested by the 
WHO,20 the threshold for defining catastrophic costs may vary between countries, and 
should be carefully assessed from one setting to the next.   
This study is the first cohort study on TB-related catastrophic costs, treatment 
adherence, and treatment outcomes in Indonesia. Although we collected data from 
urban, suburban, and rural areas of Indonesia, all these areas were located on the island 
of Java, which is home to 60% of the Indonesian population. Our findings may not 
therefore apply directly to eastern Indonesia and to the country’s other remote areas, 
where healthcare facilities are scarcer—a factor that may affect treatment outcomes and 
treatment adherence. Similarly, as our study was conducted only in PHCs, its findings 
may underestimate the costs of the treatment given by private providers (which are 
assumed to be higher), while simultaneously overestimating treatment adherence, 
which may be lower among patients who are treated by private providers.21 It is also 
uncertain whether our findings will apply to TB high-burden countries in which TB 
service delivery is different. Finally, the precise effect estimates in our study remain 
uncertain due to the limited sample size of the study. While our study is the first to 
provide evidence for Indonesia on the effects of catastrophic costs on treatment 
outcomes and treatment adherence, and one of the very few studies that do so for TB 
high-burden countries more generally, larger studies are warranted.  
We conclude that catastrophic costs negatively impacted TB treatment outcomes and 
TB adherence at the various thresholds of annual household income. This highlights the 
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need for TB control interventions to properly address both the clinical and socio-
economic aspects of the disease. 
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Abstracts 
Background:  
The World Health Organization’s End Tuberculosis Strategy states that no 
tuberculosis (TB)-affected households should endure catastrophic costs due to 
TB. To achieve this target, it is essential to provide adequate social protection. 
As only a few studies in many countries have evaluated social-protection 
programs to determine whether the target is being reached, we assessed the effect 
of financial support on reducing the incidence of catastrophic costs due to TB in 
Indonesia. 
Methods:  
From July to September 2016, we interviewed adult patients receiving treatment 
for TB in 19 primary health centres in urban, sub-urban and rural area of 
Indonesia, and those receiving multidrug-resistant (MDR) TB treatment in an 
Indonesian national referral hospital. Based on the need assessment, we 
developed eight scenarios for financial support. We assessed the effect of each 
simulated scenario by measuring reductions in the incidence of catastrophic 
costs. 
Results:  
We analysed data of 282 TB and 64 MDR-TB patients. The incidences of 
catastrophic costs in affected households were 36% and 83%, respectively. 
Patients’ primary needs for social protection were financial support to cover 
costs related to income loss, transportation, and food supplements. The optimum 
scenario, in which financial support would be provided for these three items, 
would reduce the respective incidences of catastrophic costs in TB and MDR-
TB-affected households to 11% and 23%. The patients experiencing catastrophic 
costs in this scenario would, however, have to pay high remaining costs (median 
of USD 910; interquartile range [IQR] 662) in the TB group, and USD 2613; 
[IQR 3442] in the MDR-TB group). 
Conclusions:  
Indonesia’s current level of social protection is not sufficient to mitigate the 
socioeconomic impact of TB. Financial support for income loss, transportation 
costs, and food-supplement costs will substantially reduce the incidence of 
catastrophic costs, but financial support alone will not be sufficient to achieve 
the target of 0% TB-affected households facing catastrophic costs. This would 
require innovative social-protection policies and higher levels of domestic and 
external funding. 
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Background 
Poverty is closely related to tuberculosis (TB), both as a risk and as an effect. 
People in low-income households not only have a higher risk of TB infection, 
but once they are infected, the high costs associated with diagnosis and treatment 
may reduce them to poverty.1,2 Although almost all countries provide drugs free 
of charge to patients with susceptible TB and multidrug-resistant TB (MDR-TB), 
TB patients still face high direct non-medical costs such as those for travel, food, 
and nutritional supplements.3-5 Indonesia has the world’s third largest number of 
estimated TB cases with the incidence of 842 000 (95% Confidence Interval [CI] 
767 000 – 919 000) cases. Despite its free TB services, our recent study revealed 
that the costs incurred during the treatment phase constituted more than three-
quarters of the total costs.6 These high costs can negatively affect treatment 
adherence, clinical outcomes, and drop-out rates, thereby further increasing 
future costs. The high costs also carry the risk of plunging TB patients and their 
families into poverty, or into even deeper poverty for those already living in 
poverty.7-11 
In response to this socioeconomic burden, the World Health Organization’s 
(WHO’s) End TB Strategy aims by 2020 to reduce to zero the percentage of TB-
affected families that face catastrophic costs. Catastrophic costs due to TB are 
defined as the total costs – i.e., all direct and indirect costs, including income 
loss — that exceed a specific threshold (e.g., 20%) of a household’s annual 
incom.12 One obvious option for attaining this target is by providing adequate 
social protection. In 2014, the Indonesian government started a national health 
insurance scheme that covers all the medical costs – including those of TB 
treatment – incurred in primary, secondary and tertiary healthcare. This scheme 
has substantially reduced direct medical costs. However, direct medical costs are 
not the only costs patients face in the trajectory from the pre-diagnostic phase to 
treatment completion.4,13 In 2016, the previous study we conducted in Indonesia 
showed that total costs consisted largely of direct non-medical costs and income 
loss.6 As these are not covered by the health insurance scheme, TB patients are 
still at a high risk of facing catastrophic costs. This highlights the importance of 
providing additional financial protection to cover direct non-medical costs and 
income loss.13  
Chapter 6 
92 
 
There are three approaches to delivering additional social protection.14 The first 
is the TB-specific approach, which offers protection only to TB patients or TB-
affected households, for example by providing food-supplements or travel 
vouchers to those undergoing TB treatment in health facilities that are linked to 
the network of the National Tuberculosis Program (NTP).14,15 The second, the 
TB-inclusive approach, is a broader intervention in which TB patients or TB-
affected households are one of the inclusion criteria in a social-protection 
program. The third, the TB-inclusive approach, involves protection policies that 
do not explicitly include TB patients or TB-affected families in their eligibility 
criteria but include TB risk-reduction strategies for groups at a high risk for TB 
infection, such as general cash transfers and premium-free national health 
insurance for people in poor households.  
However, there is little evidence on the effectiveness of financial protection 
(including cash transfers) in reducing the incidence of catastrophic costs due to 
TB, particularly in TB high-burden countries (HBCs). Although recent studies 
have shown that cash transfers could defray the costs endured by TB-affected 
households,15,16 the transfers in question were either given conditionally (on the 
basis of adherence to the intervention program), or were given on the basis of 
published national average cost data rather than of patients’ actual needs. There 
is limited evidence on the effect of social-protection schemes that take account 
of patients’ needs and preferences.17 
In this study we therefore aimed to measure the socioeconomic impact of TB and 
MDR-TB (including the incidence of catastrophic costs), and to assess patients’ 
perceived needs for social protection in Indonesia. Additionally, to assess the 
effects of financial support on the incidence of catastrophic costs due to TB and 
MDR-TB in poor and non-poor households, we developed and ran hypothetical 
scenarios in which patients were offered different combinations of financial 
support.  
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Methods 
Study design 
To measure the socioeconomic impacts of TB and the perceived needs for social 
protection, we interviewed TB and MDR-TB patients. For TB patients, we 
applied stratified clustered sampling in three districts of Java, one representing 
an urban area of Indonesia (Jakarta), one representing a suburban area (Depok), 
and one representing a rural area (Tasikmalaya). In each district, we randomly 
selected 5‒8 primary health centres (PHCs) that were linked with the Indonesian 
NTP. Then, from July to September 2016, we selected consecutive TB patients 
consecutive TB patients as they registered at these PHCs. Assuming that the 
incidences of TB-affected household facing catastrophic costs were 20% 
(urban), 25% (suburban) and 30% (rural), assuming a 1:1:1 ratio of TB incidence 
in urban, suburban and rural district, and assuming a power of 0.80, we required 
a minimum of 90 TB patients who met the inclusion criteria in each district. We 
included adults aged 18 years or above who had been diagnosed with TB and 
had either received TB treatment for at least one month or had finished the 
treatment no more than one month previously. In this study, we focused on 
pulmonary TB and excluded extra-pulmonary TB patients because of potentially 
different seeking care pattern and costs. With regard to MDR-TB, we 
interviewed adult patients who had been diagnosed on the basis of GeneXpert® 
(Cepheid, Sunnyvale, CA, USA) or sputum culture and had been undergoing 
treatment for at least one month in Persahabatan Hospital, an MDR-TB referral 
hospital in Jakarta.  
In both groups of patients, we assessed the following variables: the incidence of 
catastrophic costs, the socioeconomic impacts of TB or MDR-TB, and patients’ 
perceived needs for social protection. On the basis of the needs assessment, we 
then developed several scenarios for financial support. In each scenario, we 
measured the reduction in the incidence of catastrophic costs after the 
hypothetical provision of financial support. 
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Socioeconomic impacts due to TB and MDR-TB 
To measure the socioeconomic impacts of TB, we used the Tool to Estimate 
Patient Costs,12,18 which we adapted to the Indonesian context, also translating it 
to Indonesian Bahasa. We recruited ten medical students and public health 
graduates as interviewers and trained them in the use of the adapted tool. The 
socioeconomic impacts we studied the incidence of TB-affected households 
facing catastrophic costs; patients’ perception of the their TB or MDR-TB is 
having on their households’ financial capacity expressed on a scale of 1‒5, from 
no problem to a very serious problem; coping strategy (loaning money or selling 
property); job and income loss due to TB; and the proportional reduction in 
patients’ and households’ income. Patient and household income loss were 
calculated both in absolute terms (in United States dollars, USD) and in relative 
terms (percentage of loss of previous income).  
As well as collecting information on all types of cost (i.e., direct medical costs, 
direct non-medical costs, and indirect costs) that had been incurred by the TB-
affected households in the period between the pre-diagnostic phase and treatment 
completion, we also collected information on these households’ annual income. 
Following the latest WHO protocol, we measured the incidence of catastrophic 
costs (defined as total direct and indirect costs) that exceeded 20% of each TB-
affected household’s annual income [6,12]. Details of the methods we used to 
calculate the incidence of catastrophic costs due to TB are provided in our 
previous study.6 
Perceived needs for social protection 
To assess patients’ knowledge of social protection and their perceived needs for 
additional social protection, we added three questions at the end of the adapted 
tool: “Have you ever heard of social protection?”, followed by an open question: 
“If yes, what is social protection? Can you explain it?”  
Patients’ answers were grouped according to six types of social protection: 
general government aid for the poor; government aid for healthcare; direct 
government aid (general cash transfer); government aid for education: 
government aid for transportation costs; and other government aid. A patient’s 
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inability to name or explain any type of social protection was defined as ‘did not 
know’. These questions were important to our ability to assess patients’ 
knowledge before questioning them on their needs for social protection. After 
obtaining the patients’ answers, the interviewers explained the definition of 
social protection and gave examples of several types of social-protection 
scheme.19 They then asked the patients whether they needed any social 
protection, or additional protection if they already receiving.  
Patients who stated that they needed social protection were asked to choose one 
cost item they wanted to be covered, and its value in Indonesian Rupiahs (IDR). 
These items comprised consultation fee per visit, transportation costs per visit, 
food costs per visit, drug costs per month, income loss per month, and food-
supplement costs per month. Food-supplement costs were defined as a patient’s 
monthly spending on nutritional or food supplements such as vitamins, fruits, 
milk, meats, or other nutritional supplements that were consumed either with or 
without a doctor’s TB-related recommendation [19]. After the patients’ answers 
had been obtained, the cost items that needed to be covered were listed in order 
of priority (from those that had been indicated most to those that had been 
indicated least). The median (interquartile range [IQR]) of these cost items was 
then calculated. In the scenarios that we developed, we then used the median 
values of these cost items as the value of financial support.  
Effects of financial support 
On the basis of the needs assessment, we selected the three cost items that 
patients chose, and then developed several hypothetical scenarios for financial 
support. These comprised the following: no provision of a cash transfer 
(baseline); the provision of a cash transfer to cover a single cost item (i.e., income 
loss, transportation costs, or food-supplementation); and the provision of a cash 
transfer to cover a combination of two or three cost items. In total, we developed 
eight such scenarios. As well as the baseline scenario (no cash transfers; Scenario 
I), we formulated seven hypothetical cash-transfer scenarios for the following: 
(II) transportation costs for all patients, (III) food-supplement costs for all 
patients, (IV) income loss for patients who had lost their jobs, (V) income loss 
for patients who lost their income whether or not they had lost their jobs, (VI) a 
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combination of transportation costs and income loss, (VII) a combination of 
food-supplement costs and income loss, and (VIII) a combination of 
transportation costs, food-supplement costs, and income loss.  
We simulated the hypothetical scenarios in the people who had been included in 
this study, assuming that the cash transfers had been made after patients had 
started TB or MDR-TB treatment.  The value of the cash transfer (𝐶𝑇) for 
specific cost items was extrapolated to a complete treatment period (denoted 
𝐶𝑇 
𝐶𝐼, ℎ
𝑖
 in which 𝐶𝐼 identifies a specific cost item, 𝑖 identifies the patient, and 
ℎ identifies his/her household). For transportation costs, the total cash transfer 
was calculated by multiplying 𝐶𝑇 by the number of PHC or hospital visits during 
the intensive phase 𝑉 
𝐼𝑃
𝑖
 and continuation phase 𝑉 
𝐶𝑃
𝑖
 until the expected end date 
of treatment. For income loss and food-supplement costs, the total value of the 
cash transfer was calculated by multiplying 𝐶𝑇 by the duration (in months) of 
the patients’ complete treatment, 𝑀.  
Box 1 Cash-transfers formula 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑇 𝑡𝑟𝑎𝑛𝑠𝑝𝑜𝑟𝑡𝑎𝑡𝑖𝑜𝑛 = ∑((𝐶𝑇𝑖
𝐶𝐼,ℎ𝑥 𝑉𝑖
𝐼𝑃) + (𝐶𝑇𝑖
𝐶𝐼,ℎ𝑥 𝑉𝑖
𝐶𝑃))
𝑛
𝑖=1
 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑇 𝑖𝑛𝑐𝑜𝑚𝑒 𝑙𝑜𝑠𝑠 = ∑(𝐶𝑇𝑖
𝐶𝐼,ℎ𝑥 𝑀)
𝑛
𝑖=1
 
𝑇𝑜𝑡𝑎𝑙 𝐶𝑇 𝑓𝑜𝑜𝑑 𝑠𝑢𝑝𝑝𝑙𝑒𝑚𝑒𝑛𝑡 = ∑(𝐶𝑇𝑖
𝐶𝐼,ℎ𝑥 𝑀)
𝑛
𝑖=1
 
Total costs were defined as the sum of all types of cost, including out-of-pocket 
payments (OOPs) for medical diagnosis and treatment (OOPM); OOPs for non-
medical expenditures (OOPNM); and patients’ and guardians’ income losses 
(IN). After calculating the total simulated costs after the cash transfer (total costs 
for TB-related services minus the total cash transfer), we estimated the incidence 
of catastrophic costs after the cash transfer in each scenario. To define 
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catastrophic costs, we used the threshold of 20% of annual household income 
(denoted 𝜏
𝑇𝐵
).  
𝐼
𝑇𝐵
𝑁𝑇𝑃
=
1
𝑛
𝑇𝐵
𝑁𝑇𝑃
∑ 1 (
∑
𝑛_𝑖
𝑗 = 1 ((𝑂𝑂𝑃𝑀
𝑇𝐵, ℎ
𝑗
 + 𝑂𝑂𝑃𝑁𝑀 
𝑇𝐵, ℎ
𝑗
+ 𝐼𝑁 
𝑇𝐵, ℎ
𝑗
 ) − 𝑇𝑜𝑡𝑎𝑙 𝐶𝑇 )
𝑦
ℎ
𝑖
> 𝜏
𝑇𝐵
)
𝑛 𝑇𝐵
𝑁𝑇𝑃
𝑖=1
 
TB patient is denoted as 𝑗 while the household is denoted as 𝑖.12 If there is more 
than one TB patient in one household, costs for all patient within the household 
will be collected or estimated. Although the hypothetical scenarios were based 
on the optimistic assumption that all patients would receive 100% of the potential 
cash transfer, some intervention studies have shown that 10‒36% of targeted 
beneficiaries did not receive complete financial support.15,20,21 To obtain valid 
estimates of the effect of the cash transfers, we ran sensitivity analyses that 
assumed patients would receive 60%, 70%, 80%, and 90% of the potential cash 
transfer. 
Data analysis 
Data were entered into EpiInfoTM for Windows (Centers for Disease Control and 
Prevention (CDC), Atlanta, GA, USA) and Microsoft® Office Excel 2010 
(Microsoft). For data cleaning and analysis, we used IBM SPSS Statistics for 
Windows, Version 21 (IBM Corp., Armonk, NY, USA). Categorical variables 
were displayed as numbers (n) and proportions (%). All costs, incomes, and 
values of financial support for each cost item were collected in IDR and then 
converted to US Dollars (USD) using the average exchange rate by the World 
Bank for 2016 (USD 1 = IDR 13 389.41).22 These numerical data were 
abnormally distributed and therefore displayed as median values (IQRs). 
We compared the socioeconomic impacts, the perceived needs for social 
protection, and the effect of financial support between poor and non-poor 
households. A poor household was defined as a household earning below USD 
1.9 per capita per day.23 To compare the socioeconomic impacts due to TB and 
the effects of financial support between poor and non-poor TB-affected 
households, we applied generalized linear mixed models with random effects to 
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adjust for a cluster sampling design (19 PHCs). For the MDR-TB group, we used 
chi-square, Fisher, and Mann-Whitney tests to analyze the impacts between poor 
and non-poor households. To compare the effects of financial support between 
scenarios, we used McNemar tests with stratification for cluster sampling for TB 
(19 PHCs), and without stratification for MDR-TB. For each scenario we used 
bootstrapping for internal validations of the incidence of catastrophic costs after 
cash transfer and the average budget per patient required in each scenario 
(N=1000). The difference was considered statistically significant if P-value was 
below than 0.05. 
Ethical statement 
Ethical clearances for this study were obtained from the Ethical Committee at 
the Faculty of Medicine of Universitas Indonesia–Cipto Mangunkusumo 
Hospital, Jakarta Indonesia (No. 416/UN2.F1/ETIK/VI/2016) and the Ethical 
Committee at Persahabatan Hospital, Jakarta, Indonesia (No. 
DL.01.03/II.3/3817/2016). We provided written and oral explanations to patients 
before their decision to sign the informed-consent form.  
 
Results 
In total, we analysed the data for 282 TB and 64 MDR-TB patients. The details 
of patients’ characteristics are provided in our previous study on catastrophic 
costs due to TB.6  
Socioeconomic impacts of TB or MDR-TB  
The incidence of catastrophic costs due to TB was high, and was significantly 
higher among MDR-TB-affected households (83%) than among TB-affected 
ones (36%, P < 0.001). Most MDR-TB patients (78%) perceived that TB created 
moderate to severe problems for the financial capacity of their household. This 
proportion was lower among TB patients (48%; P-value for the difference 
between MDR-TB and TB patients = 0.009). These financial problems led more 
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MDR-TB patients than TB patients to loan money (50% vs 32%, P = 0.042) and 
to sell property (28% vs 12%, P = 0.008) (see Table 1). 
Among TB-affected households, poor households suffered much more than non-poor 
households: they had a higher incidence of catastrophic costs (43% vs 25%, P = 0.006) 
and a higher proportion of patients who loaned money (38% vs 22%, P = 0.014) and 
sold property (15% vs 6%, P = 0.029). A more substantial proportion also suffered from 
moderate to severe financial problems (54% vs 38%, P = 0.030). Conversely, in MDR-
TB-affected households, these economic impacts did not differ significantly between 
poor and non-poor households. 
Before diagnosis, more than three-quarters of all patients had an income-earning job. 
Among them, TB and MDR-TB caused a high rate of job loss, which was higher in 
MDR-TB patients than in TB patients (69% vs 32%, P = 0.001). In addition to job loss, 
TB also caused income loss: although some patients maintained their jobs after 
diagnosis, their income decreased. The proportion of patients who lost income was 
much higher than the proportion who experienced job loss, and was higher among 
MDR-TB patients than among TB patients (86% vs 61%, P = 0.011).  
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The extent of income loss among patients who had had an income-earning job 
before diagnosis was substantial in both relative and absolute terms. Relative 
income loss was very high among MDR-TB patients (median of 100% [IQR 
54%]) and was significantly higher than among TB patients (P = 0.002). 
Patient’s income loss subsequently reduced household income (median of 40% 
[IQR 38%] in MDR-TB and 20% [IQR 55%] in TB patients, P = 0.299). While 
the point estimates of relative income loss suggest that the loss was much higher 
among poor TB patients than among non-poor TB ones, the difference was not 
significantly different.  
 
Figure 1 Patient and household income in (a) TB and (b) MDR-TB-affected households. 
Pre: income before TB diagnosis. Post: income after TB diagnosis. P-values above the bar charts indicates 
the statistical significance of the absolute difference in income loss between poor and non-poor households. 
Per bar, red rhombs indicate the mean value of income, upper horizontal lines indicate the q75 value, middle 
horizontal lines indicate the median value, and lower horizontal lines indicate the q25 value. 
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Absolute loss (in USD) in patient’s monthly income was higher in non-poor 
households than in poor households, both in the TB (P-value for difference poor 
and non-poor: < 0.001) and MDR-TB group (P = 0.004) (Figure 1). Household 
income loss was also greater in non-poor households than in poor households, 
both in the TB (P < 0.001) and MDR-TB group (P = 0.005).  
 
Patients’ perceived needs for social protection  
Most patients (84% of TB patients and 80% of MDR-TB patients) did not know 
existing social-protection schemes (Table 2). Even 81% of patients who had 
health insurance did not know what social protection was and were unable to 
name existing social-protection schemes. Knowledge of existing schemes did not 
differ significantly between TB and MDR-TB patients (P = 0.794), or between 
those with and without health insurance (P = 0.112). The forms of social 
protection that were most commonly named by those who knew of such schemes 
were government aid for poor people (in general) and government aid for 
healthcare.  
Table 2 TB and MDR-TB patients’ knowledge of social-protection schemes  
Knowledge of existing social-
protection scheme 
Type of TB 
P 
Having 
insurance 
P 
TB  
n (%) 
MDR-TB  
n (%) 
Yes  
n (%) 
No  
n (%) 
Did not know what social 
protection was 
236 
(84) 51 (80) 0.794 
187 
(81) 100 (88) 0.112 
Knew and could name the 
following social-protection 
schemes: 46 (16) 13 (20)  45 (19) 14 (12)  
 
Government aid for poor 
people (in general) 19 (7) 4 (6)  19 (8) 4 (4)  
 
Government aid for 
healthcare 13 (5) 2 (3)  11 (5) 4 (4)  
 
Direct government aid, cash 
transfer a  11 (4) 1 (2)  9 (4) 3 (3)  
 
Government aid for 
transportation costs 0 (0) 3 (5)  3 (1) 0 (0)  
 Government aid for education 1 (0) 2 (3)  2 (1) 1 (1)  
  Other government aid 0 (0) 1 (2)   0 (0) 1 (1)   
a known as Bantuan Langsung Tunai in Indonesian Bahasa  
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After it had been explained what social protection was, most patients perceived 
that they needed social protection. The perceived need was higher among MDR-
TB patients than among TB patients (95% vs 73%, P = 0.004). Perceived need 
did not differ significantly between poor and non-poor patients in either the TB 
group (75% vs 70%, P = 0.334) or the MDR-TB group (100% vs 93%, P = 
0.547). 
TB and MDR-TB patients all indicated that the three cost items that most needed 
to be covered were income loss (indicated by 24% of TB patients and 34% of 
MDR-TB patients); transportation costs (19% and 42%); and costs for food 
supplements (15% and 8%) (Table 3). Patients who reported that they required 
financial support were asked about the value of support they needed. As the wide 
interquartile ranges show, the value of financial support required varied strongly 
per cost item. MDR-TB patients perceived a need for a much higher value of 
financial support per month for their income loss than TB patients (median of 
USD 205 [IQR 121] vs USD 75 (IQR 112), P < 0.001). However, with regard to 
transportation costs per treatment visit and food-supplement costs per month, the 
values of the financial support required did not differ between the groups. 
Among MDR-TB patients, the values of the financial support needed did not 
differ between poor and non-poor households. But in the TB group, non-poor 
households perceived a need for a slightly higher value of financial support for 
income loss, transportation, and food supplements (P < 0.001).  
The needs perceived by patients who indicated that they needed financial support 
were compared with the actual costs incurred by all patients. For income loss, 
we compared the value of perceived needs with the actual income loss suffered 
by (a) patients who had experienced job loss after diagnosis and (b) patients who 
had experienced any income loss due to TB regardless of whether or not they 
had experienced job loss. Among TB patients, the median value of the perceived 
need for financial support to cover income loss was lower than the actual costs. 
Conversely, among MDR-TB patients, the perceived value of financial support 
was higher than their actual costs. For transportation and food-supplement costs, 
we compared the value of perceived needs with the costs actually incurred by all 
patients. The values of financial support needed for these two cost items among 
patients who expressed the need for support were higher than the actual median 
costs among all patients.  
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Effect of financial support on the incidence of catastrophic costs 
In our simulated scenarios, we used the median values of the financial support required 
(see Table 3) to determine the value of cash transfers. The value of the cash transfer for 
transportation costs used in the simulations was USD 4 per visit. Due to differences in 
the number of visits per month, this suggests that the hypothetical monthly transfer for 
transportation costs would vary according to treatment regimen and treatment phase 
(intensive and continuation phase). For TB patients undergoing Category I treatment, 
the average number of visits was 4 visit per month during intensive phase and one visit 
per month during continuation phase. These resulted in the average value of the monthly 
cash transfer of USD 16 in the intensive phase and USD 4 in the continuation phase. 
For TB patients undergoing Category II treatment, with daily visit during intensive 
phase, the average value of the monthly cash transfer would be USD 120 in the intensive 
phase and USD 4 in the continuation phase. For MDR-TB patients, the average value 
of the monthly cash transfer for transportation would be USD 120 in both the intensive 
and continuation phases. The value of the cash transfer used in the simulations for food 
supplements was USD 22 per month, both for TB and MDR-TB patients. For income 
loss, the value of the cash transfer used in the simulations was USD 75 per month for 
TB patients and USD 205 per month for MDR-TB patients.  
If TB-affected households were given support for transportation, food supplements and 
income loss (Scenario VIII), the incidence of catastrophic costs would be reduced by 
25 percentage points, from 36% to 11% (Table 4). This scenario would have the greatest 
effects on reducing the incidence of catastrophic costs than any other scenario, reducing 
it by 17 percentage points if patients received only 60% of the potential cash transfer 
(Annex F). In this scenario, total median costs for TB patients would be reduced from 
USD 133 (IQR 522) to USD 0 (IQR 106) (results not reported in the table). Even so, 
catastrophic costs would still be faced by 11% of TB-affected households (95% 
confidence interval [CI] 8‒15%). Among TB patients who still faced catastrophic costs 
after cash transfer, the total median costs would be reduced from USD 1527 (IQR 1023) 
to USD 910 (IQR 662). 
Although having lower effects than Scenario VIII, cash-transfer modalities for two cost 
items (Scenarios VI and VII) would substantially reduce the incidence of catastrophic 
costs: between these two scenarios, there was no significant difference (Annex G). Of 
the cash-transfer modalities that would provide support for one cost item, Scenario V 
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would provide the most substantial effect. Other modalities of providing support for one 
cost item (Scenarios II-IV) would provide much smaller effects than Scenario VIII (P 
< 0.001). Between Scenarios II-IV, there were no significant differences. 
 
Table 4 The incidence of catastrophic costs in eight hypothetical scenarios  
Simulated hypothetical scenario 
Incidence of 
catastrophic costs 
Average budget per 
patient for full 
duration of 
treatment, in USD  
% (95% CI) Mean (95% CI) 
TB     
I Baseline (no cash transfer) 36 (31‒42) - 
II Transportation costs 28 (23‒33) 114 (100‒127) 
III Food-supplement costs 26 (21‒30) 143 (141‒145) 
IV Income lossa 26 (21‒30) 110 (88‒134) 
V Income lossb 17 (13‒21) 210 (183‒236) 
VI Transportation costs and income loss 17 (13‒22) 224 (197‒253) 
VII Food-supplement costs and income loss 16 (12‒20) 253 (231‒278) 
VIII 
Transportation, food supplement, and income 
loss 
11 (8‒15) 367 (338‒398) 
MDR-TB   
I Baseline (no cash transfer) 83 (73‒92) - 
II Transportation costs 59 (47‒71) 1337 (1327‒1344) 
III Food-supplement costs 77 (65‒87) 269 (269‒269) 
IV Income lossa 58 (46‒70) 1309 (1010‒1617) 
V Income lossb 52 (39‒65) 1617 (1338‒1899) 
VI Transportation costs and income loss 28 (18‒40) 2647 (2351‒2958) 
VII Food-supplement costs and income loss 53 (41‒66) 1578 (1279‒1886) 
VIII 
Transportation, food supplement, and income 
loss 
23 (13‒35) 2916 (2620‒3227) 
aThe hypothetical cash transfer was assumed to have been delivered to TB patients who had experienced job 
loss, bThe hypothetical cash transfer was assumed to have been delivered to TB patients who had experienced 
any income loss regardless of whether or not they had experienced job loss. 
In the MDR-TB group, cash transfers for transportation, food supplements and income 
loss (Scenario VIII) would reduce the incidence of catastrophic costs by 60 percentage 
points, from 83% to 23%. Of all the scenarios, Scenario VIII would have the greatest 
effect on reducing the incidence of catastrophic costs. Under Scenario VIII, median total 
costs for MDR-TB patients would decrease from USD 2804 (IQR 3317) to USD 0 (IQR 
801). Twenty-three percent of MDR-TB-affected households would nonetheless face 
catastrophic costs after the transfer (95% CI: 13‒35%). Under the same scenario, 
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median total costs for MDR-TB patients who still faced catastrophic costs after cash 
transfer would be reduced from USD 5606 (IQR 4430) to USD 2613 (IQR 3442). 
Using the above cash-transfer values for each scenario, we estimated the average budget 
required per patient for the full duration of treatment under a social-protection program 
(Table 4, Figure 3) Scenario VIII would produce the most significant effect, but would 
also require the highest average budget per patient. For the MDR-TB group, the effect 
and the average budget of Scenario VI were only slightly smaller than those of Scenario 
VIII. Other scenarios would produce a much lower effect for a much lower average 
budget.  
 
Figure 2 The incidence of catastrophic costs in poor and non-poor households in (a) TB and (b) 
MDR-TB-affected households. P-values indicate the differences per scenario between poor and 
non-poor households. 
In the TB group, cash transfers would reduce the incidence of catastrophic costs to a 
much greater extent in poor households than in non-poor households (Figure 2). In 
Scenarios V-VIII, the gap between poor and non-poor households would disappear. A 
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sensitivity analysis showed that the gap would also disappear under Scenarios V-VIII 
if patients received only 60‒90% of the cash transfers (Annex H, Annex I).  
In the MDR-TB group, the incidence of catastrophic costs at baseline was equally high 
in the poor and non-poor households. With most scenarios, the impact was similar for 
poor and non-poor MDR-TB households. Only cash transfers for transportation costs 
(Scenario II) would produce a significantly lower incidence of catastrophic costs among 
poor households than among non-poor ones.  
 
Figure 3 The remaining incidence of catastrophic costs and the average budget per patient for 
each scenario in (a) the TB group and (b) the MDR-TB group. Vertical lines in each colored circle 
are standard errors of the incidence of catastrophic costs. Horizontal lines in each colored circle 
are standard errors of the average budget per patient. 
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Discussion 
Our results suggest that current levels of social protection in Indonesia are not enough 
to mitigate the socioeconomic impacts of TB, which include a high incidence of 
catastrophic costs, high rates of job and income loss, and a high proportion of patients 
who have to borrow money and sell their property. Due to these enormous impacts, TB 
patients urgently need social protection, mainly to cover the three costs they had 
indicated as most important: income loss, transportation costs, and food-supplement 
costs. In our simulations, the incidences of catastrophic costs were substantially reduced 
by a hypothetical scenario (Scenario VIII) that provided financial support for these three 
cost items. Nevertheless, a financial support system in which patients received fixed 
amounts of money for income loss, transport and food-supplement costs would not be 
able to reduce the incidence of catastrophic costs to zero percent, the target set by the 
WHO.  
Our findings suggest that future policies should not rely on cash transfers for only one 
cost item. Although cash transfers to cover patient income loss can make a substantial 
contribution to reducing catastrophic costs, a single cash transfer of the sort examined 
in our study would not be enough to eliminate catastrophic costs. The existing types of 
support that patients may currently receive are equally inadequate; these mainly cover 
direct non-medical costs, such as food or nutritional supplement packages and travel 
vouchers from either government or international donors.21,24,25 The impacts of financial 
support would be greater if cash transfers were provided for a combination of income 
loss, travel costs, and food-supplement costs.  
Despite their substantial impact on reducing catastrophic costs, the cash transfers in our 
scenarios would not be enough to achieve the WHO’s target of zero percent of 
households facing catastrophic costs. This failure is likely to be due to the high 
variability of costs between patients, and particularly of the cost due to income loss, 
which was the greatest component of the total costs incurred due to TB. Actual monthly 
income losses were also higher than the cash transfers simulated in our hypothetical 
scenarios. For example, while the transfer was set at USD 75 per month, actual median 
monthly income loss among TB patients who experienced job loss was USD 75 (IQR 
77) for poor patients, and USD 149 (IQR 185) for non-poor patients.  
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As actual costs and the perceived needs for financial support vary greatly between 
patients, it is difficult to determine the value of any cash transfer to be delivered. We 
based the value of cash transfers on the median value of patients’ perceived needs. 
Although the median value of cash transfer to cover transportation and food-supplement 
costs was higher than the median value of their actual costs, the actual value of transport 
and food supplements latter was sometimes higher than the cash transfer. The transfer 
in these cases did not cover the actual costs. However, the cash transfers simulated in 
our study would increase the NTP budget per capita by between approximately 46% 
(Scenario II) and 148% (Scenario VIII) for TB patients, and by between approximately 
8% (Scenario II) and 20% (Scenario VIII) for MDR-TB patients.26 While increasing the 
value of the cash transfers might be effective in terms of further reducing catastrophic 
costs, its affordability and sustainability should be carefully considered.  
A way of reducing the incidence of catastrophic costs more effectively might be to 
target the financial support to those patients most likely to experience catastrophic 
expenditures. The targeting system could differ between settings, and could use various 
criteria to identify patients who need financial support.14 Such criteria might include the 
determinants of catastrophic costs, such as household poverty level, job status before 
and after diagnosis, breadwinner status in the family, having had previous TB treatment, 
and experiencing adverse effects.6 The disadvantages of such an approach would 
include the risks of greater stigmatization and of the greater bureaucracy needed to 
manage the targeting system, and may also prompt patients to pretend to remain sick in 
order to keep their entitlement to financial support.14,24 
Our findings stress that the WHO’s target of eliminating the incidence of catastrophic 
costs requires innovations in social-protection programs. If this objective is to be 
attained, a combination of strategies will be required to reduce the costs patients incur 
in the trajectory between the pre-diagnostic phase and the end of treatment. To reduce 
medical costs in the pre-diagnostic and diagnostic phases, TB service delivery under 
the NTP – which currently provides free TB treatment in NTP-linked health services 
only after diagnosis – should be fully integrated into the national health insurance 
scheme. In turn, such integration would speed up diagnostic procedures and improve 
access to TB treatment, possibly reducing transport costs and potentially even income 
loss. However, as the proportion of costs incurred in this phase is much smaller than the 
proportion of costs in the treatment phase,6 the strategy would have limited impact on 
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total cost reduction. The strategy should therefore be combined with strategies for 
preventing socioeconomic impacts in the treatment phase of TB.  
Since income loss was the greatest cost in the treatment phase, income loss must be 
limited by preventing unnecessary job loss. In the formal sector, this could be done by 
strengthening job-security policies so as to avoid the dismissal of workers with TB and 
MDR-TB. In the informal sector, resolving the problem of income loss would be more 
of a challenge. Whatever the case, it is important to design a legal framework that 
provides additional social protection, not only to compensate patient’s income loss, but 
also to prevent further severe TB-related socioeconomic impact by ensuring that 
patients are covered by national health insurance, .  
Another possible way of reducing treatment costs is to shorten the TB treatment 
period.15,27 The development of a new TB drug regimen with a shorter treatment period 
is currently being evaluated.28 Positive evidence that this shorter period is just as cost-
effective would allow a reduction in direct non-medical costs and, as a result, a 
reduction in the likelihood of catastrophic cost.29 For patients with MDR-TB, a possible 
way of reducing transportation costs and possible income loss is to increase the number 
of MDR-TB drug-delivery centres. 
Unfortunately, the strategies for eliminating catastrophic costs named above would 
require considerable resources, while most of the TB high-burden countries are low- to 
middle-income countries with limited resources for social-protection policies.3 If global 
action to combat TB does not become more innovative and is not given more funding, 
such countries will be left with very little chance of attaining the target stipulated in the 
WHO’s 2020 and 2025 milestones of zero percent of families that face catastrophic 
costs.  
The limitations of this study fall into two main categories. First, we enrolled only TB 
and MDR-TB patients who had been treated in public health services, and thus not in 
the private sector. We did not interview patients who had dropped out of treatment, and 
we excluded any TB patients or suspected TB patients who had not followed standard 
TB diagnostic and treatment procedures. Similarly, the only MDR-TB patients we 
interviewed were those who had been treated in a national pulmonary referral hospital 
in an urban area (Jakarta). With regard to the extent of patients’ needs for social 
protection and to the value of cash transfers, these strict inclusion criteria may have led 
us to underestimate the needs of TB patients and to overestimate the needs of MDR-TB 
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patients. MDR-TB patients treated in other MDR-TB centers or referred to PHCs after 
culture conversion may have lower direct non-medical costs, and may thus have lower 
requirements with regard to social protection.  
Secondly, while these findings may apply to the island of Java, which constitutes 60% 
of the Indonesian population,30 they may not apply directly to the eastern part and other 
remote areas of Indonesia, where travel costs may be much higher than in Java, and 
where income loss may be much lower. It is also uncertain whether these findings will 
apply to other TB high-burden countries with a low- to middle-income. 
Conclusions 
Indonesia’s current level of social protection is not sufficient to mitigate the 
socioeconomic impact of TB. Financial support for income loss, transportation costs, 
and food-supplement costs will substantially reduce the incidence of catastrophic costs, 
but financial support alone will not be sufficient to achieve the target of 0% TB-affected 
households facing catastrophic costs. This would require innovative social-protection 
policies and higher levels of domestic and external funding.  
 
Ethics approval and consent to participation 
Ethical clearance for this study was provided by the Ethical Committee at the Faculty of Medicine of 
Universitas Indonesia–Cipto Mangunkusumo Hospital, Jakarta Indonesia (No. 
416/UN2.F1/ETIK/VI/2016); and the Ethical Committee at Persahabatan Hospital, Jakarta, Indonesia 
(No. DL.01.03/II.3/3817/2016). Before their decision to sign the informed-consent form, patients were 
provided with written and oral explanations. We confirmed that all respondents had received written 
and oral explanations of the study, and that they had signed an informed consent form before the 
interview.  
Funding 
This study was funded by the Indonesian Endowment Fund for Education (Lembaga Pengelola Dana 
Pendidikan, LPDP), Indonesia. 
Acknowledgments 
We would like to thank the following: Daan Nieboer for his support with the statistical analysis; the 
Director of Persahabatan Hospital, the Head of Jakarta Provincial Health Office, the Head of 
Tasikmalaya District Health Office, and the Head of Depok District Health Office for allowing data 
collection in their institutions and areas; and Diah Handayani, Dedi Suhendar, the TB Program Officers 
in Primary Health Centres, and all enumerators for their support with data collection. 
Effect of financial support 
113 
 
References 
1. Siroka A, Law I, Macinko J, et al. The effect of household poverty on tuberculosis. Int J Tuberc Lung 
D. 2016;20:1603-8. 
2. Oxlade O, Murray M. Tuberculosis and poverty: why are the poor at greater risk in India? Plos One. 
2012; 7:11. 
3. World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. 
4. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis patients 
in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43:1763-75. 
5. Mauch V, Bonsu F, Gyapong M, et al. Free tuberculosis diagnosis and treatment are not enough: patient 
cost evidence from three continents. Int J Tuberc Lung Dis. 2013;17:381-7. 
6. Fuady A, Houweling TAJ, Mansyur M, Richardus JH. Catastrophic total costs in tuberculosis-affected 
households and their determinants since Indonesia’s implementation of universal health coverage. 
Infectious Diseases of Poverty. 2018;7:3. 
7. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard GJ, Sinanovic E. The economic burden of TB 
diagnosis and treatment in South Africa. Social Science & Medicine. 2015;130. 
8. Laokri S, Dramaix-Wilmet M, Kassa F, Anagonou S, Dujardin B. Assessing the economic burden of 
illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health 
expenditures and inequities. Trop Med Int Health. 2014;19:1249-58. 
9. Daftary A, Padayatchi N. Social constraints to TB/HIV healthcare: accounts from coinfected patients in 
South Africa. AIDS Care. 2012;24:1480-6. 
10. Richter LM, Lönnroth K, Desmond C, Jackson R, Jaramillo E, Weil D. Economic support to patients in 
HIV and TB grants in rounds 7 and 10 from the Global Fund to fight AIDS, tuberculosis and malaria. 
Plos One. 2014;9: e86225. 
11. Ukwaja KN, Alobu I, Igwenyi C, Hopewell PC. The high cost of free tuberculosis services: patient and 
household costs associated with tuberculosis care in Ebonyi state, Nigeria. Plos One. 2013;8:8. 
12. World Health Organization. Protocol for survey to determine direct and indirect costs due to TB and to 
estimate proportion of TB-affected households experiencing catastrophic total costs due to TB. Geneva: 
World Health Organization; 2015. 
13. Lonnroth K, Glaziou P, Weil D, Floyd K, Uplekar M, Raviglione M. Beyond UHC: monitoring health 
and social protection coverage in the context of tuberculosis care and prevention. PLoS Med. 
2014;11:e1001693. 
14. Boccia D, Pedrazzoli D, Wingfield T, et al. Towards cash transfer interventions for tuberculosis 
prevention, care and control: key operational challenges and research priorities. BMC Infect Dis. 
2016;16:307. 
15. Wingfield T, Tovar MA, Huff D, et al. Socioeconomic support to improve initiation of tuberculosis 
preventive therapy and increase tuberculosis treatment success in Peru: a household-randomised, 
controlled evaluation. Lancet. 2017;389:16. 
16. Rudgard WE, Evans CA, Sweeney S, et al. Comparison of two cash transfer strategies to prevent 
catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An 
economic modelling study. Plos Medicine. 2017;14:11. 
17. Hidrobo M, Hoddinott J, Peterman A, Margolies A, Moreira V. Cash, food, or vouchers? Evidence from 
a randomized experiment in northern Ecuador. J Dev Econ. 2014;107:144-56. 
18. TB-CTA. The tool to estimate patient's costs. The Hague: KNCV; 2009. 
19. Fuady A, Houweling TA, Mansyur M, Richardus JH. Adaptation of the tool to estimate patient costs 
questionnaire into Indonesian context for tuberculosis-affected households. Acta Med Indones. 
2018;50:3-10. 
20. Lutge E, Lewin S, Volmink J. Economic support to improve tuberculosis treatment outcomes in South 
Africa: a qualitative process evaluation of a cluster randomized controlled trial. Trials. 2014;15:236. 
Chapter 6 
114 
 
21. Lutge E, Lewin S, Volmink J, Friedman I, Lombard C. Economic support to improve tuberculosis 
treatment outcomes in South Africa: a pragmatic cluster-randomized controlled trial. Trials. 
2013;14:154. 
22. World Bank. Exchange rate. 2016. http://databank.worldbank.org/data/ 
reports.aspx?source=2&series=PA.NUS.FCRF&country.  Accessed 15 October 2016. 
23. Ferreira FHG, Chen S, Dabalen AL, Dikhanov YM, Hamadeh N, Jolliffe DM, et al. A global count of 
the extreme poor in 2012 : data issues, methodology and initial results (English). Policy Research 
working paper No. WPS 7432. Washington, D.C.: World Bank Group; 2015. 
24. Lutge EE, Wiysonge CS, Knight SE, Sinclair D, Volmink J. Incentives and enablers to improve 
adherence in tuberculosis. Cochrane Database of Systematic Reviews. 2015; 9:1-51. 
25. Martins N, Morris P, Kelly PM. Food incentives to improve completion of tuberculosis treatment: 
randomised controlled trial in Dili, Timor-Leste. BMJ. 2009;339:b4248. 
26. Jarrah Z, Collins D, Hafidz F. The cost of scaling up TB services in Indonesia. TB CARE I – 
Management Sciences for Health. Cambridge: Management Science for Health; 2013. 
27. Wingfield T, Tovar MA, Huff D, et al. The economic effects of supporting tuberculosis-affected 
households in Peru. European Respiratory Journal. 2016;48:1396-410. 
28. Moodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the 
STREAM trials. Eur Respir Rev. 2016;25:29-35. 
29. Gomez GB, Dowdy DW, Bastos ML, et al. Cost and cost-effectiveness of tuberculosis treatment 
shortening: a model-based analysis. BMC Infectious Diseases. 2016;16:726. 
30. Badan Pusat Statistik. Distribusi persentase penduduk menurut provinsi, 2000-2015. 2015. 
https://www.bps.go.id/linkTableDinamis/view/id/843. Accessed 1 March 2017. 
  
 
 
 
 
 
 
 
 
 
Chapter 7 
Discussion 
 
Chapter 7 
116 
 
This thesis is intended to provide three evidence bases related to TB in the context of 
UHC in Indonesia: the household-level economic impact of TB, the relationship 
between catastrophic costs and TB treatment outcomes, and the social-protection 
improvements that are required to further reduce TB-related catastrophic costs. Below, 
I first describe the economic impact of TB and the contribution made by private 
healthcare providers to the economic impact of TB. Next, I present evidence on the 
relationship between catastrophic costs, treatment adherence and treatment outcomes. 
Finally, I explore the potential effect of further social-protection measures (i.e. those 
beyond UHC) on the incidence of catastrophic costs.  
To answer the research questions outlined in my Introduction, this chapter provides a 
detailed discussion of the main findings. It also addresses several methodological issues 
and the implications for further research and policy making. 
 
Main findings 
The economic impact of TB 
Research Question 1: What is the economic impact of TB faced by TB-affected 
households? 
Despite the implementation of UHC in Indonesia, we found that TB-affected 
households still incurred high costs to access TB-related services. These costs were 
often catastrophic. We also found that, after diagnosis, many TB patients quit their jobs, 
had to deal with high costs by borrowing money or selling property, and found that 
access to TB-related services causes them moderate to severe financial problems.  
The incidence of catastrophic costs is an important indicator of the economic impact of 
TB. It is one of the targets addressed in the WHO’s End TB Strategy: to reduce to zero 
percent the incidence of catastrophic costs faced by TB-affected households. In Chapter 
3, we show that the incidence of catastrophic costs in Indonesia remains high: 36% for 
TB-affected households and 83% for MDR-TB-affected households. 
The households most affected by catastrophic costs were poor ones – even though, in 
absolute terms, they spent less than non-poor households to access TB-related services. 
On the basis of a threshold of 20% of annual household income, the incidence of 
catastrophic costs faced by poor TB-affected households (43%) was significantly higher 
Discussion 
117 
 
than that faced by non-poor TB-affected households (25%). As well as this higher 
incidence of catastrophic costs (H), poor households also had to deal with a mean gap 
(G) of 13%. This gap, which represents the average amount whereby total costs as a 
proportion of household income exceed the threshold of catastrophic costs, was much 
higher than the mean gap of 5% faced by non-poor households. In terms of the mean 
positive gap (MPG), which is calculated by G/H in order quantify the excessive cost 
incurred by households experiencing catastrophic costs, poor households also suffered 
much more than non-poor households: 30% vs 18%. Among MDR-TB-affected 
households, poor households also suffered more than non-poor households. Although 
the incidences of catastrophic costs were the same in poor and non-poor households 
(83% when we used a threshold of 20% of annual household income), poor households 
faced a deeper impact; this is indicated by both the G (138% vs 45%) and the MPG 
(167% vs 55%).  
As shown Chapters 3 and 4, patients incurred high costs even during the pre-diagnostic 
phase, i.e. the period between starting to seek care to relieve TB-related signs and 
symptoms and finally obtaining a diagnosis of TB. It is important to note that it was in 
this phase that the effect of Indonesia’s national health insurance program on TB-related 
costs for households was expected to become apparent. This is because, if patients 
received TB treatment at facilities linked to the National Tuberculosis Program (NTP), 
the direct medical costs incurred during the treatment phase would already have been 
covered. The introduction of Indonesia’s national health insurance program in 2014 had 
also ensured that, provided diagnosis was sought at healthcare providers linked with 
BPJS-K – the national health insurance agency (Badan Penyelenggara Jaminan Sosial 
Kesehatan) – direct medical costs incurred during the pre-diagnostic phase would also 
be covered.  
However, despite the national health insurance program, the reality is that patients still 
faced high direct costs during the pre-diagnostic phase – not only direct medical costs 
such as consultation fees and diagnostic tests, but also direct non-medical costs, such as 
transportation and food costs. The direct medical costs incurred during the pre-
diagnostic phase resulted mainly from medical consultations with private health 
providers. These providers are discussed in detail below, under the sub-heading ‘Private 
healthcare providers and the economic impacts of TB.’ 
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Chapters 3 and 5 nonetheless demonstrate that most of the costs of accessing TB-related 
services were indeed faced during the treatment phase, amounting to 88% of the median 
total costs for TB-affected households, and 98% for MDR-TB-affected households. 
Although the NTP covers the direct medical costs, including free TB and MDR-TB 
drugs, these were not the only direct medical costs patients incurred: there were also 
others, such as administrative costs for patients with TB, and hospitalization for those 
with MDR-TB. Nevertheless, the contribution of these two items to the total costs was 
very small (<1% of the median total costs). During the treatment phase, direct costs 
consisted mostly of non-medical costs: those for transportation (5% of the median total 
costs in TB-affected households and 14% in MDR-TB-affected households) and for 
food supplements (10% and 6% respectively). 
After being diagnosed with TB, the proportion of patients who lost their jobs was high: 
32% of those who had had an income-earning job before the diagnosis of TB, and 69% 
of those with MDR-TB. These people quit their jobs for various reasons, including 
stigmatization in the workplace,1 frequent visits to healthcare services,2 and worse 
health.3, 4 The impact of job loss is clear: once patients lose their job, they also lose 
much of their income, thereby reducing the financial capacity of their households. The 
average income loss to those who lost their job amounted to 80% of total costs. Even 
though some patients maintained their jobs during the treatment phase, healthcare visits 
often caused their incomes to fall, particularly in the case of those working in the 
informal sector. Indeed, our data show that income loss was high, even among patients 
who kept their jobs: the income of TB patients who had maintained their job, their 
income reduced by 24% (95% CI 18-30%) compared to their previous income. In the 
case of MDR-TB patients, this was 24% (95% CI 8-21%). As a result, household 
incomes fell by 15% (95% CI 8-22%) in TB-affected households and 20% (95% CI 7-
33%) in MDR-TB affected households. 
For many patients, the perceived economic impact of TB was severe. In Chapter 6, we 
found in the context of UHC that TB and MDR-TB patients perceived a need for 
financial support to cover direct non-medical costs (transportation costs and food 
supplements costs) and indirect costs (income loss). The need for support to recover 
income loss was higher than for support to cover other costs. This highlights the critical 
nature of the impact of TB on income and job loss – a problem that should be addressed 
properly in the global and national frameworks for combating TB. 
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The effect of Indonesia’s national health insurance program on catastrophic costs for 
TB and MDR TB patients is limited because of two reasons. First, most medical costs 
incurred for TB treatment in PHCs were already covered by the NTP, while the national 
health insurance covered medical costs incurred during the pre-diagnostic phase. In the 
pre-diagnostic phase, nonetheless the effect of national health insurance is indeed 
limited according to TB-related costs incurred between patients who were beneficiaries 
and patients who were non-beneficiaries of the national health insurance program. 
While some 61% of TB patients were beneficiaries, statistically, the direct medical costs 
they incurred in the pre-diagnostic phase were not significantly lower than those 
incurred by non-beneficiaries. This indicates that, despite their health-insurance 
coverage, many patients sought care for diagnosis at private healthcare facilities that 
were not linked to the NTP and the BPJS-K. Neither did the incidence of catastrophic 
costs between the insurance beneficiaries and the non-beneficiaries differ significantly. 
Second, while the national health insurance covers direct medical costs, the largest part 
of the total costs incurred by TB-affected household consisted of indirect costs. 
Our findings suggest that the economic impact of TB remains high. While this is due 
partly to the role of private healthcare providers in the pre-diagnostic phase, the most 
important factor is income loss in the treatment phase. In the context of UHC, 
Indonesia’s national health insurance program is similar to the universal health 
insurance programs elsewhere that cover most direct medical costs. But while it is 
essential to these costs, they are only part of the financial burden, and covering them is 
not enough to mitigate the impact. A much higher economic burden is often imposed 
by direct non-medical costs and the indirect costs caused by job and income loss.  
 
Private healthcare providers and the economic impacts of TB 
Research Question 2: What is the contribution of private healthcare providers to this 
economic impact of TB? 
During the pre-diagnostic phase we found that private healthcare providers had 
contributed significantly to the economic impact of TB. Despite the national health 
insurance, suspected TB patients often sought care first either at private clinics (33%) 
or at private hospitals (7%). The preference for these private institutes as a first point of 
care was significantly more common in the rural district than in the urban district, and 
the costs incurred at them during this phase were significantly higher than those incurred 
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by patients who had first visited a PHC. These high costs were due to higher direct 
medical costs (e.g., diagnostic tests) and direct non-medical costs (e.g., transportation 
costs). 
The higher preference for first seeking care from a private provider (rather than at a 
public provider) in the rural district than in the urban may have been due to the limited 
number of PHCs in the rural and their limited opening hours. If so, patients may have 
felt encouraged to visit private healthcare providers – whether clinics, solo practices, or 
hospitals – that were closer to their homes or were open in the afternoon or evening. In 
principle, such a preference would save time and money on transportation, and avoid 
potential income loss. But many patients in the urban district (27%) had also sought 
care first from a private provider, even though their choice of public health providers 
was much greater. Various factors may have affected this preference: unawareness of 
the free TB service provided by the PHCs, the inconvenient consultation hours and long 
waiting times at PHCs, or perceptions that the quality of care provided there was low.5  
In Chapter 4, we also reported that the preference for first seeking care from a private 
clinic had led to a significantly higher average number of healthcare visits (3.06, 95% 
CI 2.83-3.30) than first seeking care from a PHC (2.18, 95% CI 1.96-2.41). This higher 
average number may have resulted from additional visits needed for referral for 
diagnostic tests. As many private providers have no laboratory facilities, they referred 
suspected TB patients for diagnostic tests to a PHC, hospital, or referral laboratory.6 
The higher number of visits may also have been due to the low quality of TB diagnostic 
care given by a private healthcare provider, or to its poor adherence to the TB care 
guidelines.7  
Although it is assumed that the UHC provided through the national health insurance 
program would reduce costs in the pre-diagnostic phase, we found no difference 
between insurance beneficiaries and non-beneficiaries with regard to the following: 
their choice of public or private providers as the first point of care, the number of 
healthcare visits they had made, and the costs they had incurred during the pre-
diagnostic phase. Instead, we did find that average total pre-diagnostic costs were higher 
for patients whose first point of contact had been a private clinic (USD 32; 95% CI USD 
23-41) or a private hospital (USD 37; 95% CI USD 22-52) than whose first point of 
contact had been a PHC (USD 14; 95% CI USD 10-17).  
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In principle there are four main explanations for the higher TB-related costs incurred 
by those who visited private providers. First, as many private providers are not linked 
to the BPJS-K, patients still pay for medical costs. Our additional analysis did indeed 
show that the medical costs incurred at private clinics (USD 21; 95% CI USD 15-28) 
and private hospitals (USD 32; 95% CI USD 17-48) were significantly higher than those 
at PHCs (USD 5; 95% CI USD 3-7), while travel costs between private providers and 
PHCs did not differ significantly (see Annex E).  
Second, patients who first sought care from private hospitals breached the referral 
system. It is also the case that the national health insurance program does not allow 
patients to visit a private hospital unless they have been referred by a provider at 
primary-care level; the costs are otherwise paid out-of-pocket, which is very expensive. 
Nonetheless, in Chapter 4, we found that 7% of TB patients had first sought care from 
a private hospital rather than from a primary healthcare facility.  
The third possible explanation for the higher TB-related costs incurred by those who 
visited private providers is that while private providers may be linked to the BPJS-K, 
their poor quality of TB service leads patients to misdiagnosis or delays in undergoing 
diagnostic TB tests, both of which can result in higher direct and indirect costs.  
The fourth possible explanation lies in the fragmented connection between the national 
health insurance program and the system under the NTP. Despite their linkage to the 
BPJS-K, private providers may be unaware of the current guidelines for TB care 
management5 and the free TB diagnostic tests available from BPJS-K-linked or NTP-
linked facilities.8 Such unawareness might have led to the higher direct medical costs 
during pre-diagnostic phase. On the other hand, coordination between BPJS-K and 
private providers is often poor, as is the exchange of information between them. In many 
cases, private providers are also afraid that if they refer a patient to another facility, the 
patient will be transferred completely, thereby losing them the patient and the income 
from the capitation payment – payment system based on the number of members 
registered in a primary-level healthcare provider.9 As a result, private providers prefer 
to keep their patients, and not to refer them to other healthcare facilities. Potentially this 
leads to misdiagnosis, delay to diagnosis, and eventually higher costs incurred by 
patients.  
In summary, as a high proportion of suspected TB patients first seek care from private 
healthcare providers, the costs they incur in the pre-diagnostic phase are higher than 
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they would have been at a PHC. This is due largely to the higher medical costs (e.g., 
consultation fee, drug costs, and diagnostic tests costs). However, the costs incurred in 
this phase make only a limited contribution to the total TB-related costs, the greater part 
of which is incurred during the treatment phase, and consists mainly of indirect costs 
due to income loss. These findings makes it imperative to develop a comprehensive 
strategy for overcoming the economic impact of TB, which could be mitigated by taking 
action on three fronts: bridging the gap between the BPJS-K and the NTP in the TB 
care-delivery system, improving the quality of the TB care given by private providers, 
and, once a patient has been diagnosed, following a suitable strategy to ensure that he 
or she does not suffer income loss.  
 
Catastrophic costs, treatment outcome and treatment adherence 
Research Question 3: Do catastrophic costs affect patients’ TB treatment adherence and 
treatment outcome? 
Our study shows that TB-related catastrophic costs have a negative impact on treatment 
outcome. The odds of an unsuccessful treatment outcome were two to three times higher 
among patients who had experienced catastrophic costs than among those who had not. 
While our findings were statistically significant at a threshold for catastrophic costs of 
30%, there was an indication that this may also be the case at thresholds between 10% 
and 25%. Due to the possibility of reverse causation, the association between 
catastrophic costs and TB treatment adherence is more complicated. Catastrophic costs, 
on one side, may cause poor adherence. On the other side, poor adherence can also lead 
to prolonged treatment that results in a higher proportion of households to face 
catastrophic costs. After adjustment for such reverse causation, we found at thresholds 
of 10% and 15% that catastrophic costs had negatively affected treatment adherence. 
The odds of poor treatment adherence were approximately twice as high for patients 
who had experienced catastrophic costs than for those who had not.  
In Chapter 5, we found at a threshold of 30% that catastrophic costs had had a 
statistically significantly negative impact on treatment outcome; we also found an 
indication that this may also be the case at thresholds between 10% and 25%. At a 
threshold of 30% of annual household, the odds of unsuccessful treatment outcome were 
3.86 times higher (95% CI 1.11-13.38, P=0.03) in patients who had experienced 
catastrophic costs than in those who had not. On the basis of this adjusted odds ratio, 
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the population-attributable fraction (PAF) is 38.6%, meaning that the unsuccessful 
outcome experienced by 38.6% of patients cases whose treatment outcome were 
unsuccessful could be attributed to catastrophic costs.  
The association between catastrophic costs and TB treatment adherence is more 
complicated than the association between catastrophic costs and treatment outcomes. 
This is due mainly to potential reverse causation. We found that higher costs, including 
catastrophic costs, were associated with poor treatment adherence. At a threshold of 
15% of annual household income, the odds of poor treatment adherence were 2.35 (95% 
CI 1.08-5.14, P=0.03) times higher in patients who had experienced catastrophic costs 
than in those who had not. However, it is possible that, due to financial constraints, a 
patient does not visit the PHC regularly, but still remains in treatment. Despite poor 
adherence, a patient may remain in TB treatment, either out of a feeling of obligation 
towards medical staff to finish TB treatment, or because he or she wishes to avoid any 
future recurrence. Such behaviour may extend TB treatment in a way that eventually 
leads not only to higher costs for transportation and food, but also to higher loss of 
income loss. Eventually, such a sequence would lead to a higher incidence of 
catastrophic costs. After adjusting for such reverse causation, we found that, at the 10% 
threshold, the odds of poor adherence were 2.11 times higher (95% CI 0.97-4.59, 
P=0.059) in patients who had experienced catastrophic costs than in those who had not. 
Findings were similar at the 15% threshold (aOR 2.06, 95% CI 0.95-4.46, P=0.07). 
However, due to the size of our study and lack of statistical power, although there is 
indication of a similar effect at the thresholds of 20-30%, we need to be cautious with 
drawing firm conclusions with respect to these levels. 
Our findings provide evidence of the effect of catastrophic costs on treatment outcomes 
and treatment adherence in a middle-income, TB high-burden country. Until now, the 
only study which assessed the association between catastrophic costs and poor 
treatment outcome was the Peruvian study (2014) which suggested a threshold of 
20%.10 Apart the evidence provided by that Peruvian study, there is very little evidence 
on the effect of catastrophic costs on treatment outcomes. Although the WHO now 
recommends that sensitivity analyses use several thresholds to measure the incidence 
of catastrophic costs,11 it is also essential to define which indicators are important in the 
context of a TB-control program at national and regional levels. Our findings suggest 
that if poor treatment adherence is an important issue, it would be better to consider 
defining catastrophic costs on the basis of a lower threshold, i.e., 15% of annual 
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household income. If TB treatment outcome is an important issue, a higher threshold – 
30% of annual household income – might be considered.  
TB-related catastrophic costs negatively affect TB treatment outcomes and adherence. 
The new evidence provided by our findings can inform a review of the threshold at 
which these costs should be measured in future global policy. However, the effect of 
catastrophic costs on treatment outcomes and adherence – and at which threshold – 
should be carefully assessed according to the definition of variable measurement, the 
national burden of TB, and the targets of the TB control program. These findings 
highlight the need for TB control interventions to properly address the socioeconomic 
aspects of the disease. 
 
Potential effect of further social protection beyond UHC 
Research Question 4: What is the potential effect on the incidence of catastrophic costs 
of further social-protection measures beyond UHC? 
Indonesia’s current national health insurance program covers the direct medical costs 
incurred at healthcare providers linked to the BPJS-K, while the NTP provides free TB 
treatment with healthcare providers linked to the NTP. Nonetheless, these two programs 
are not enough to mitigate the economic impact of TB, and the incidence of catastrophic 
costs remains high. Patients therefore need additional financial support to cover three 
prominent cost items: income loss, transportation costs, and food supplement costs. The 
simulation study we present in Chapter 6 shows that the provision of support for a 
combination of these three items would substantially reduce the incidence of 
catastrophic costs. But as financial support alone will not be enough to eliminate this 
incidence to zero percent, other social-protection measures – such as job security policy 
and social community support – are also necessary. 
In short, TB-affected households need additional financial protection to mitigate the 
socioeconomic impact of TB. Our study shows that 48% of TB patients and 78% of 
MDR-TB patients perceive TB to cause moderate to severe financial problems in their 
households. The proportion of patients who face income loss is also high (61% in TB-
affected households and 86% in MDR-TB-affected households). As 24% of TB patients 
and 34% of MDR-TB patients indicate, income loss is at the top of the list of items that 
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most need to be covered. Next on the list are financial protection to cover transportation 
costs (19% and 42%) and food supplements (15% and 8%).  
As our simulation studies show, providing cash transfers beyond UHC would 
substantially reduce the incidence of catastrophic costs. Cash transfers for a 
combination of three cost items – income loss, transportation, and food supplements – 
would do most to reduce the incidence of catastrophic costs: by 25 percentage points in 
TB-affected households (from 36% to 11%), and by 60 percentage points in MDR-TB-
affected households (from 83% to 23%). However, these alternative scenarios did not 
consider patients or households’ behavioural effects in response to the cash transfer. In 
the case of cash transfer, patients or houesholds may consume it for other purposes that 
are not related to TB treatment, such as for covering transportation costs to healthcare 
facility. Therefore, we need to be cautious with drawing firm conclusions with regards 
to the effect of the cash transfers. 
Cash transfers to TB-affected households would have a greater effect in poor 
households than in non-poor households: in the baseline scenario without cash transfers, 
it is in poor households that the incidence of catastrophic costs is significantly higher. 
If both groups were provided with a cash transfer consisting of the same amount for 
everyone, the gap between poor and non-poor households would disappear. On the other 
hand, in the baseline scenario without cash transfer, the incidence of catastrophic costs 
among poor and non-poor MDR-TB-affected households is equally high. In most 
simulated scenarios, the incidence of catastrophic costs would fall, but would still 
remain equally high in both.  
Implementing cash transfer for TB- and MDR-TB-affected households beyond UHC 
nevertheless requires careful assessment. First, it is difficult to determine the value of a 
cash transfer that would fit all patients, as the value of the cash transfers required covers 
a very wide range.  
Second, cash transfers would demand an additional budget, whose affordability and 
sustainability should be considered carefully. Our simulations suggest that providing 
cash transfers would lead to a substantial increase in government spending on the TB 
and MDR-TB programs. With regard to TB-affected households, public spending on 
the TB program would increase by between 46% (to provide cash transfers for 
transportation) and 148% (cash transfers for a combination of income loss, 
transportation, and food supplements). With regard to MDR-TB-affected households, 
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the expected increase in public spending would be less: between 8% (cash transfers for 
transportation) and 20% (cash transfers for a combination of income loss, 
transportation, and food supplements). This is because MDR-TB already requires high 
costs for treatment.  
The third matter to assess is this: to avoid the risk of stigmatization and moral hazard, 
the provision of cash transfers would require a systematic targeting and delivery 
system.12 
As well as the national health insurance program, Indonesia has another social-
protection program, the Hope Family Program (Program Keluarga Harapan, PKH). 
Previously known as the ‘cash-transfer program’ (Bantuan Langsung Tunai),13 this 
targets poor households as beneficiaries of cash transfers, irrespective of whether a 
household member suffers from TB. Since 2019, the cash transfer has consisted of 
several components: a fixed cash transfer; a health-related cash transfer (if a household 
has one or more pregnant women and/or one or more child under five years of age); an 
education-related cash transfer (if a household has one or more school-aged child); a 
socially-related cash transfer (if a household has one or more person aged over 60; or 
one or more person with a disability). According to its components, the amount of cash 
transferred ranges between USD 67 to USD 778 per year. The transfer is made every 
three months, and is conditional on the household beneficiary fulfilling certain criteria, 
such as a minimum of four pregnancy visits for a pregnant woman and a minimum 
attendance of >85% of the total annual number of school days for school-aged 
children.14  
In the context of TB, the PKH is a TB-sensitive initiative that has the potential to 
improve TB prevention, access to TB-related services, or TB treatment outcome, as 
poor people have a higher risk of TB and are vulnerable to deeper impoverishment as a 
result of it.12 However, although the PKH is conditional, the indicator focuses much 
more on mother-and-child health, does not includes a TB-related indicator in the health 
component, and does not specifically includes access to healthcare services. To date, 
there has been no evidence of its effect on improving the TB control program or 
reducing the economic impact of TB.  
Despite the UHC, additional financial support is needed for TB-affected households. 
Potentially, financial support in the form of cash transfers to these households can 
substantially reduce the incidence of catastrophic costs. Support that was specific for 
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TB-affected households would have a greater impact on reducing the incidence of TB-
related catastrophic costs than support that was provided to a broad, non-TB-specific 
group, such as the support to poor households provided under the PKH. The 
combination of TB-specific and TB-sensitive initiatives would have a greater effect of 
financial support to reduce the incidence of catastrophic costs. Nevertheless, developing 
a cash transfer system for TB patients would be a complex process, as the amount of 
cash transfer that was affordable and sustainable would have to be formulated. Since 
cash transfers based on our simulated scenarios would require a 46-148% increase on 
the current TB program budget and a 8-20% increase on the current MDR-TB program 
budget, a strong commitment from government is imperative. To improve the effect of 
financial support, other innovative social-protection policies would also be required, 
such as strengthening policies on job security in order to avoid income loss. Neither 
should an income-protection system be also restricted only to TB-affected households. 
Instead, it should include other chronic illnesses that are in danger of leading to income 
loss after diagnosis. 
 
Methodological issues 
Generalizability is one of the methodological issues in our studies. While these studies 
captured the incidence of catastrophic costs, their association with treatment outcome 
and adherence, and the effect of financial support in reducing the incidence of 
catastrophic costs in urban, suburban, and rural districts, the districts in question were 
all on the island of Java. While this is the most populous island in Indonesia, and is 
home to 60% of Indonesian population, Indonesia covers a very wide geographical area, 
with many islands and remote areas. For this reason, our findings are not necessarily 
generalizable to parts of Indonesia whose sociodemographic and geographical 
characteristics and whose levels of health-service readiness differ.  
It is clear that different sociodemographic and geographical characteristics may lead to 
different cost levels. In islands and remote areas, transportation costs are much higher 
than in Java, as many patients travel by boat, ferry, or taxi-bike, all of which are more 
expensive than more usual forms of public transport.15 Similarly, the proportions of 
patients who work in the informal sector may be higher on other islands and in remote 
areas. While we assume that incomes will be lower than in Java, income losses may – 
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arguably – also be lower. Nonetheless, as patients in other parts of Indonesia incur 
higher transportation costs15 but lower income losses16 than the patients in our study, 
the incidence of catastrophic costs may differ only slightly from the incidence we found 
in our study. While income loss contributed most to catastrophic costs, we would not 
expect the need for additional socioeconomic support in other parts of Indonesia to 
differ greatly from that in our study. Meanwhile, the value of financial support that 
needed to be covered might be slightly lower.  
With regard to other islands and other areas, it is equally clear that different levels of 
health-service readiness and access to healthcare services may also affect TB treatment 
outcomes and treatment adherence, and the relationship of both with catastrophic costs. 
If the number of healthcare facilities is limited and the quality of TB care is poor, this 
may lead to poor treatment adherence and to outcomes that prolong treatment, and thus 
to higher costs and greater loss of income. In such areas, the associations between 
catastrophic costs, treatment outcome and treatment adherence are therefore likely to 
be stronger than those we found in our study. 
The generalizability of our findings was also limited by our inclusion criteria, which 
were restricted to TB patients who had undergone TB treatment in a PHC. In other 
words, as we did not consider TB patients treated by private providers, we did not 
consider the costs they incurred, the socioeconomic impact of TB, their treatment 
adherence, or their treatment outcomes. However, as we discussed before, the high costs 
incurred at private providers that were not linked to the NTP and the BPJS-K may also 
have increased not only the risk of poor adherence or loss to follow up, but also have 
led to a high number of cases with unsuccessful treatment. Private providers that are not 
linked to the NTP have no obligation to notify new TB cases, to follow up treatment, or 
to report treatment outcomes. They are also assumed to provide low quality of TB care.7 
In this context, the relationship between catastrophic costs and treatment adherence and 
treatment outcome may be more noticeable.  
We should also indicate that private providers in Indonesia are concentrated in urban 
areas and in Java – all densely populated areas. Since patients elsewhere rely much more 
on PHCs than on private providers,17 we believe that our restriction of inclusion to 
patients who had been treated in a PHC was reasonably representative for the 40% of 
the Indonesian population that does not live in Java.  
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With regard to their application to other countries, our findings naturally require careful 
appraisal. Private providers’ levels of engagement in TB-control programs vary from 
one country to another.18 The provision of UHC may also vary, especially with regard 
to population levels, service, and cost coverage, and also to the degree of linkage 
between national health insurance and private providers. For all these reasons, UHC in 
other countries may or may not mitigate the economic impact of TB to a greater extent 
than in Indonesia.  
 
Recommendation for further research and policy 
It is vital that the target for eliminating the incidence of TB-related catastrophic costs is 
achieved. Our studies provide evidence that might improve TB policy in this regard, but 
further investigations are required.  
 
Recommendations for further research 
In 2020, Indonesia will conduct a national survey of TB costs. The most important 
quality it should ensure is the generalizability of the study through a robust sampling 
method and a sample size that is sufficient to capture the situation throughout Indonesia.  
It is also important that it captures the TB costs incurred by patients of private healthcare 
providers. For comparative purposes, samples of private providers should therefore 
include private providers that have links to the NTP only, those that have links to the 
BPJS-K only, those that have links to both, and those that have no affiliation to either 
the NTP or the BPJS-K. The 2020 cost survey can use the adapted questionnaire 
provided in this thesis. 
While the incidence of catastrophic costs is obvious, it is essential that further research 
determines how social protection should ensure that future costs of this sort are avoided. 
This study has already highlighted the need for additional social-protection measures in 
terms of cost items and the value of cash transfers.  
A further step towards formulating financial protection for an intervention study is to 
involve as many TB-related stakeholders as possible. Protection should not be limited 
to finances alone, but should also include social issues such as the provision of 
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community support19, 20 and workplace-based interventions for avoiding unnecessary 
job loss.  
Before a final recommendation for social-protection measures is produced, qualitative 
studies through interviews and focus group discussions are also necessary. These will 
also help harmonize social-protection measures not only for TB patients, but also for 
other groups. 
 
Recommendations for further policy 
As there is no single recipe for formulating a social-protection package, the context 
needs to be considered carefully. Eliminating catastrophic costs requires a clear 
understanding not just of patients’ needs and the government resources required, but 
also of the strategies that can be combined.  
First, we recommend that the TB control program is integrated into the national health 
system. Any strategy for this should ensure that the referral system between healthcare 
providers for TB diagnosis and treatment is redefined in ways that allow (1) TB drugs 
to be covered by the national health insurance benefit package, (2) TB-related indicators 
to be incorporated with the performance-based capitation payment, and (3) 
improvements in the quality of TB care in both public and private healthcare providers.  
Second, action should be undertaken to increase patients’ – and potential patients’ – 
awareness not only of the signs and symptoms of TB, but also of the wider range of 
facilities they can approach. The number of public healthcare facilities, particularly in 
rural districts, should be increased. If the role of community health workers (CHWs) is 
reinforced, it may be possible to avoid (or at least reduce) the transportation costs and 
income loss caused by visits to healthcare facilities 
Third, our findings show that the incidence of catastrophic costs would be reduced by 
combining the financial support. However, to formulate the support that could be 
provided, needs assessment will be necessary. To establish the affordability and 
sustainability of providing socioeconomic support, we recommend consultation with 
key stakeholders including the NTP, local government, public and private healthcare 
providers, community health workers, and patients. 
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Fourth, we recommend that TB control programs should incorporate a broader social-
protection strategy. This should include improvement of TB awareness and education 
in the workplace, reinforcement of the national job security policy (to avoid unnecessary 
job loss); and enhancement of the sickness fund policy in order to cover situations in 
which TB patients need to take temporary leave. Finally, as a high proportion of workers 
in informal sectors are still not covered by Indonesian national health insurance,21 the 
financial burden imposed upon them by medical costs must be reduced by bringing 
these workers into the national health insurance program.  
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Summary 
Tuberculosis (TB) is an infectious disease with a very long history. Although there have 
been strategies including drug development, effective treatment and socioeconomic 
development to eliminate TB, still an estimated 10 million TB incident cases and 1.33 
million TB patients died in 2017. The incidence of TB also remains high in Indonesia 
– a country with the third highest incidence in the worldwide.  
Meanwhile, accessing TB-related services is often costly, and can be catastrophic for 
TB-affected households. In addition to eliminate the incidence of TB, the WHO End 
TB Strategy also sets a target to reduce to zero percent the percentage of TB-affected 
households that faced catastrophic costs – defined as the total costs incurred by TB-
affected households that exceed a specific threshold of the household’s annual income. 
In 2014, Indonesia started a national health insurance program (Jaminan Kesehatan 
Nasional, JKN) to achieve universal health coverage (UHC). An extensive network of 
public and private providers has been improving. As beneficiaries of the national health 
insurance can access free essential health services, this program is assumed to reduce 
TB-related direct medical costs. Even though patients receive free TB drugs and 
medical consultations, they still incur high costs for direct non-medical costs, such as 
transportation and food during their visits to the healthcare facility, indirect costs that 
are resulted from income or job loss. Such economic consequences can be still 
catastrophic, particularly for poor households. In Indonesia, no evidence has yet been 
produced on measurements of the incidence of catastrophic costs due to TB, neither is 
there currently any evidence on the extent to which households still face catastrophic 
costs since UHC was implemented through the JKN program.  
In the context of UHC in Indonesia, this thesis aims to provide an evidence-base on the 
household-level economic impact of TB, the relationship between catastrophic costs 
and TB treatment outcomes, and the social-protection improvements required to further 
reduce TB-related catastrophic costs. 
We find that, despite the implementation of UHC in Indonesia, TB-affected households 
still incur high costs to access TB-related services. The incidence of catastrophic costs 
is high: 36% for TB-affected households and 83% for MDR-TB-affected households. 
Also, TB patients often quit their job after diagnosis, must cope with the high cost by 
borrowing money and selling property, and perceive that accessing TB-related services 
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causes moderate to severe financial problems. In the context of UHC, the national health 
insurance program in Indonesia is comparable to universal health insurance programs 
in many countries that cover most direct medical costs. Although covering direct 
medical costs is essential, it is only a part of the financial burden; and it is not enough 
to mitigate the financial impact of TB. Direct non-medical costs and indirect costs due 
to job and income loss often constitute a much higher economic burden than the direct 
medical costs.  
There is still a high proportion of suspected TB patients seeking care first with private 
healthcare providers. A first contact with a private provider contributes to higher costs 
during the pre-diagnostic phase compared to a first contact at a PHC. The higher costs 
in this phase largely result from the higher medical costs (e.g., consultation fee, drug 
costs, and diagnostic tests costs). However, the costs incurred in the pre-diagnostic 
phase have limited contribution to the total costs due to TB because the largest part of 
the total costs are incurred during the treatment phase – and mostly consist of indirect 
costs due to income loss. To mitigate the economic impact of TB, bridging the gap 
between the national health insurance agency (Badan penyelenggaran Jaminan Sosial 
Kesehatan, BPJS-K) and the National Tuberculosis Program (NTP) in TB care delivery 
system and improving the quality of TB care in private providers should be combined 
with a strategy to avoid income loss once a patient is diagnosed with TB. 
Mitigating TB-related costs is important since catastrophic costs due to TB – according 
to our findings – negatively affect TB treatment outcomes and adherence. Our findings 
provide new evidence that can inform a review of the threshold at which catastrophic 
costs should be measured in the future global policy. However, the effect of catastrophic 
costs – and at which threshold – on treatment outcomes and adherence should be 
carefully assessed according to how an NTP defines treatment outcome and adherence 
in its national context, and targets of the TB control program. 
Additional financial support beyond UHC is needed for TB-affected households. 
Potentially, financial support in the form of cash transfers to these households can 
substantially reduce the incidence of catastrophic costs. The financial support that 
combine TB-specific and TB-sensitive approach would provide a greater effect on 
reducing the incidence of catastrophic costs. Nevertheless, developing a cash transfer 
system for TB patients would be a complex process, as the amount of cash transfer that 
is affordable and sustainable would have to be formulated. To improve the effect of 
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financial support, other innovative social-protection policies are required, such as 
strengthening policies on job security in order to avoid income loss. Neither should an 
income-protection system be restricted to TB-affected households. Instead, it should 
include other chronic illnesses that may lead to income loss after diagnosis. 
As there is no single recipe for formulating a social-protection package, the context 
needs to be considered carefully. Eliminating catastrophic costs requires a clear 
understanding not just of patients’ needs and the government resources required, but 
also of the strategies that can be combined including (1) the integration between the TB 
control program and the national health system, (2) the improvement of awareness of 
the signs and symptoms of TB, as well as of the wider range of facilities patients can 
approach, (3) the combination of the financial support, and (4) the incorporation of the 
TB control program into a broader social-protection strategy. 
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Samenvatting 
Tuberculose (tbc) is een besmettelijke ziekte met een zeer lange geschiedenis. Hoewel 
er gecombineerde strategieën zijn geweest, waaronder de ontwikkeling van 
geneesmiddelen, effectieve behandeling en sociaaleconomische ontwikkeling om tbc te 
elimineren, waren er in 2017 nog steeds naar schatting 10 miljoen gevallen van tbc en 
stierven 1,33 miljoen tbc-patiënten. De incidentie van tbc blijft ook hoog in Indonesië - 
een land met de derde hoogste incidentie in de wereld. 
Ondertussen is toegang tot tbc-gerelateerde diensten vaak duur en kan het financieel 
catastrofaal zijn voor huishoudens met tbc. Naast het elimineren van de incidentie van 
tbc, heeft de WHO End TB-strategie ook de doelstelling geformuleerd om het 
percentage tbc-getroffen huishoudens met catastrofale kosten tot nul procent terug te 
brengen. Catastrofale kosten worden hierbij gedefinieerd als de totale kosten gemaakt 
door tbc-getroffen huishoudens die, als proportie van het jaarinkomen van huishoudens, 
een specifieke drempel overschrijden.  
In 2014 startte Indonesië een nationaal ziekteverzekeringsprogramma (Jaminan 
Kesehatan Nasional, JKN) om een nationale dekking van ziektekostenverzekering 
(UHC) te bereiken. Een uitgebreid netwerk van publieke en private 
gezondheidszorgaanbieders is verbeterd. Omdat begunstigden van de nationale 
ziektekostenverzekering toegang hebben tot gratis essentiële gezondheidszorg, wordt 
ervan uitgegaan dat dit programma de tbc-gerelateerde directe medische kosten 
vermindert. Hoewel patiënten gratis tbc-medicijnen en medische consulten ontvangen, 
maken ze nog steeds hoge directe niet-medische kosten, zoals voor vervoer en voedsel 
tijdens hun bezoeken aan de kliniek, en indirecte kosten die het gevolg zijn van 
inkomensverlies of zelfs het verlies van hun baan. Dergelijke economische gevolgen 
kunnen nog steeds catastrofaal zijn, vooral voor arme huishoudens. In Indonesië is er 
nog geen wetenschappelijke bewijs over de incidentie van catastrofale kosten als gevolg 
van tbc. Er is momenteel ook geen bewijs voor de mate waarin huishoudens nog steeds 
geconfronteerd worden met catastrofale kosten sinds UHC werd geïmplementeerd via 
het JKN-programma. 
In de context van UHC in Indonesië beoogt dit proefschrift wetenschappelijke evidentie 
te leveren met betrekking tot de economische impact van tbc op huishoudensniveau, de 
relatie tussen catastrofale kosten en de effecten van tbc-behandeling, en de 
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verbeteringen in het sociale zekerheidsstelsel die nodig zijn om tbc-gerelateerde 
catastrofen verder te verminderen.. 
We constateren dat, ondanks de implementatie van UHC in Indonesië, tbc-getroffen 
huishoudens nog steeds hoge kosten maken om toegang te krijgen tot tbc-gerelateerde 
diensten. De incidentie van catastrofale kosten is hoog: 36% voor huishoudens met tbc 
en 83% voor huishoudens met MDR-tbc (multiresistente tbc). Ook moesten tbc-
patiënten na diagnose vaak hun baan opzeggen en moesten ze manieren vinden om om 
te gaan met de hoge kosten door geld te lenen en onroerend goed te verkopen. Tbc-
patiënten waren van mening dat het gebruik van tbc-gerelateerde diensten matige tot 
ernstige financiële problemen veroorzaakten. In de context van UHC is het nationale 
ziekteverzekeringsprogramma in Indonesië vergelijkbaar met universele ziektekosten-
verzekeringsprogramma's in veel andere landen waar de meeste directe medische kosten 
worden gedekt. Hoewel het dekken van directe medische kosten essentieel is, is het 
slechts een deel van de financiële last; en het is niet voldoende om de impact te 
verzachten. Directe niet-medische kosten en indirecte kosten als gevolg van verlies van 
baan en inkomsten vormen vaak een veel hogere financiële last dan de directe medische 
kosten. 
Nog steeds zoekt een groot deel van vermoedelijke tbc-patiënten eerst hulp bij 
particuliere zorgverleners. Een eerste contact met een particuliere zorgverlener draagt 
bij aan hogere kosten tijdens de pre-diagnostische fase in vergelijking met een eerste 
contact bij een PHC. De hogere kosten in deze fase zijn grotendeels het gevolg van de 
hogere medische kosten (bijvoorbeeld consultatiekosten, medicijnkosten en 
diagnostische testkosten). De kosten in de pre-diagnostische fase hebben echter een 
beperkte bijdrage aan de totale kosten als gevolg van tbc omdat het grootste deel van de 
totale kosten wordt gemaakt tijdens de behandelingsfase - en meestal bestaan uit 
indirecte kosten als gevolg van inkomensverlies. Om de financiële gevolgen van tbc te 
verzachten, moet de kloof tussen de nationale zorgverzekeraar (Badan Penyelenggaran 
Jaminan Sosial Kesehatan, BPJS-K) en het nationale tbc-programma (NTP) in het 
zorgsysteem voor tbc worden gedicht en de kwaliteit van de tbc-zorg door particuliere 
zorgverleners worden verbeterd en gecombineerd met een strategie om inkomensverlies 
te voorkomen zodra een patiënt wordt gediagnosticeerd met tbc. 
Het verminderen van tbc-gerelateerde kosten is belangrijk omdat catastrofale kosten als 
gevolg van tbc, volgens onze bevindingen, een negatieve invloed hebben op de 
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behandelingsresultaten en therapietrouw bij tbc. Onze bevindingen kunnen een 
evaluatie van de drempelwaarde voor catastrofale kosten in toekomstig beleid 
informeren. Het effect van catastrofale kosten - en bij welke drempelwaarde - op de 
behandelresultaten en therapietrouw moet echter zorgvuldig worden beoordeeld aan de 
hand van hoe een NTP de behandeluitkomst en therapietrouw definieert in de nationale 
context en in de doelstellingen van het tbc-bestrijdingsprogramma. 
Aanvullende financiële ondersteuning naast de nationale ziektekostenverzekering is 
nodig voor huishoudens die getroffen zijn door tbc. Financiële steun in de vorm van 
contant geldoverdrachten aan deze huishoudens kan de incidentie van catastrofale 
kosten aanzienlijk verminderen. De financiële steun die een tbc-specifieke en tbc-
gevoelige aanpak combineert, zou een groter effect hebben op het verminderen van de 
incidentie van catastrofale kosten. Desalniettemin zal het ontwikkelen van een systeem 
voor financiële uitkeringen aan tbc-patiënten een ingewikkeld proces zijn, aangezien de 
hoogte van het uit te keren bedrag zodanig moet worden vastgesteld dat het programma 
betaalbaar en duurzaam is. Om het effect van financiële steun te versterken, zullen ook 
andere innovatieve beleidsmaatregelen op het gebied van sociale zekerheid nodig zijn, 
zoals een versterking van het beleid om baanverlies en inkomstenverlies bij ziekte te 
voorkomen. Een inkomensbeschermingssysteem mag niet alleen worden beperkt tot 
huishoudens die door tbc zijn getroffen. In plaats daarvan zou het ook andere chronische 
ziekten moeten omvatten die na diagnose kunnen leiden tot inkomensverlies. 
Er is geen uniform recept voor het formuleren van een pakket van sociale 
zekerheidsmaatregelen. De context waarin dergelijke maatregelen worden 
geformuleerd moet zorgvuldig worden overwogen. Het elimineren van catastrofale 
kosten vereist een duidelijk inzicht, niet alleen in de behoeften van patiënten en de 
benodigde overheidsmiddelen, maar ook van de strategieën die kunnen worden 
gecombineerd, waaronder (1) de integratie tussen het tbc-bestrijdingsprogramma en het 
nationale gezondheidssysteem, (2) de verbetering van kennis in de bevolking van de 
symptomen van tbc, evenals van het bredere scala aan gezondheidszorgfaciliteiten die 
ze kunnen benaderen, (3) de combinatie van de financiële steun en (4) de integratie van 
het tbc-bestrijdingsprogramma in een bredere strategie voor sociale zekerheid. 
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Annex A  
Changes of the tool from the Generic Tool to the Phase 1 Tool and to the definitive 
Phase 2 Tool 
No Question Changes 
applied in 
Phase 1 Study Phase 2 Study 
1 Category of facility Choices Generic Tool 
retained 
Adapted to type of facilities in 
Indonesia: PHCs, private 
clinics, public hospitals, private 
hospitals, and others  
2 Ethnicity Question Question added Generic Tool retained; 
Question in Phase 1 Study 
deleted  
3 Education Question Question added Choices added 
4 Type of TB Choices Generic Tool 
retained 
Translated "smear" to "BTA" 
5 Currently in intensive 
or continuation phase? 
Choices Choices added for 
MDR TB 
Generic Tool retained 
6 Date of first diagnostic 
examination 
Question Question deleted Generic Tool retained 
7 Date of starting 
treatment 
Question Question deleted Generic Tool retained 
8 What symptoms did 
you experience? 
Question Question deleted Generic Tool retained, choice 
changed from "months" to 
"weeks"  
9 Where did you seek 
treatment? 
Question Question deleted Generic Tool retained, choices 
referring to “category of 
facility” adapted  
10 Have you visited a 
traditional healer? 
Question Question deleted Phase 1 study retained; 
question deleted  
11 Why didn’t you go to 
the public health 
facility? 
Question Question deleted Generic Tool retained, choice 
of "belief system" deleted  
12 Patient income loss Question Question added Phase 1 study retained; 
question added  
13 Insurance 
reimbursement 
Question Pengembalian 
asuransi  
Reimbursement asuransi 
14 Guardian costs (pre-
diagnostic and 
diagnostic) 
Form Changed to table 
form  
Phase 1 study retained; changed 
to table form (four questions in 
four columns)  
15 Cost-related DOT Question set (6 
questions) 
Generic Tool 
retained 
Question set deleted (6 
questions) 
16 How often do you 
travel to health facility 
to take TB drugs? 
Sub-question Generic Tool 
retained 
Sub-questions "intensive 
phase" and "continuation 
phase" added  
17 Cost related to follow-
up test 
Form Generic Tool 
retained 
Form changed to three columns 
to ease filling in the form  
18 Income loss suffered 
by guardian (someone 
accompanying patient) 
Question Question added Phase 1 study retained; 
question added  
19 How much does your 
friend/family earn per 
day? 
Choices Choices changed Phase 1 study retained; choices 
changed 
20 Why did someone 
accompany you to 
Question Question deleted Phase 1 study retained; 
question deleted 
Annexes 
145 
 
No Question Changes 
applied in 
Phase 1 Study Phase 2 Study 
travel to health facility 
to take TB drugs?  
21 How much did you 
pay in the hospital?  
Sub-question Generic Tool 
retained 
Sub-question deleted 
22 How much does your 
friend/family earn per 
day?  
Choices Choices changed  Phase 1 study retained; choices 
changed 
23 Did any other 
family/friend visit you 
to while you were in 
hospital?  
Question set (4 
questions) 
Question deleted Phase 1 study retained; 
Questions deleted (4 questions)  
24 Moving costs Question set (2 
questions) 
Question set added Question set added, and sub-
questions added to allow 
participant to state room/house 
rental price "per week", "per 
month", or "per year"  
25 Type of supplement Sub-question Generic Tool 
retained 
"Drinks" changed to "milk"  
26 Other illnesses Question set (6 
questions) 
Question set deleted Question set deleted (6 
questions) 
27 Adverse effects of TB 
drugs 
Question set (2 
questions) 
Question set added Question set added and 
wordings changed 
28 Insurance type Choices Generic Tool 
retained 
Adapted to insurance type in 
Indonesia: BPJS Kesehatan 
(PBI, non-PBI), swasta  
29 How much have you 
received as 
reimbursement?  
Sub-question Sub-questions added Phase 1 study retained; sub-
questions added 
30 Additional support Question Question added Generic Tool retained; question 
in Phase 1 Study deleted  
31 To what extent does 
TB illness affect your 
household financial 
situation? 
Question Question added Question added and choices 
changed  
32 Where did you earn 
money to pay the TB 
costs incurred? 
Question Question added Generic Tool retained; question 
in Phase 1 Study deleted  
33 What is the interest 
rate on the loan?  
Choices Choices changed Phase 1 study retained; choices 
changed 
34 What is the estimated 
market value of 
property you sold?  
Choices Choices added Generic tool retained; the order 
of questions changed by 
substituting the next question 
for this one  
35 How much did you 
earn from selling that 
property? 
Choices Choices added Generic tool retained; the order 
of questions changed by 
substituting the previous 
question for this one  
36 Did the money you 
earn from selling 
property conform to 
the market value of 
property you sold?  
Question Generic Tool 
retained 
Question and choices inserted 
37 Who is the primary 
income earner?  
Choices Choices changed Phase 1 study retained; choices 
changed 
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No Question Changes 
applied in 
Phase 1 Study Phase 2 Study 
38 What is the level of 
education of… 
Question set (4 
questions) 
Question set deleted Question set deleted (4 
questions) 
39 Are you currently 
formally employed? 
Question Generic Tool 
retained 
"Currently" changed to "before 
being diagnosed with TB"  
40 Is the (patient’s) 
reason for not working 
related to TB? 
Question Question deleted Phase 1 study retained; 
question deleted 
41 If Yes, when was the 
last time you were 
working? 
Question Question deleted Phase 1 study retained; 
question deleted 
42 How were you usually 
paid? 
Choices Generic Tool 
retained 
Adapted to situation in 
Indonesia  
43 What was your 
estimated personal 
take home earning per 
month BEFORE the 
TB illness? 
Question Question deleted Phase 1 study retained; 
question deleted 
44 What is your 
estimated personal 
take home earning per 
month NOW? 
Question Question deleted Phase 1 study retained; 
question deleted 
45 Is the change related 
to TB illness?  
Question Question deleted Phase 1 study retained; 
question deleted 
46 If Yes (stopped 
working/going to 
school/doing 
housework): for how 
long? 
Choices Generic Tool 
retained 
Choices deleted; question 
changed to open question 
47 How regularly did you 
work before you fell 
ill with TB?  
Question Question deleted Phase 1 study retained; 
question deleted 
48 Did you have to 
change jobs before 
you came ill with TB?  
Question Question deleted Phase 1 study retained; 
question deleted 
49 What is your main 
occupation? 
Question Question deleted Phase 1 study retained; 
question deleted  
50 How many hours did 
you work on average 
before you came ill 
with TB?  
Question Question deleted Phase 1 study retained; 
question deleted 
51 How many hours do 
you work on average 
now? 
Question Question deleted Phase 1 study retained; 
question deleted 
52 Is the change related 
to TB illness? 
Question Question deleted Phase 1 study retained; 
question deleted  
53 Is someone doing the 
work that you used to 
do? 
Choices Choices changed Phase 1 study retained; choices 
changed 
54 Do you have children 
of or below school 
age? 
Question Question deleted Phase 1 study retained; 
question deleted 
55 Do all of your children 
attend school 
regularly? 
Question Question deleted Phase 1 study retained; 
question deleted 
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No Question Changes 
applied in 
Phase 1 Study Phase 2 Study 
56 If no, why not? Question Question deleted Phase 1 study retained; 
question deleted  
57 Are you financially 
independent? 
Question Question deleted Phase 1 study retained; 
question deleted  
58 Has this resulted in 
financial burden?  
Question Question deleted Phase 1 study retained; 
question deleted 
59 Has the TB illness 
affected your social or 
private life? 
Question, 
choices 
Changing wording Phase 1 study retained; 
changing wording, adapting 
choices  
60 What is your 
tribe/ethnic 
group/religion?  
Question Question deleted Phase 1 study retained; 
question deleted 
61 How many people 
regularly sleep in your 
household? 
Question Question deleted Generic Tool retained, the 
question was moved to section 
before “household income and 
spending” section  
62 How many of the 
household members 
are paid for working?  
Question Question deleted Phase 1 study retained; 
question deleted 
63 Besides yourself, does 
anyone else of your 
household receive 
treatment for TB?  
Question Question deleted Phase 1 study retained; 
question deleted 
64 How much food did 
your household 
consume before the 
TB illness?  
Question Question deleted Phase 1 study retained; 
question deleted 
65 How much food does 
your household 
consume now? 
Question Question deleted Phase 1 study retained; 
question deleted 
66 Has the amount of 
food consumed 
changed due to TB? 
Question Question deleted Phase 1 study retained; 
question deleted 
67 Socioeconomic 
indicators 
Question set Deleting 5 questions Phase 1 study retained; 5 
questions deleted  
68 Do you own standard 
assets below... 
Question set Change questions 
and form 
Phase 1 study retained; 
questions changed and formed 
in separated table  
69 If the government 
could provide you 
with some service to 
ease the burden of TB 
on you and your 
household, 
what would you prefer 
to have?  
Question Generic Tool 
retained 
Question deleted 
70 How much would you 
have been willing to 
pay not to become ill 
with TB in the first 
place? 
Question Question deleted Phase 1 study retained; 
question deleted 
71 Have you ever heard 
of “social protection”?  
Question No question Question added 
72 With regard to the 
costs incurred for TB 
Question set No questions Question set added, formed in 
two columns (the first column 
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No Question Changes 
applied in 
Phase 1 Study Phase 2 Study 
treatment, which types 
of cost created 
financial hardship for 
you, and how much 
financial support do 
you expect to receive 
from the government?  
was type of costs, the second 
column was amount that is 
expected to receive from the 
government) 
 
Fuady et al. Acta Medica Indonesiana. 2018; 50 (1), 3-10 
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Annex B  
Definitive version of adapted Tool to Estimate Patient Costs in Bahasa Indonesia 
 
Perangkat untuk memperkirakan biaya yang dikeluarkan pasien 
 
Nama Pewawancara : …………… 
No Registrasi Pasien di Fasilitas TB: ……………………. 
Tanggal 
wawancara 
(dd/mm/yy) 
Nama Provinsi 
Nama Kabupaten / 
Kota 
Nama kelurahan 
Tempat wawancara 
(rumah/nama fasilitas 
kesehatan) 
     
Kategori 
Fasilitas 
Kesehatan 
tempat 
berobat 
 
1. Puskesmas        2. Klinik swasta       3. RSUD/ Pemerintah    4. RS Swasta     5. RS 
lainnya, sebutkan.......        
Memperkenalkan diri kepada pasien:  
Nama saya adalah.... Saya bekerja bersama dr. Ahmad Fuady, MSc dari Fakultas Kedokteran Universitas 
Indonesia. Kami melakukan studi  untuk mengetahui biaya yang dikeluarkan oleh pasien karena penyakit 
Tuberkulosis. Oleh karena itu, kami ingin menanyakan berapa banyak biaya yang dikeluarkan untuk pelayanan 
kesehatan, khususnya Tuberkolusis, saat sebelum dan selama diagnosis, serta sepanjang pengobatan. Kami 
memohon agar Anda dapat memberikan informasi dalam tiga bulan terakhir dan sebagian besar biaya yang 
terkait dengan TB yang dikeluarkan sebelumnya. 
Sangat penting untuk Anda pahami bahwa partisipasi Anda dalam studi ini bersifat sukarela. Kami akan sangat 
berterima-kasih apabila Anda bersedia ikut serta dalam studi ini, namun Anda dapat menolaknya. Jika Anda 
tidak bersedia ikut serta, tidak akan ada konsekuensi untuk Anda dan Anda akan tetap menerima semua 
pelayanan dan pengobatan di fasilitas kesehatan seperti biasa. Jika Anda membatalkan keikutsertaan Anda, 
Anda tidak akan kehilangan manfaat yang seharusnya Anda terima seperti pelayanan dan pengobatan yang 
diberikan di klinik. 
Jika Anda memilih untuk ikut-serta dalam studi, Anda perlu mengetahui bahwa Anda dapat mengundurkan 
diri pada setiap tahap studi tanpa harus memberikan penjelasan atas pengunduran diri Anda. Semua jawaban 
Anda akan dirahasiakan. Pada beberapa poin kami akan menanyakan tentang penghasilan pribadi dan 
penghasilan rumah tangga Anda. Kami TIDAK AKAN memberikan informasi ini kepada lembaga berwenang 
atas pajak dan kesejahteraan, hal ini berlaku pula setelah penelitian ini berakhir. 
Survey ini membutuhkan waktu sekitar 30 menit. 
Apakah Anda memiliki pertanyaan?  Apakah Anda akan berpartisipasi? (lingkari)   Ya   /   Tidak 
Tanda tangan Responden:  ………………….. 
 
Jika Ya      : Terima kasih! 
Jika Tidak  : alasan tidak berpartisipasi? (lingkari) 1. Tidak cakap berbahasa      2. Kendala waktu       
          3. Tidak nyaman                    4. Lainnya, sebutkan …………… 
Kuesioner 
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Informasi Pasien (diisi oleh Pewawancara, tambahkan keterangan dari kartu pasien; diisi juga bila pasien menolak 
diwawancarai untuk analisis non-response ) 
Responden 
1. Pasien                       
2. Pengawas Minum Obat (PMO)1 / wali yang tinggal di rumah tangga 
yang sama dengan pasien       
1. Jenis Kelamin     1. Laki-laki      
                                2. Perempuan 
Usia:  …… tahun 
2. Apakah pendidikan tertinggi Anda?   
     1. Tidak Sekolah       2. SD        3. SMP        4.SMA           5. Diploma        6. Sarjana        7. Pasca sarjana 
3. Tipe TB  (lingkari) 1.  Paru BTA +           2. Paru BTA -        3. Paru, tidak tahu status BTA     4. Ekstra Paru       
4. Regimen Terapi 
       (lingkari) 
1. Kat I (penderita baru)                                  2. Kat II (terapi kambuh atau gagal)        
3. Terapi MDR 
5. Fase terapi dan lama 
terapi? 
1. Intensif       2. Lanjutan 
6. Status HIV 
(lihat di kartu pasien!) 
1. Positif                 2. Negatif            3. Tidak dites       4. Tidak ada informasi 
7. Tanggal pemeriksaan dahak atau Foto toraks 
pertama (dd/mm/yy) 
  
8. Tanggal mulai pengobatan (dd/mm/yy)  
9. Berapa lama waktu yang diperlukan untuk mencapai 
tempat pengobatan Anda saat ini dari rumah Anda? 
……  menit dengan berjalan kaki/bersepeda……  menit dengan 
kendaraan pribadi atau angkutan umum  
Pengobatan Sebelumnya 
10. a) Pernahkah Anda mendapatkan pengobatan TB 
sebelumnya? Cocokkan dengan kartu pasien; 
Jika Tidak,lanjut ke11 
1. Ya. (mm/yy pengobatan selesai)……………. 
2. Tidak 
b) Jika YA: Apakah Anda menyelesaikan pengobatan 
TB Anda terdahulu? 
1. Ya 
2. Tidak 
   c) Jika TIDAK, mengapa? 
 
1. Kekurangan biaya untuk pengobatan           
2. Efek samping obat                   
3. Jarak tempuh ke fasilitas kesehatan 
4. Lainnya (sebutkan): …… 
Keterlambatan, Biaya Pradiagnosis dan Diagnosis    
11. Gejala apa yang Anda alami sehingga Anda memutuskan pergi berobat untuk penyakit Anda yang sekarang? Berapa 
lama Anda mengalami gejala-gejala tersebut sebelum Anda pergi mencari pengobatan?   
  
1. Batuk                        YA  □   TIDAK  □ 
_______minggu        
2. Keringat malam        YA  □   TIDAK  □ _______ 
minggu  
3. Batuk berdarah         YA  □   TIDAK  □ 
_______minggu       
4. Berat badan turun     YA  □   TIDAK  □ ______ minggu         
5. Lainnya  (Jelaskan )  YA  □   TIDAK □ _____ minggu   
______________        
12. Ke mana saja Anda mencari pengobatan untuk mengatasi gejala-gejala tersebut? Centang semua yang sesuai 
 
 
1 PMO: Pengawas Minum Obat yang secara khusus ditunjuk oleh pasien/penyedia layanan 
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1. RSUD                                          YA  □    TIDAK  □            
2. RS Swasta                                   YA  □    TIDAK  □    
3. Puskesmas                                  YA  □     TIDAK  □   
4. Klinik Swasta                               YA  □     TIDAK  □ 
5. Lainnya (Jelaskan                          □ ________   
       Ke mana Anda pergi pertama kali? Lingkari tempat pertama pengobatan tersebut di atas 
Jika selain dari fasilitas kesehatan pemerintah yang dipilih di 12):  
   
13. Mengapa Anda tidak pergi ke fasilitas kesehatan pemerintah, seperti Puskesmas atau RSUD, ketika Anda pertama kali 
ingin berobat? Lingkari yang paling sesuai.  
1. Jarak terlalu jauh          
2. Biaya terlalu mahal         
3. Waktu tunggu terlalu lama         
4. Fasilitas tidak lengkap/tersedia 
5. Tidak percaya pada kualitas fasilitas kesehatan 
pemerintah        
6. Tidak ada obat-obatan tersedia 
7. lainnya (Jelaskan)  : ________________________ 
 
14. Berapa banyak biaya yang Anda habiskan untuk setiap kunjungan sebelum Anda didiagnosis TB, 
termasuk kunjungan ketika Anda benar-benar menerima diagnosis Anda?  
Untuk pasien MDR-TB,  tanyakan hanya tentang biaya untuk diagnosis MDR-TB; untuk pasien TB lainnya, 
tanyakan tentang biaya untuk diagnosis TB. Untuk semua yang tidak berhubungan, tandai dengan N/A, isi 
satu baris per kunjungan. Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. 
Jangan hanya dikosongkan 
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Kehilangan 
penghasil-
an pasien
Reimburse
ment 
Asuransi 
Jika ya: 
jumlah dan 
untuk apa, 
jika tidak 
n/a 
Diantar 
oleh Orang 
lain 
( lingkari 
jawaban 
yang tepat)
Biaya 
perjalanan 
untuk 
pengantar 
(total pulang 
pergi)
Biaya 
akomodasi 
untuk 
pengantar 
(total)
Kehilangan 
pendapatan 
yang 
dialami 
Pengantar 
Kunjungan 1 Ya / Tidak 
Kunjungan 2 Ya / Tidak 
Kunjungan 3 Ya / Tidak 
Kunjungan 4 Ya / Tidak 
Kunjungan 5 Ya / Tidak 
Kunjungan 6 Ya / Tidak 
Kunjungan 7 Ya / Tidak 
Kunjungan 8 Ya / Tidak 
TOTAL Ya / Tidak 
Total Biaya Pra-Diagnosis & Diagnosis (jumlah subtotal) dikurangi Biaya yang diganti 
asuransi =    …………………………………………. Rupiah 
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Biaya Pengobatan (Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. 
Jangan hanya dikosongkan 
 
 
Biaya yang dikeluarkan untuk pengantar saat mengambil obat dan pemeriksaan/tes evaluasi atau tindak 
lanjut selama pengobatan. Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. 
Jangan hanya dikosongkan 
23. a) Apakah ada yang menemani Anda pada waktu mengambil obat dan 
melakukan pemeriksaan laboratorium/Foto toraks lanjutan, atau menggantikan 
Anda untuk mengambilkan obat Anda? Jika tidak, lanjut ke P 244. 
1. Ya           
2. Tidak 
b) Jika YA, Apakah orang tersebut kehilangan pendapatannya karena pergi 
menemani Anda?  
1. Ya          2. Tidak 
Jika ya, berapa 
jumlah total  
……… 
Biaya untuk pengambilan obat, baik yang langsung diminum di fasilitas tersebut, atau diminum di rumah 
Biaya yang dikeluarkan untuk pemeriksaan  dan tes selama pengobatan. 
15. Apakah Anda pernah menjalani pemeriksaan/tes  untuk evaluasi 
pengobatan sejak pengobatan dimulai? Jika TIDAK, lanjut ke P 23.  
 
       Sputum /Tes lab    Berapa kali? _____ kali     Biaya Sputum (total) 
Rp    ____________  
       Foto toraks            Berapa kali? _____ kali     Biaya foto toraks 
(total) Rp    ____________ 
      Pemeriksaan lain   Berapa kali? _____ kali     Biaya Pemeriksaan 
lain (total) Rp    ____________ 
1. Ya           
2. Tidak 
 
 
 
 
16. Seberapa sering Anda pergi ke fasilitas kesehatan untuk mengambil obat TB 
Anda? 
a. Fase intensif 
b. Fase lanjutan 
……  kali / bulan 
……  kali / bulan 
17.  Berapa lama waktu yang Anda butuhkan untuk 
sampai ke tempat tersebut (sekali perjalanan)? 
 
....   menit berjalan kaki    .....   menit dengan 
kendaraan pribadi          
 ......   menit dengan angkutan umum 
18. Berapa rata-rata total waktu yang dibutuhkan untuk sekali kunjungan, termasuk 
waktu perjalanan dan waktu tunggu (total waktu hingga selesai)? 
 ….. menit        
19. Dari rumah ke fasilitas kesehatan, berapa biaya transportasi yang Anda 
keluarkan? (pulang pergi) 
……. 
20. Jika Anda pergi ke fasilitas kesehatan untuk mengambil obat Anda, berapa 
biaya yang Anda keluarkan untuk makanan dan minuman pada hari tersebut? (di 
jalan, saat menunggu, dll)  
Total   
………………
…… 
21. a) Apakah Anda harus membayar biaya administrasi pada saat mengambil obat 
TB? 
Jika TIDAK, lanjut ke P 21. 
 b) Jika YA, berapa? 
1. Ya       
2.Tidak 
 
…………. 
22. a) Apakah ada biaya akomodasi yang harus Anda tanggung saat mengambil 
obat TB Anda?  
Jika TIDAK, lanjut ke P 22. 
b) Jika YA: berapa? 
1. Ya      2. 
Tidak 
 
………… 
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c)  Jika YA , berapa kali orang tersebut menemani atau menggantikan Anda? 
 
.............. kali 
 
Rawat Inap  Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
Catatan untuk pewawancara: jika pasien masih dirawat inap, tanyakan tentang kondisi terkini termasuk 
saat diwawancarai.  
24. Apakah Anda pernah dirawat sebelumnya (karena TB) atau selama 
pengobatan TB Anda?  
Jika TIDAK, lanjut ke P30. 
1. Ya            2. Tidak 
25. Jika YA: berapa hari Anda dirawat di rumah sakit atau Puskesmas?  …… Hari 
26. Berapa biaya yang Anda keluarkan selama dirawat di rumah sakit atau 
Puskesmas? 
 
Total: Rp  ………. 
27. Apakah ada keluarga / teman yang menemani Anda selama di rumah sakit? 
Jika Tidak, lanjut ke  P30. 
1. Ya            2. Tidak 
28. Jika YA: Berapa hari ia tinggal bersama Anda (menginap di rumah sakit)? 
 
29. Apakah ada biaya lain yang dikeluarkan untuk keluarga/teman Anda selama 
tinggal di rumah sakit? 
 
Akomodasi (rumah sakit atau lainnya):    ……..             Makanan:   ……….                  
Transportasi:     ………...                                                Kehilangan Pendapatan:  
…….. 
Lain-lain:   ………… 
 …… Hari 
 
1. Ya                   
2. Tidak 
 
 
Total Biaya: ……… 
 
Biaya Pindah Tempat Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. 
Jangan hanya dikosongkan 
30. Apakah Anda harus pindah untuk dapat menerima pengobatan TB ? 1. Ya            2. Tidak 
a) Jika YA: Anda menyewa: 
           Per Minggu 
           Per Bulan 
           Per Tahun 
 
Biaya Sewa 
Rp 
……………………. 
Biaya Lain-lain  Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan 
hanya dikosongkan 
 
31. a) Apakah Anda membeli suplemen khusus untuk diet Anda dikarenakan 
penyakit TB, contohnya vitamin, daging, minuman berenergi, minuman ringan, 
buah-buahan, atau obat-obatan? Jika Tidak, lanjut ke P32. 
1. Ya              
2. Tidak    
3. Tidak tahu/tidak 
jawab 
b) Jika YA: Apakah jenisnya? (sebutkan)    
 
1. Buah-buahan           2. Susu           3. Vitamin/Herbal           4. Daging           5. Lainnya (sebutkan): 
c) Berapa perkiraan biaya yang Anda keluarkan untuk membeli barang-barang 
tersebut dalam 30 hari terakhir? 
………… 
32. a) Apakah Anda mengalami efek samping atau keluhan akibat minum obat TB 
selama pengobatan  (MDR-)TB?  
1. Ya               
2. Tidak 
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(Efek samping adalah permasalahan kesehatan tambahan yang muncul selama 
pengobatan (MDR-) TB dan kemungkinan berhubungan dengan pengobatan) Jika 
Tidak, lanjut ke  P33 
 
 
b) Jika YA: Apakah Anda sampai menghentikan minum obat TB karena keluhan 
tersebut dan butuh pengobatan untuk mengatasinya? Termasuk perubahan regimen 
obat TB!  
1. Ya            
2. Tidak 
c) Jika YA, Berapa perkiraan biaya yang Anda keluarkan untuk membeli obat 
untuk mengatasi efek samping obat TB? 
Total: 
Rp 
………………..… 
 
Asuransi 
Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
33. a) Apakah Anda memiliki asuransi kesehatan baik dari pemerintah maupun 
swasta? 
Jika Tidak, lanjut ke P 34 
1. Ya            2. 
Tidak  
3. Tidak tahu/tidak 
jawab 
b) Jika YA: Tipe Asuransi?                     
1. BPJS Kesehatan (Penerima Bantuan Iuran) 
2. BPJS Kesehatan (Ditanggung Institusi) 
3. BPJS Kesehatan (Mandiri) 
4. Asuransi Swasta (Reimbursement) 
5. Asuransi Swasta (Tanpa Reimbursement)      
c) Apakah Anda telah mendapatkan penggantian biaya yang berkaitan dengan 
penyakit TB?  
Cocokkan dengan P Error! Reference source not found. (tabel biaya pra-
diagnosis & diagnosis) Jika Tidak, lanjut ke Poin 34 
1. Ya             
2. Tidak 
d) Jika ya, berapa jumlah penggantian biaya yang telah Anda terima?  
Untuk diagnosis: ……. 
Untuk pengobatan: ……. 
Untuk  biaya transportasi:…… 
Lainnya: ………….. 
Total: ……….. 
 
Penyelesaian Masalah Keuangan 
Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
34. Sejauh mana penyakit TB mempengaruhi kondisi keuangan 
keluarga?* (lingkari) 
0 = tidak ada masalah 
1 = kecil 
2 = cukup serius 
3 = serius 
4 = sangat serius 
35. a) jika Anda meminjam uang untuk membantu pembiayaan 
penyakit Anda, berapa jumlah uang yang Anda pinjam? Jika Tidak 
meminjam, lanjut ke P36.  
 
b) Kepada siapa Anda melakukan pinjaman (paling banyak)? 
Lingkari yang paling sesuai 
 
 
Jumlah uang yang dipinjam: 
……. 
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1. Keluarga       2. Tetangga/Teman        3. Bank Swasta        4. 
Koperasi 
5. Lainnya (sebutkan): …………… 
c) Berapa besar bunga dari hutang tersebut? (%) 
 
 
1. ….. %  
2. Saya tidak membayar bunga. 
3. Saya tidak diminta 
mengembalikan pinjaman uang 
tersebut. 
36. a) Apakah Anda menjual properti Anda untuk membayar biaya dari penyakit 
TB?  
Jika Tidak, lanjut  ke P37. 
 1. Ya             2. 
Tidak 
b) Jika YA: Apa yang telah Anda jual? Lingkari yang paling sesuai 
 
1. Tanah           2. Ternak            3. Alat Transportasi/Kendaraan        4. Alat rumah tangga         5. Hasil 
Pertanian       
6. Lainnya (sebutkan): ……… 
c) Berapa jumlah yang Anda dapatkan dari hasil penjualan properti Anda?                 Rp 
……………………………….. 
d) Apakah harga tersebut sesuai dengan harga pasaran? 
1. Ya, sesuai harga pasar 
2. Lebih rendah dari harga pasaran 
3. Lebih tinggi dari harga pasaran 
e) Jika TIDAK: berapa perkiraan harga pasarannya?                                                         Rp  
……………………………  
 
Informasi Sosial-Ekonomi Situasi dan Pendapatan  
Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
37. Siapa pencari nafkah utama dalam rumah tangga?  
 
1. Pasien            2. Lainnya (sebutkan): ……. 
38. Apakah Anda bekerja sebelum didiagnosis TB (termasuk pekerjaan 
non-formal)? 
1. Ya            2. Tidak  
(lanjut ke P 43) 
39. Bagaimana biasanya Anda digaji sebelum didiagnosis TB?  
 
1. Digaji 
2. Tidak menentu (misalnya, berdagang atau parkir) 
3. Dibayar barang 
4. Tidak dibayar 
5. Lainnya .............. 
 
 
40. Apakah Anda harus mengganti atau berhenti dari pekerjaan pada saat 
Anda mengidap TB?  
1. Ya       2. Tidak  
41. Bila Anda masih bekerja, berapa hari rata-rata Anda absen dari 
pekerjaan Anda dalam sebulan, pada 3 bulan terakhir, sejak Anda sakit TB  
…..  hari 
Jika jawaban untuk P 41 adalah “1 hari” atau lebih: 
42.  Apakah seseorang melakukan pekerjaan yang seharusnya Anda 
kerjakan? 
1. Ya, anggota keluarga  
2. Ya, orang lain 
3. Tidak ada 
43. Apakah ada orang lain yang melakukan pekerjaan rumah tangga Anda 
dan Anda membayarnya karena Anda mengidap TB?   
    1. Tidak      2. Ya, jumlah total (sampai sekarang)?  
Jumlah Total: …………… 
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44. a) Berapa anggota keluarga yang tinggal bersama Anda dalam satu 
rumah? 
 
b) Apakah ada seorang yang khusus tinggal di rumah Anda untuk 
mengurus Anda?  
Jika TIDAK, lanjut ke P47 
Jika YA: 
c)   untuk berapa lama? 
d) Apakah mereka berhenti mencari nafkah untuk tinggal di rumah dan 
mengurus Anda? 
e)  Apakah Anda membayar seseorang untuk mengurus Anda?  
               Jika ya, berapa nilai tunai atau dalam nilai ? 
................ orang 
1. Ya            2. Tidak 
 
 
 …… Minggu 
1. Ya            2. Tidak 
1. Ya            2. Tidak 
Total Nilai/Jumlah: ….. 
45.  Apakah ada anggota keluarga (termasuk anak-anak atau anak di bawah 
usia sekolah) yang harus bekerja atau bekerja lebih untuk membayar biaya 
yang disebabkan karena penyakit TB? 
1. Ya               2. Tidak 
46. Apakah penyakit TB menyebabkan Anda kehilangan pekerjaan atau pendidikan?  
 
1. Tidak            2. Kehilangan Pekerjaan           3. Putus Sekolah         4. Cuti di luar tanggungan    5. Cuti 
sekolah  
 
Pendapatan dan Pengeluaran Rumah Tangga 
Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
47.  Berapa perkiraan penghasilan rumah tangga Anda rata-rata per bulan SEBELUM mengidap TB ?  
(untuk seluruh anggota keluarga, termasuk pasien, untuk semua orang di rumah, termasuk pasien) 
             
1. Pendapatan pasien :  ………….  
2. Pendapatan anggota rumah tangga lainnya:   ………….  
3. Jaminan kesejahteraan (klaim asuransi kecacatan, dll): ……….        
4. Bantuan pemerintah: ……….             
5. Lainnya: ………………………..……                    
 TOTAL: ……………………… 
48. Berapa perkiraan penghasilan rumah tangga Anda rata-rata per bulan SEKARANG ?   
 
1. Pendapatan pasien :  ………….  
2. Pendapatan anggota rumah tangga lainnya:  ………….  
3. Jaminan kesejahteraan (klaim asuransi kecacatan, dll):: ……….        
4. Bantuan pemerintah: ……….             
5. Lainnya: ………………………..……                    
 TOTAL: ……………………… 
49. Jika penghasilan di 47 berbeda dengan 48: 
Apakah perubahan ini sebagai akibat dari penyakit TB?   
1. Ya         2.Tidak 
 
Indikator Sosial Ekonomi 
Untuk pertanyaan biaya, bila pasien tidak bisa menjawab, tulis “tidak tahu”. Jangan hanya 
dikosongkan 
 
50. Apakah ada anggota keluarga 
yang saat ini memiliki aset berikut 
yang dapat digunakan ?  
Isi 
dengan: 
1. Ya 
2. Tidak 
Sebutkan perkiraan nilai dari kekayaan tersebut saat ini 
(diusahakan) 
Jika tidak dapat menyebutkan nilainya, sebutkan  jenis, 
jumlah atau ukurannya 
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1. Mobil   
2. Sepeda motor   
3. Kulkas/ freezer   
4. AC   
5. Perhiasan emas   
6. Rumah   
7. Tanah   
8. Tanah pertanian   
9. Telepon / HP   
10. Saham perusahaan/Investasi   
11. Ternak   
12. Alat pertanian   
13. Bisnis non pertanian   
14. Daya listrik di rumah 
(Watt) 
  450           900      1300          2200        > 2200 
 
Ada beberapa pertanyaan yang akan kami ajukan untuk dapat mengeksplorasi kebutuhan terhadap 
proteksi sosial bagi pasien TB dan keluarganya.  
1. Pernahkah anda mendengar tentang proteksi sosial?  
a. Jika YA, apa yang Anda pahami dengan proteksi sosial? Apakah Anda dapat jelaskan?  
b. Jika TIDAK. Lanjut ke pertanyaan berikutnya. 
2. Dengan biaya yang dikeluarkan untuk mendapatkan pengobatan TB, bagian biaya yang mana 
yang membuat Anda merasa mengalami kesulitan finansial dan berapa Rupiah yang Anda 
inginkan untuk dapat ditanggung oleh Pemerintah? 
 
Lingkari yang paling dirasakan sulit oleh responden dan tuliskan berapa ! 
Kode Jenis biaya Biaya dalam Rp/Barang Unit 
A Biaya konsultasi (bayar sendiri)  Per konsultasi 
B Obat-obatan (bayar sendiri)  Per bulan 
C Transportasi  Per kunjungan 
D Akomodasi   Per hari 
E Makanan, snack, minuman (saat 
kunjungan) 
 Per kunjungan 
F Makanan dan suplementasi  Jenis makanan atau 
suplementasi, per bulan 
G Kehilangan pendapatran atau biaya 
produktivitas 
 Per bulan 
H Biaya orang yang menemani  Per hari 
I Pengobatan penyakit lainnya (jika ada)   
 
3. Apakah Anda berpikir bahwa kondisi Anda yang terinfeksi TB berkaitan dengan kondisi tubuh, 
rumah dan lingkungan Anda? YA/TIDAK 
Jika TIDAK, wawancara selesai. 
Jika YA, Mohon pilih salah satu yang Anda anggap paling berkaitan! Lingkari 
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Kode Kondisi 
A Makanan (tidak mampu memperoleh cukup makanan 
sehat 
B Tubuh (malnutrisi, akibat penyakit/kondisi lain) 
C Rumah (kurang ventilasi) 
D Tidak punya rumah 
E Lingkungan (kumuh, padat) 
 
4. Apa yang Anda sarankan kepada Pemerintah untuk memecahkan masalah tersebut? 
 
 
 
 
Terima kasih atas kerjasama Anda! Apakah ada yang ingin Anda tanyakan atau katakan? 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………….……………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………………….. 
 
Komentar oleh pewawancara:  
Antusiasme subyek :  
0                                              1                  2                  3               4              5 
Sama sekali tidak antusias                                                                              Sangat antusias  
………………………………………………………………………………………………………
………………………………………………………………………………………………………
…………………..……………………………………………………………………………………
………………………………………………………………………………………………………
…………………………………….. 
 
 
Tanggal   dan   Tanda tangan pewawancara 
dd/mm/yy 
 
 ……………           ………………………. 
 
Fuady et al. Acta Medica Indonesiana 50 (1), 3-10 
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Annex C  
Explanations of the Tool and guidance for researcher and interviewers  
 
Penjelasan Kuesioner 
Perangkat untuk memperkirakan biaya yang dikeluarkan pasien 
No Pertanyaan Pilihan Penjelasan 
Pendahuluan 
 ID Responden X – X – XX  Diisi kode (Provinsi) – 
(Kabupaten/Kota) – (Urutan ID 
Subyek, dari 01-xx) 
 Nama Pewawancara  Jelas 
 No Registrasi pasien di 
Fasilitas TB 
 No Rekam medik pasien. Dapat 
dikosongkan 
 Tanggal wawancara 
(dd/mm/yy) 
 Jelas 
 Nama provinsi  Jelas 
 Nama Kabupaten/Kota  Jelas 
 Nama Kelurahan  Jelas 
 Tempat wawancara Rumah/Nama fasilitas 
kesehatan 
Jelas. Dapat diisi dengan nama 
Puskesmas atau RS jika dilakukan 
di Puskesmas atau RS 
 Kategori fasilitas 
kesehatan tempat berobat 
1. Puskesmas        
2. Klinik swasta        
3. RSUD/ Pemerintah     
4. RS Swasta      
5. RS lainnya, 
sebutkan.......        
Tempat berobat utama saat ini atau 
saat diwawancara 
 Apakah Anda memiliki 
pertanyaan?  Apakah Anda 
akan berpartisipasi? 
Ya / Tidak Jelas 
 Tanda tangan Responden  Responden dapat menandatangani 
di sini atau cukup di lembar 
informed consent di ampiran 
tersendiri 
 Jika Tidak  : alasan tidak 
berpartisipasi? 
1. Tidak cakap berbahasa      
2. Kendala waktu       
3. Tidak nyaman                    
4. Lainnya, sebutkan…… 
Jelas 
 
Informasi Pasien 
 Responden 1. Pasien                       
2. Pengawas Minum Obat 
(PMO) / wali yang 
tinggal di rumah tangga 
yang sama dengan pasien       
Jelas 
PMO: Pengawas Minum Obat yang 
secara khusus ditunjuk oleh 
pasien/penyedia layanan 
1 Jenis kelamin 1. Laki-laki 
2. Perempuan 
Jelas 
 Usia …. Tahun Jelas 
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No Pertanyaan Pilihan Penjelasan 
2 Apakah pendidikan 
tertinggi Anda?   
1. Tidak Sekolah  2. SD         
3. SMP                  4. 
SMA           
5. Diploma            6. 
Sarjana        7. Pasca 
sarjana 
Jelas 
3 Tipe TB 1. Paru BTA +           
2. Paru BTA -         
3. Paru, tidak tahu status 
BTA      
4. Ekstra Paru       
Tanyakan apakah hasil pemeriksaan 
dahaknya positif atau negatif, dan 
apakah terkena tuberkulosis paru 
atau organ lain. 
 
Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat.  
4 Regimen terapi 1. Kat I (penderita baru)                                  
2. Kat II (terapi kambuh 
atau gagal)        
3. Terapi MDR 
Regimen pengobatan yang diterima 
subyek. 
 
Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat. 
5 Fase terapi dan lama terapi 1. Intensif 
2. Lanjutan 
Tanyakan sudah bulan ke berapa 
berobat? Atau, warna apakah obat 
yang diterima (merah – intensif, 
kuning – lanjutan).  
Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat. 
6 Status HIV 1. Positif 
2. Negatif 
3. Tidak dites 
4. Tidak ada informasi 
Lihat kartu berobat subyek atau 
tanyakan petugas setempat 
7 Tanggal pemeriksaan 
dahak atau Foto toraks 
pertama (dd/mm/yy) 
 Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat. 
8 Tanggal mulai pengobatan 
(dd/mm/yy) 
 Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat. 
9 Berapa lama waktu yang 
diperlukan untuk mencapai 
tempat pengobatan Anda 
saat ini dari rumah Anda? 
 Jelas 
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No Pertanyaan Pilihan Penjelasan 
Pengobatan sebelumnya 
10a Pernahkah Anda 
mendapatkan pengobatan 
TB sebelumnya? 
1. Ya  
2. Tidak 
Jelas 
Jika subyek tidak tahu, ragu-ragu, 
atau jawabannya tidak meyakinkan, 
lihat kartu berobat subyek atau 
tanyakan petugas setempat. 
Konfirmasi dengan jawaban no 4. 
10b Jika YA: Apakah Anda 
menyelesaikan pengobatan 
TB Anda terdahulu? 
1. Ya  
2. Tidak 
Jelas 
10c Jika TIDAK: Mengapa? 1. Kekurangan biaya 
untuk pengobatan           
2. Efek samping obat                   
3. Jarak tempuh ke 
fasilitas kesehatan 
4. Lainnya (sebutkan): 
…… 
Pilih salah satu yang paling tepat 
atau mendekati. 
11 Gejala apa yang Anda 
alami sehingga Anda 
memutuskan pergi berobat 
untuk penyakit Anda yang 
sekarang? 
 
 
Berapa lama Anda 
mengalami gejala-gejala 
tersebut sebelum Anda 
pergi mencari pengobatan?   
1. Batuk 
2. Keringat malam 
3. Batuk berdarah 
4. Berat badan turun 
5. Lainnya 
Tanyakan satu per satu dan contreng 
(YA/TIDAK) 
 
 
 
 
 
Jawab dalam minggu.  
- Jika subyek menjawab dalam 
HARI, gunakan ANGKA 
DESIMAL atau PECAHAN, 
misalnya 3/7 atau tuliskan X 
HARI 
- Jika subyek menjawab dalam 
bulan, kalikan jumlah bulan 
dengan 4 atau tuliskan XX 
BULAN 
12 Ke mana saja Anda 
mencari pengobatan untuk 
mengatasi gejala-gejala 
tersebut? 
1. RSUD 
2. RS Swasta 
3. Puskesmas 
4. Klinik Swasta 
5. Lainnya 
Tanyakan satu per satu dan contreng 
(YA/TIDAK) 
 
 
 Ke mana Anda pergi 
pertama kali?  
Lingkari tempat pertama 
pengobatan tersebut di atas 
 Lingkari NOMOR PILIHAN di 
POIN 12 yang disebutkan subyek 
sebagai tempat pertama subyek 
berobat  
13 Jika selain dari fasilitas 
kesehatan pemerintah 
yang dipilih di 12): 
   
8. Jarak terlalu jauh          
9. Biaya terlalu mahal         
10. Waktu tunggu 
terlalu lama  
Pilih salah satu yang paling tepat 
atau mendekati. 
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Mengapa Anda tidak pergi 
ke fasilitas kesehatan 
pemerintah, seperti 
Puskesmas atau RSUD, 
ketika Anda pertama kali 
ingin berobat?  
Lingkari yang paling 
sesuai. 
11. Fasilitas tidak 
lengkap/tersedia 
12. Tidak percaya 
pada kualitas fasilitas 
kesehatan pemerintah        
13. Tidak ada obat-
obatan tersedia 
14. Lainnya 
(Jelaskan)   
14 Berapa banyak biaya yang 
Anda habiskan untuk 
setiap kunjungan sebelum 
Anda didiagnosis TB, 
termasuk kunjungan ketika 
Anda benar-benar 
menerima diagnosis Anda?  
 
 
 
 
Penyedia Layanan :  
 
 
 
 
 
 
 
Total Waktu (bolak balik) 
 
Biaya administrasi 
 
 
Biaya Tes Lab 
 
Biaya Foto toraks 
 
Biaya Obat-obatan 
 
 
 
 
 
 
Biaya perjalanan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. RSUD 
2. RS Swasta 
3. Puskesmas 
4. Klinik Swasta 
5. Lainnya, misalnya 
klinik alternatif, 
dukun, mantri, bidan, 
dsb 
 
Untuk pasien MDR-TB,  tanyakan 
hanya tentang biaya untuk 
diagnosis MDR-TB; untuk pasien 
TB lainnya, tanyakan tentang biaya 
untuk diagnosis TB. Untuk semua 
yang tidak berhubungan, tandai 
dengan N/A, isi satu baris per 
kunjungan.  
 
Untuk pertanyaan biaya, bila pasien 
tidak bisa menjawab, tulis “tidak 
tahu”. Jangan hanya dikosongkan 
 
Diurut dari pertama kali subyek 
berobat ketika mengalami keluhan 
yang dijawab di POIN 11 
 
SELF MEDICATION atau beli obat 
sendiri tidak dimasukkan. 
 
 
 
Dalam jam. Jelas 
 
Biaya pendaftaran, konsultasi 
dokter (di luar biaya obat-obatan).  
 
Untuk tes dahak atau darah, bukan 
Foto toraks 
 
Khusus untuk Foto toraks 
 
Khusus untuk biaya obat-obatan 
 
Jika subyek tidak dapat 
membedakan item biaya antara 
administrasi, tes lab, Foto toraks, 
dan obat-obatan, TOTAL BIAYA 
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Biaya makan 
 
 
 
Biaya akomodasi 
 
 
Sub-Total biaya tiap 
kunjungan 
dapat dijadikan satu di ITEM 
BIAYA ADMINISTRASI 
 
Biaya Total Perjalanan pulang 
pergi, termasuk ke Lab, Foto toraks 
(jika di tempat yang berbeda). Jika 
menggunakan kendaraan pribadi 
(motor/mobil), tuliskan biaya Parkir 
dan sejenisnya (jika ada) 
 
Biaya makan yang dikeluarkan 
ketika subyek pergi ke fasilitas 
kesehatan, misalnya mengemil atau 
makan siang (jika ada) 
 
Biaya menginap jika subyek harus 
pergi ke tempat yang jauh dan 
menginap 
 
Dijumlahkan per setiap kunjungan. 
Dapat dikosongkan dan dihitung 
secara otomatis pada saat analisis.  
 Kehilangan penghasilan 
pasien 
 
 
 
 
Reimbursement asuransi 
 
 
 
Diantar oleh orang lain 
 
 
Biaya perjalanan untuk 
pengantar 
 
 
 
 
Biaya akomodasi untuk 
pengantar 
 
Kehilangan pendapatan 
yang dialami pengantar 
Dalam rupiah 
 
 
 
 
 
 
 
 
Ya / Tidak  
Jika subyek  
- Dipotong gaji ketika absen 
bekerja 
- Kehilangan potensi pendapatan 
ketika tidak bekerja informal, 
misalnya berdagang atau buruh 
harian 
 
Jika subyek memiliki asuransi 
(swasta atau perusahaan) dan 
pengeluaran untuk berobatnya 
diganti oleh asuransi/perusahaan 
 
Jika subyek diantar oleh orang lain 
yang merupakan anggota keluarga 
 
Biaya Total Perjalanan pulang pergi 
pengantar, termasuk ke Lab, Foto 
toraks (jika di tempat yang 
berbeda). Jika menggunakan 
kendaraan pribadi (motor/mobil), 
tuliskan biaya Parkir dan sejenisnya 
(jika ada) 
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Biaya menginap jika pengantar 
harus pergi ke tempat yang jauh dan 
menginap 
 
Jika pengantar 
- Dipotong gaji ketika absen 
bekerja 
- Kehilangan potensi pendapatan 
ketika tidak bekerja informal, 
misalnya berdagang atau buruh 
harian 
 Total Biaya Pra-Diagnosis 
dan Diagnosis dikurangi 
Biaya diganti asuransi 
 Dapat dikosongkan dan dihitung 
secara otomatis pada saat analisis. 
Biaya Pengobatan 
15 Seberapa sering Anda 
pergi ke fasilitas kesehatan 
untuk mengambil obat TB 
Anda? 
 
a. Fase intensif 
b. Fase lanjutan 
 
 
 
 
…. Kali/bulan 
…. Kali/bulan 
- Jika subyek datang setiap hari 
untuk mengambil obat dan 
makan obat di fasilitas 
kesehatan, tuliskan 30 
- Jika subyek datang hanya untuk 
mengambil obat dan memakan 
obat di rumah, tuliskan berapa 
kali subyek mengambil obat ke 
fasilitas kesehatan 
16 Berapa lama waktu yang 
Anda butuhkan untuk 
sampai ke tempat tersebut 
(sekali perjalanan)? 
 Cukup isi MENIT pada MODA 
(pilih: jalan kaki, kendaraan pribadi, 
angkutan umum)  yang paling 
sering dilakukan 
17 Berapa rata-rata total 
waktu yang dibutuhkan 
untuk sekali kunjungan, 
termasuk waktu perjalanan 
dan waktu tunggu (total 
waktu hingga selesai)? 
 Jelas 
18 Dari rumah ke fasilitas 
kesehatan, berapa biaya 
transportasi yang Anda 
keluarkan? (pulang pergi) 
 Biaya Total Perjalanan pulang pergi 
pengantar. Jika menggunakan 
kendaraan pribadi (motor/mobil), 
tuliskan biaya Parkir, tol, dan 
sejenisnya (jika ada) 
 
19 Jika Anda pergi ke fasilitas 
kesehatan untuk 
mengambil obat Anda, 
berapa biaya yang Anda 
keluarkan untuk makanan 
dan minuman pada hari 
tersebut? 
 Biaya makan yang dikeluarkan 
ketika subyek pergi ke fasilitas 
kesehatan, misalnya mengemil atau 
makan siang (jika ada) 
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20a Apakah Anda harus 
membayar biaya 
administrasi pada saat 
mengambil obat TB? 
Ya / Tidak Biaya administrasi pendaftaran atau 
biaya konsultasi dokter 
20b Jika YA, berapa?  Jelas 
21a Apakah ada biaya 
akomodasi yang harus 
Anda tanggung saat 
mengambil obat TB Anda? 
 Biaya menginap jika subyek harus 
pergi ke tempat yang jauh dan 
menginap 
 
21b Jika YA, berapa?  Jelas 
22 Apakah Anda pernah 
menjalani pemeriksaan/tes  
untuk evaluasi pengobatan 
sejak pengobatan dimulai? 
Jika TIDAK, lanjut ke P 
23. 
1. Sputum / tes lab 
2. Foto toraks 
3. Pemeriksaan lain 
Pemeriksaan yang dilakukan 
SETELAH subyek mendapat 
pengobatan TB. 
 
Tanyakan satu per satu. 
Biaya yang dikeluarkan untuk pengantar 
23a Apakah ada yang 
menemani Anda pada 
waktu mengambil obat dan 
melakukan pemeriksaan 
laboratorium/ Foto toraks 
lanjutan, atau 
menggantikan Anda untuk 
mengambilkan obat Anda? 
Jika tidak, lanjut ke P 244 
Ya / Tidak Jelas 
23b Jika YA, Apakah orang 
tersebut kehilangan 
pendapatannya karena 
pergi menemani Anda? 
 
Jika Ya, berapa jumlah 
total 
Ya / Tidak 
 
Jika pengantar 
- Dipotong gaji ketika absen 
bekerja 
- Kehilangan potensi pendapatan 
ketika tidak bekerja informal, 
misalnya berdagang atau buruh 
harian 
 
Jelas 
23c Jika YA , berapa kali orang 
tersebut menemani atau 
menggantikan Anda? 
 Jelas 
Rawat Inap 
24 Apakah Anda pernah 
dirawat sebelumnya 
(karena TB) atau selama 
pengobatan TB Anda?  
Jika TIDAK, lanjut ke P30. 
Ya / Tidak Dirawat di RS atau Puskesmas: 
- Yang dalam perawatannya 
kemudian ditemukan atau 
didiagnosis TB 
- Perawatan pada masa 
pengobatan yang terkait TB 
- Jika perawatan tidak terkait TB, 
misalnya usus buntu, DBD, atau 
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kecelakaan saja, DIANGGAP 
TIDAK 
25 Jika YA: berapa hari Anda 
dirawat di rumah sakit atau 
Puskesmas? 
 Jelas 
26 Berapa biaya yang Anda 
keluarkan selama dirawat 
di rumah sakit atau 
Puskesmas? 
 Biaya untuk perawatan. Tulis 
ANGKA 0 jika ditanggung oleh 
asuransi (BPJS, swasta, atau 
perusahaan) 
27 Apakah ada keluarga / 
teman yang menemani 
Anda selama di rumah 
sakit? Jika Tidak, lanjut ke  
P30. 
Ya / Tidak Jelas 
28 Jika YA: Berapa hari ia 
tinggal bersama Anda 
(menginap di rumah 
sakit)? 
... Hari Jelas 
29 Apakah ada biaya lain 
yang dikeluarkan untuk 
keluarga/teman Anda 
selama tinggal di rumah 
sakit? 
 
Akomodasi (RS atau 
lainnya) 
 
Makanan 
Transportasi 
Kehilangan pendapatan 
 
 
 
Lain-lain 
 
Ya / Tidak Jelas 
 
 
 
 
Jika harus membayar penginapan, 
rumah singgah, dan sejenisnya 
Makan siang dan/atau cemilan 
selama menunggu pasien  
Transportasi bolak-balik, parkir, tol, 
dan sejenisnya 
Jika anggota keluarga 
- Dipotong gaji ketika absen 
bekerja 
- Kehilangan potensi pendapatan 
ketika tidak bekerja informal, 
misalnya berdagang atau buruh 
harian 
Lain-lain (jika ada) 
 
Masing-masing ITEM 
DIJUMLAHKAN sesuai jumlah 
orang yang menemani dan jumlah 
hari menemani 
Biaya Pindah Tempat 
30 Apakah Anda harus pindah 
untuk dapat menerima 
pengobatan TB ? 
Ya / Tidak Misalnya, subyek harus mengontrak 
di sekitar fasilitas kesehatan atau 
pindah ke rumah sanak keluarga 
yang dekat dengan fasilitas 
kesehatan 
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30a Jika YA: Anda menyewa 1. Per Minggu 
2. Per Bulan 
3. Per Tahun 
Tulis ANGKA 0 subyek tidak 
mengeluarkan biaya, misalnya 
pindah ke rumah keluarga 
Biaya Lain-lain 
31a Apakah Anda membeli 
suplemen khusus untuk 
diet Anda dikarenakan 
penyakit TB, contohnya 
vitamin, daging, minuman 
berenergi, minuman 
ringan, buah-buahan, atau 
obat-obatan? Jika Tidak, 
lanjut ke P32. 
1. Ya 
2. Tidak 
3. Tidak tahu/Tidak 
jawab 
Suplemen yang HANYA DIBELI 
ketika melakukan pengobatan TB 
31b Jika YA: Apa jenisnya? 1. Buah-buahan 
2. Susu 
3. Vitamin/Herbal 
4. Daging 
5. Lainnya (sebutkan) 
Jelas 
Jelas 
Termasuk vitamin dari dokter 
Jelas 
Tuliskan, misalnya jamu, madu, dll 
31c Berapa perkiraan biaya 
yang Anda keluarkan 
untuk membeli barang-
barang tersebut dalam 30 
hari terakhir? 
 Jelas 
32a Apakah Anda mengalami 
efek samping atau keluhan 
akibat minum obat TB 
selama pengobatan  
(MDR-)TB? 
Jika Tidak, lanjut ke  P33 
Ya / Tidak Efek samping adalah permasalahan 
kesehatan tambahan yang muncul 
selama pengobatan (MDR-) TB dan 
kemungkinan berhubungan dengan 
pengobatan 
32b Jika YA: Apakah Anda 
sampai menghentikan 
minum obat TB karena 
keluhan tersebut dan butuh 
pengobatan untuk 
mengatasinya? Termasuk 
perubahan regimen obat 
TB! 
 Jelas 
32c Jika YA, Berapa perkiraan 
biaya yang Anda 
keluarkan untuk membeli 
obat untuk mengatasi efek 
samping obat TB? 
 Jelas 
Asuransi 
33a Apakah Anda memiliki 
asuransi kesehatan baik 
dari pemerintah maupun 
swasta? 
Jika Tidak, lanjut ke P 34 
Ya / Tidak Jelas 
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33b Jika YA: Tipe asuransi? 1. BPJS Kesehatan 
(Penerima Bantuan Iuran) 
2. BPJS Kesehatan 
(Ditanggung Institusi) 
3. BPJS Kesehatan 
(Mandiri) 
4. Asuransi Swasta 
(Reimbursement) 
5. Asuransi Swasta 
(Tanpa Reimbursement)      
Jelas 
33c Apakah Anda telah 
mendapatkan penggantian 
biaya yang berkaitan 
dengan penyakit TB?  
Cocokkan dengan P 
Error! Reference source 
not found. (tabel biaya 
pra-diagnosis & 
diagnosis) Jika Tidak, 
lanjut ke Poin 34 
Ya / Tidak Termasuk voucher transport dari 
Program TB 
33d Jika ya, berapa jumlah 
penggantian biaya yang 
telah Anda terima?  
 
Untuk diagnosis: ……. 
Untuk pengobatan: ……. 
Untuk  biaya 
transportasi:…… 
Lainnya: ………….. 
 Jika subyek tidak dapat memilah per 
item, tulis jumlah penggantian biaya 
secara keseluruhan. 
Penyelesaian masalah keuangan 
34 Sejauh mana penyakit TB 
mempengaruhi kondisi 
keuangan keluarga?* 
(lingkari) 
0 = tidak ada masalah 
1 = kecil 
2 = cukup serius 
3 = serius 
4 = sangat serius 
Berikan penjelasan terlebih dahulu 
antara 0-4 dan persilakan subyek 
memilih. Jika subyek bingung 
dalam memilih, berikan PILIHAN 
yang mendekati.  
Misalnya, ”Apakah maksud Ibu: 
Cukup serius?” 
35a Jika Anda meminjam uang 
untuk membantu 
pembiayaan penyakit 
Anda, berapa jumlah uang 
yang Anda pinjam?  
Jika Tidak meminjam, 
lanjut ke P36. 
 Kosongkan atau beri Tanda X jika 
subyek tidak melakukan pinjaman 
 
Jika melakukan pinjaman LEBIH 
DARI SATU KALI, tulis total 
pinjamannya 
35b Kepada siapa Anda 
melakukan pinjaman 
(paling banyak)? Lingkari 
yang paling sesuai 
1. Keluarga        
2. Tetangga/Teman         
3. Bank Swasta         
4. Koperasi 
5. Lainnya (sebutkan):  
Pilih yang paling sesuai atau paling 
banyak 
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35c Berapa besar bunga dari 
hutang tersebut? (%) 
1. ….. %  
2. Saya tidak membayar 
bunga. 
3. Saya tidak diminta 
mengembalikan pinjaman 
uang tersebut. 
Jelas 
36a Apakah Anda menjual 
properti Anda untuk 
membayar biaya dari 
penyakit TB?  
Jika Tidak, lanjut  ke P37. 
Ya / Tidak Menjual untuk keperluan 
pengobatan TB, bukan karena 
masalah keuangan lain, misalnya 
hutang, dsb 
36b Jika YA: Apa yang telah 
Anda jual? Lingkari yang 
paling sesuai 
1. Tanah            
2. Ternak             
3. Alat transportasi/ 
Kendaraan         
4. Alat rumah tangga          
5. Hasil Pertanian         
6. Lainnya (sebutkan):  
Jelas 
36c Berapa jumlah yang Anda 
dapatkan dari hasil 
penjualan properti Anda?                  
 Jelas 
36d Apakah harga tersebut 
sesuai dengan harga 
pasaran? 
1. Ya, sesuai harga 
pasaran 
2. Lebih rendah dari 
harga pasaran 
3. Lebih tinggi dari harga 
pasaran 
Jelas 
36e Jika TIDAK: berapa 
perkiraan harga 
pasarannya?                                                          
 Biarkan subyek menjawab sendiri 
terlebih dahulu. 
Jika subyek tidak tahu atau bingung 
menjawab, berikan pilihan 
(challenge).  
Misalnya, ”Apakah sekitar 2 juta?” 
Informasi Sosial-Ekonomi 
37 Siapa pencari nafkah 
utama dalam rumah 
tangga? 
1. Pasien 
2. Lainnya (sebutkan) 
Pencari nafkah utama, yang bekerja 
dan penghasilannya paling besar 
untuk menutupi kebutuhan rumah 
tangga 
38 Apakah Anda bekerja 
sebelum didiagnosis TB 
(termasuk pekerjaan non-
formal)? 
Ya / Tidak Pekerjaan yang mendapatkan gaji 
atau dibayar 
39 Bagaimana biasanya Anda 
digaji sebelum didiagnosis 
TB?  
1. Digaji 
2. Tidak menentu 
(misalnya, berdagang 
atau parkir) 
3. Dibayar barang 
4. Tidak dibayar 
Pensiunan dimasukkan dalam 
lainnya 
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5. Lainnya .............. 
40 Apakah Anda harus 
mengganti atau berhenti 
dari pekerjaan pada saat 
Anda mengidap TB? 
Ya / Tidak Jelas 
41 Bila Anda masih bekerja, 
berapa hari rata-rata Anda 
absen dari pekerjaan Anda 
dalam sebulan, pada 3 
bulan terakhir, sejak Anda 
sakit TB? 
… Hari Jelas 
42 Jika jawaban untuk P 41 
adalah “1 hari” atau 
lebih: 
 
Apakah seseorang 
melakukan pekerjaan yang 
seharusnya Anda 
kerjakan? 
1. Ya, anggota keluarga  
2. Ya, orang lain 
3. Tidak ada 
 
Jelas 
43 Apakah ada orang lain 
yang melakukan pekerjaan 
rumah tangga Anda dan 
Anda membayarnya 
karena Anda mengidap 
TB?   
1. Tidak       
2. Ya, jumlah total 
(sampai sekarang) 
Jelas 
44a Berapa anggota keluarga 
yang tinggal bersama 
Anda dalam satu rumah? 
 Jelas 
44b Apakah ada seorang yang 
khusus tinggal di rumah 
Anda untuk mengurus 
Anda?  
Jika TIDAK, lanjut ke P47 
Ya / Tidak Orang yang ditunjuk khusus untuk 
merawat pasien 
44c Jika YA: untuk berapa 
lama? 
... Minggu Jelas 
44d Apakah mereka berhenti 
mencari nafkah untuk 
tinggal di rumah dan 
mengurus Anda? 
Ya / Tidak Jelas 
44e Apakah Anda membayar 
seseorang untuk mengurus 
Anda?  
Jika ya, berapa nilai tunai 
atau dalam nilai ? 
Ya / Tidak 
 
 
….. (Rp) 
KHUSUS jika ada orang yang 
DIBAYAR 
45 Apakah ada anggota 
keluarga (termasuk anak-
anak atau anak di bawah 
usia sekolah) yang harus 
Ya / Tidak Karena subyek sakit, maka apakah 
ada orang lain yang HARUS 
BEKERJA?  
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bekerja atau bekerja lebih 
untuk membayar biaya 
yang disebabkan karena 
penyakit TB? 
46 Apakah penyakit TB 
menyebabkan Anda 
kehilangan pekerjaan atau 
pendidikan?  
1. Tidak             
2. Kehilangan Pekerjaan           
3. Putus Sekolah         
4. Cuti di luar tanggungan    
5. Cuti sekolah 
Pensiunan dimasukkan kategori 
TIDAK 
Pendapatan dan Pengeluaran Rumah Tangga 
47 Berapa perkiraan 
penghasilan rumah tangga 
Anda rata-rata per bulan 
SEBELUM mengidap TB 
?  (untuk seluruh anggota 
keluarga, termasuk pasien, 
untuk semua orang di 
rumah, termasuk pasien) 
1. Pendapatan pasien :   
 
 
2. Pendapatan anggota 
rumah tangga lainnya:    
3. Jaminan kesejahteraan 
(klaim asuransi 
kecacatan, dll):    
4. Bantuan pemerintah:  
           
 
5. Lainnya:                    
 
 
TOTAL:  
Pendapatan pasien per bulan. Jika 
tidak menentu, hitung: JUMLAH 
HARI KERJA X (RERATA) 
PENDAPATAN PER HARI 
Idem. Jumlahkan untuk semua 
anggota rumah tangga yang 
mendapatkan penghasilan 
 
 
Jika ada bentuk Santunan dari 
Pemerintah/Yayasan yang bersifat 
regular, misalnya, BLT. KJP, KIS, 
BPJS, tidak termasuk. 
Pemasukan lain, misalnya 
“Diberikan rutin oleh anak, per 
bulan” 
 
Dikosongkan saja. 
48 Berapa perkiraan 
penghasilan rumah tangga 
Anda rata-rata per bulan 
SEKARANG ?   
1. Pendapatan pasien :   
 
 
2. Pendapatan anggota 
rumah tangga lainnya:    
3. Jaminan kesejahteraan 
(klaim asuransi 
kecacatan, dll):    
4. Bantuan pemerintah:  
 
 
5. Lainnya:                    
 
 
TOTAL:  
Pendapatan pasien per bulan. Jika 
tidak menentu, hitung: JUMLAH 
HARI KERJA X (RERATA) 
PENDAPATAN PER HARI 
Idem. Jumlahkan untuk semua 
anggota rumah tangga yang 
mendapatkan penghasilan 
 
 
Jika ada bentuk Santunan dari 
Pemerintah/Yayasan yang bersifat 
regular, misalnya, BLT. KJP, KIS, 
BPJS, tidak termasuk. 
Pemasukan lain, misalnya 
“Diberikan rutin oleh anak, per 
bulan” 
 
Dikosongkan saja. 
49 Jika penghasilan di 47 
berbeda dengan 48: 
Ya / Tidak Tanyakan kepada subyek 
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Apakah perubahan ini 
sebagai akibat dari 
penyakit TB?   
Indikator Sosial Ekonomi 
50 Apakah ada anggota 
keluarga yang saat ini 
memiliki aset berikut yang 
dapat digunakan ? 
Ya / Tidak Sebutkan perkiraan nilai dari 
kekayaan tersebut saat ini 
(diusahakan) 
Jika tidak dapat menyebutkan 
nilainya, sebutkan  jenis, jumlah 
atau ukurannya 
 15. Mobil   
 16. Sepeda motor   
 17. Kulkas/ freezer   
 18. AC   
 19. Perhiasan emas   
 20. Rumah   
 21. Tanah   
 22. Tanah pertanian   
 23. Telepon / HP   
 24. Saham 
perusahaan/Investasi 
  
 25. Ternak   
 26. Alat pertanian   
 27. Bisnis non pertanian   
 28. Daya listrik di rumah 
(Watt) 
450            900 
1300          2200 
> 2200 
Jika tidak tahu daya watt-nya, 
LIHAT barang elektronik yang ada 
di rumah. Jika ada AC, diasumsikan 
>1300. Jika mendapat subsidi (tidak 
bayar), diasumsikan 450.  
Pertanyaan tambahan 
1 Pernahkah Anda 
mendengar tentang 
proteksi sosial?  
Ya / Tidak Jelas 
 a. Jika Ya, apa yang 
Anda pahami dengan 
proteksi sosial? 
Apakah Anda dapat 
jelaskan? 
b. Jika TIDAK. Lanjut 
pertanyaan berikutnya 
 Jelas 
2 Dengan biaya yang 
dikeluarkan untuk 
mendapatkan pengobatan 
TB, bagian biaya yang 
mana yang membuat Anda 
merasa mengalami 
kesulitan finansial dan 
berapa Rupiah yang Anda 
1. Biaya konsultasi 
(bayar sendiri) 
2. Obat-obatan (bayar 
sendiri) 
3. Transportasi 
4. Akomodasi 
Biarkan subyek menjawab sendiri 
terlebih dahulu.  
 
Jika subyek merasa tidak ada yang 
perlu ditanggung, KOSONGKAN.  
 
Jika subyek bingung, berikan 
pertanyaan satu per satu dan 
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No Pertanyaan Pilihan Penjelasan 
inginkan untuk dapat 
ditanggung oleh 
Pemerintah? 
5. Makanan, snack, 
minuman (saat 
kunjungan) 
6. Makanan dan 
suplementasi 
7. Kehilangan 
pendapatran atau biaya 
produktivitas 
8. Biaya orang yang 
menemani 
9. Pengobatan penyakit 
lainnya (jika ada) 
dijawab (Ya/Tidak), kemudian 
sebutkan jumlah yang menurut 
subyek perlu ditanggung. 
 
Upayakan bertanya ITEM yang 
TERLIHAT MEMBERATKAN 
pada pertanyaan-pertanyaan 
sebelumnya terlebih dahulu.  
 
Misalnya, subyek mengeluarkan 
biaya transport besar, sedangkan 
tidak mengeluarkan biaya makan. 
Maka, tanyakan ”Apakah biaya 
transportasi perlu ditanggung?”, 
bukan biaya makan 
Penutup 
 Terima kasih atas 
kerjasama Anda! Apakah 
ada yang ingin Anda 
tanyakan atau katakan? 
 Jelas 
 Komentar oleh 
pewawancara 
  
 Antusiasme subyek 0 Sama sekali tidak 
antusias 
1 
2 
3 
4 
5 Sangat antusias 
Jelas. Pilih salah satu 
  ………………………….. Diisi jika ada komentar khusus 
lainnya.  
   Jelas 
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Annex D 
Reasons for not choosing public facilities at the first contact 
Reason 
Urban  
  n (%) 
Sub-urban  
   n (%) 
Rural  
n (%) 
Total  
n (%) 
Distance to facility 7 (21) 10 (25) 15 (30) 32 (26) 
Accustomed to private facility 4 (12) 7 (18) 14 (28) 25 (20) 
Mistrust towards public facility 4 (12) 5 (13) 4 (8) 13 (11) 
No public facility available 2 (6) 4 (10) 5 (10) 11 (9) 
Long waiting time 4 (12) 2 (5) 1 (2) 7 (6) 
Did not know PHC offered free TB service 1 (3) 1 (3) 5 (10) 7 (6) 
Assumed patient had common cough, not TB 3 (9) 0 (0) 2 (4) 5 (4) 
No answer  3 (9) 2 (5) 0 (0) 5 (4) 
PHC had limited working hours  1 (3) 1 (3) 1 (2) 3 (2) 
Others 4 (12) 8 (20) 3 (6) 15 (12) 
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Annex H 
The incidence of catastrophic costs between poor and non-poor if TB patients 
received 90%, 80%, 70% and 60% of the potential cash transfers 
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Annex I 
The incidence of catastrophic costs between poor and non-poor if MDR-TB 
patients received 90%, 80%, 70% and 60% of the potential cash transfers  
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PhD Portofolio  
Sum of registered credits (EC): 35,00 
Starting date Name EC 
Courses   
30-10-2019 Post-graduate course - An introduction to TB modelling’ 0.30 
15-10-2019 Health Financing for Universal Health Coverage 1.50 
11-10-2019 Tuberculosis - Advanced Concepts 1.00 
04-10-2019 
Webinar: Assessing country progress in Health Financing: a 
qualitative approach 
0.20 
25-04-2019 Webinar: China's changing health care 0.20 
18-04-2018 Webinar: Understanding Peer Review 0.20 
03-11-2017 Erasmus MC - Biomedical English Writing and Communication 3.00 
06-07-2017 Erasmus MC - PhD Introduction session 0.20 
15-12-2016 Erasmus MC - Scientific Integrity 0.30 
04-04-2016 Department - Research meetings 5.00 
06-04-2016 Infectious Diseases Section - Research meetings 2.40 
   
Conferences   
31-10-2019 
International Conference, The 50th Union World Conference on 
Lung Health 
1.00 
31-10-2019 SPARKS Network, TB Social Protection Meeting 0.20 
13-06-2019 RGHI Network Meeting, Social Protection in Health 0.20 
24-10-2018 
International Conference, The 49th Union World Conference on 
Lung Health 
1.00 
23-10-2018 International Conference, TB Science 2018 0.80 
22-02-2018 RGHI Network Meering, Patient costs 0.20 
14-08-2017 
International Conference - The 2nd International Conference on 
Global health 2017 
1.00 
11-05-2017 Regional conference, lolaHESG 2017 0.80 
29-03-2017 
Research Meeting, The 42nd Tuberculosis Surveillance and Research 
Unit Meeting 
1.00 
22-03-2017 
International Conference, The 6th Conference of The Union Asia 
Pacific Region 
1.00 
   
Oral and poster presentations 
31-10-2019 
Poster presentation, The 50th Union World Conference on Lung 
Health, Hyderabad, India 
1.00 
31-10-2019 
Oral presentation, The 50th Union World Conference on Lung 
Health, Hyderabad, India 
1.00 
24-10-2018 
Oral presentation, The 49th Union World Conference on Lung 
Health, The Hague, The Netherlands 
1.00 
22-02-2018 
Oral presentation, Rotterdam Global Health Initiative, Rotterdam, 
The Netherlands 
1.00 
14-08-2017 
Speaker - The 2nd International Conference on Global health 2017, 
Jakarta, Indonesia 
1.00 
11-05-2017 Oral presentation, lolaHESG 2017, Rotterdam, The Netherlands 1.00 
29-03-2017 
Oral presentation, The 42nd Tuberculosis Surveillance and Research 
Unit Meeting, Johannesburg, South Africa 
1.00 
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Starting date Name EC 
22-03-2017 
Oral presentation, The 6th Conference of The Union Asia Pacific 
Region, Tokyo, Japan 
1.00 
   
Peer reviews   
06-11-2019 Peer review, IJTLD 0.30 
30-09-2019 Peer Review, The Royal Society of Tropical Medicine and Hygiene 0.30 
03-06-2019 Peer review, BMJ Open 0.30 
13-05-2019 Peer review, The Royal Society of Tropical Medicine and Hygiene 0.30 
02-03-2019 Peer review, Medical Journal of Indonesia 0.30 
22-02-2019 Peer review, The Royal Society of Tropical Medicine and Hygiene 0.30 
28-01-2019 Peer review, BMC Public Health 0.30 
25-01-2019 Peer review, BMJ Open 0.30 
18-09-2018 Peer review, Plos ONE 0.30 
04-09-2018 Peer review, Medical Journal of Indonesia 0.30 
06-08-2018 Peer review, Medical Journal of Indonesia 0.30 
   
Teaching   
08-08-2017 
Indonesian Health Financing System, teaching for undergraduate 
medical students of Faculty of Medicine, Universitas Indonesia 
1.00 
07-08-2019 
Indonesian Health Financing System, teaching for undergraduate 
medical students of Faculty of Medicine, Universitas Indonesia 
1.00 
25-06-2019 
Preparation class for medical student in the Global Health course, 
posted in Indonesia 
0.20 
 
 
 
